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Abstract 
 
Cutaneous malignant melanoma remains an increasing world health problem. Although 
targeted therapy to hyper-activated MAPK signalling has significantly increased survival for 
patients with BRAF/NRAS mutant melanomas, the development of acquired resistance is 
inevitable and associated with the emergence of chemo-resistant subpopulations expressing 
the neurotrophin receptor CD271. The relationship between drug-induced CD271 expressing 
subpopulations and autophagy however, remains undefined. The central aim of the present 
study was to define the relationship between CD271 (both constitutive and drug-induced) 
expression and autophagy, and the impact of CD271 inhibition or autophagy modulation on 
the potential re-sensitisation of BRAF mutant metastatic melanoma cells to MEK inhibition.  
Semi-quantitative immuno-histochemical analysis (IHC) of CD271 expression in primary 
cutaneous melanomas of different AJCC stage, revealed a significant stepwise increase in 
expression in advanced, stage III melanomas, paralleled with biphasic expression of p62 and 
consistent with the paradoxical role of autophagy in cancer. Additionally, chemical inhibition 
of autophagy with chloroquine or a specific Vps34 inhibitor, selectively inhibited cell viability 
CD271 positive but not negative subpopulations, isolated from BRAF mutant melanoma cell 
line, collectively suggesting constitutive CD271 expression is associated with an increase in 
basal pro-survival autophagy.  
Prolonged exposure of BRAFV600E mutant melanoma cells to the MEK 1/2 specific inhibitor 
trametinib resulted in increased CD271 expression, LC3-II accumulation and reduced p62 
expression, again highlighting the relationship between CD271 expression and autophagy 
activation. Genetic or chemical inhibition of CD271 in trametinib-induced drug-resistant BRAF 
mutant melanoma subpopulations resulted in significant inhibition of cell viability and re-
sensitisation to trametinib-induced apoptosis.  Furthermore, Inhibition of autophagy with 
chloroquine/ Vps34 inhibitor also resulted in reduced colony forming capacity, invasion and 
the re-sensitization of CD271 expressing BRAF mutant subpopulations to the cytotoxic effects 
of trametinib in vitro, with Vps34 inhibition additionally promoting trametinib-induced death 
and the prevention of tumour invasion and dissemination of trametinib-induced drug resistant 
subpopulations in a zebra fish xenograft model.  
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Attempts to harness cytotoxic autophagy to overcome drug-induced resistance to trametinib 
additionally revealed treatment of drug-induced resistant CD271 expressing BRAF mutant 
melanoma subpopulations with 9-tetrahydrocannabinol (THC) resulted in significant inhibition 
of cell viability.  
Collectively these data underpin the intimate relationship between trametinib-induced CD271 
drug-resistant subpopulations and pro-survival autophagy and suggest the targeting of CD271 
or indirect clinical modulation of autophagy (either through selective inhibition or the 
harnessing of its cytotoxic effects induced by THC) may provide valuable therapeutic strategies 
through which to overcome the resistance of BRAF/NRAS mutant metastatic melanoma to 
MEK inhibition. 
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Chapter 1 Introduction 
 Melanocytes, melanogenesis and melanomagenesis 
1.1.1 Melanocyte origin and melanogenesis 
 
Melanocytes are an important evolutionary step in human development and play significant 
roles in both photo protection and providing pigmentation to skin, eyes and hair. Originating 
from neural crest stem cells, melanocytes are a heterogeneous group of cells that can be 
found in a variety of human structures such as the epidermis, hair, and iris but also in the inner 
ear, nervous system and heart (Brito and Kos, 2008). Melanocytes derive from pluripotent 
neural crest stem cells that arise from the dorsal neural crest, between the surface ectoderm 
and neural plate (Mackenzie et al., 1997) before the melanocyte precursor, the unpigmented 
and undifferentiated melanoblast, migrate, proliferate and differentiate en route to their 
eventual destinations. In the skin, melanocytes reside at the basal layer of the epidermis and 
interact through their dendritic processes with 30-40 epidermal keratinocytes at a ratio of 
1:10 (Park et al., 2009). Contact between the melanocyte dendrites and epidermal 
keratinocytes enables the transfer of melanin into keratinocytes, determining the skin colour. 
In the skin, melanin has several properties; mainly photoprotection by UVR absorption and 
light scattering, a protective role from DNA damage by free radical de-activation and therefore 
preventing genomic instability (Park et al., 2009). The skin is also the main barrier to the 
external environment and melanocytes provide, apart from photoprotection, 
thermoregulation by melanin prduction (Lin and Fisher, 2007). The degree of melanin 
production in each individual and their response to UV radiation, is one of the most useful 
predictors of skin cancer risk in the general population.  
Melanogenesis, the production of melanin, is regulated by a number of genetic factors and 
cell signalling pathways. Melanogenesis is primarily regulated by the α-melanocyte 
stimulating hormone (α-MSH) and its receptor MC1R via the cAMP/PKA-signalling cascade 
(Kondo and Hearing, 2011). The pro-opiomelanocortin (POMC) gene regulates the production 
of α-MSH, adrenocorticotropic hormone (ACTH) and β-endorphin, all of which are inductors 
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of pigmentation (Kondo and Hearing, 2011). Upon α-MSH stimulation through MC1R, 
increasing levels of intracellular cAMP lead to activation of the transcription factor 
microphalmia associated transcription factor (MITF), which is essential for pigment synthesis 
and production (Gaggioli et al., 2003). Melanin synthesis requires a number of enzymatic 
processes (Cichorek et al., 2013) (Figure 1-1) with the final melanin products divided into two 
groups, pheomelanin and eumelanin. Whereas the ratio of pheomelanin to eumelanin 
determines skin pigmentation, pheomelanin itself does not determine skin pigmentation. 
Eumelanin with its better photo protecting properties provides higher resistance to UVR and 
ability to reactive oxygen species neutralization (Abdel-Malek et al., 2010; Bertolotto, 2013), 
potentially explaining consistent results observed across different epidemiological studies 
that highlight malignant melanoma as a disease of primarily fair skinned individuals and that 
individuals with darker skin have a higher protective effect towards the harmful effects of 
UVR. 
Melanin production is an important physiologic response to UV radiation. The skin produces 
a biphasic response to UVR with initial melanin production resulting from the redistribution 
of existing epidermal melanin reserve and a delayed response with an increase in melanin 
synthesis and transfer to keratinocytes, a result which is obvious within hours to days 
following UVR exposure (Park et al., 2002).  
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Figure 1-1 Schematic representation of melanin synthesis in melanocytes during 
melanogenesis 
Enzymatic cascade leading to melanin production. (Cichorek et al., 2013) 
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1.1.2 Melanomagenesis 
 
Although the exact origin of malignant melanoma is not known, it is widely accepted multiple 
genetic and environmental factors contribute to the malignant transformation of 
melanocytes. The consecutive acquisition of genetic mutations has been proposed to 
contribute to the development of malignant melanoma from melanocytes though a stepwise 
process from melanocyte proliferation, immortalization and malignant transformation, 
expansion in a radial growth phase followed by vertical expansion to ultimately metastatic 
spread (Figure 1-2). 
 
Figure 1-2: Hypothetical model of Melanoma development. 
Proposed model for melanomagenesis in which melanomas arise from malignant transformation of 
melanocytes which proliferate and acquire malignant potential before they invade initially in a radial 
and then in a vertical fashion followed by metastatic spread. (Bertolotto, 2013)  
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Ultraviolet radiation (UVR) is associated with specific signature mutations directly affecting 
nucleotide base pairing in DNA (Wei et al., 2003) and is therefore considered as one of the 
major risk factors for the development of a number of skin cancers including malignant 
melanoma. Short UV wavelengths are particularly harmful to the susceptible pyrimidine bases 
resulting in characteristic transition mutational changes, including for example, a TT→CC 
switch (Kanjilal et al., 1993). Apart from a direct mutagenic effect of UVR on DNA, UVR may 
also indirectly cause melanocyte transformation via the production of reactive oxygen species 
(ROS). Nucleotides are extremely susceptible to free radical injury and oxidation of nucleotide 
bases promoting base mispairing leading to mutagenesis (Schulz et al., 2000). Nevertheless 
linked to melanomagenesis, the development of melanoma however, is not always a result of 
UV-induced mutations, but can also result from germline mutations leading to familial 
melanoma, with the most extensively described mutations in the cyclin dependent kinase 
inhibitor 2A (CDKN2A), accounting for approximately 20-30% of all cases of familial melanoma. 
The CDKN2A tumour suppressor gene encodes two proteins, p16 (INK4a) and p14 (ARF) 
(Escamez et al., 2013) and although germline mutations are strongly associated with 
melanoma, sporadic mutations may also occur. Familial melanoma is also associated with 
germline mutations in CDK4, the catalytic subunit of a protein kinase involved in controlling 
progression through the G1 phase of the cell cycle (Zuo et al., 1996).  
Another low penetrance gene extensively reported for its role as pigment regulator and its 
role in melanomagenesis is MC1R, where variants in the MC1R allele present in individuals 
with skin type I (Box et al., 1997) are significantly more common in melanoma conferring a 
relative disease risk of 3.9 (Ichii-Jones et al., 1998), and reinforcing the pivotal role of MC1R 
mutations in both pigmentation and melanoma.  
The microphthalamia-associated transcription factor (MITF) is located to chromosome 
3p12.3–14.1 in humans and is a key transcription factor in melanin biosynthesis. Mutations in 
MITF play key roles in a number of other processes including the survival, growth, and 
differentiation of melanocytes, retinal pigment epithelium, osteoclasts, and other 
hematopoietic lineages (Haq and Fisher, 2011). Although germline mutations in MITF are 
uncommon, the presence of an E318K variant is associated with multiple primary melanomas 
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and a family history of melanoma. The E318K variant corresponds to a gain of function 
associated with loss of a SUMOylation site at codon 318 (Miller et al., 2005).  
Further attempts to determine the mutational burden in cutaneous and other forms of 
malignant melanoma have also led to the discovery of activating mutations in cKIT most 
commonly affecting the region of the receptor with L576P in exon 11 (Beadling et al., 2008),  
found in approximately 40% of mucosal and 35% of acral melanomas (Curtin et al., 2006), and 
indicating different melanoma subtypes might harbour different biological and mechanistic 
tools to promote tumour growth.  
Apart from a number of genetic factors described in familial melanoma, several deregulated 
signalling mechanisms have been implicated in melanoma development and progression. 
Abnormal activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway can result to a 
cascade of biological events, from cell growth and proliferation to survival and migration. In 
addition, the PI3K/AKT pathway is a crucial regulator of angiogenic pathways and therefore is 
a major contributor to tumour initiation, progression and metastasis (Carnero et al., 2008). 
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a 
phosphatidylinositol phosphate phosphatase that is frequently inactivated in human cancers. 
Selective activation of Akt3 promotes survival in  40–60% of non-familial melanoma (Stahl et 
al., 2004) which contributes to the phenotypic plasticity of cancer cells by controlling 
Epithelial–mesenchymal transition (Larue and Bellacosa, 2005) and mediating tumour 
invasion. Interestingly, mutations in the tumour suppressor gene TP53 also play a role in 
melanomagenesis and tumour progression. TP53 gene encodes the transcription factor p53 
which is activated in response to exogenous stresses including DNA damage or hypoxia, and 
regulates many genes involved in cell cycle regulation, cell growth and apoptosis (Vousden 
and Prives, 2009). Mutations of TP53 are found in approximately 50% of all human cancers; 
however in melanoma the incidence is lower with only 1–5% of primary melanomas harboring 
mutated p53 (Giglia-Mari and Sarasin, 2003). TP53 has also been associated with 
melanomagenesis and synergizes with mutated BRAF to promote UVR-mediated 
melanomagenesis (Viros et al., 2014), however its role in spontaneous melanomas of non-sun 
exposed sites is enigmatic.  
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Strikingly, the most common deregulated signalling pathway in cutaneous melanoma is the 
Mitogen-activated protein kinase (MAPK) pathway, constitutively activated in up to 70% of all 
tumours by hyper activating mutations in the BRAF protein kinase, further details of which are 
more extensively described in 1.2.4.  
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 Cutaneous malignant melanoma 
1.2.1 Clinical characteristics of cutaneous malignant melanoma 
 
Cutaneous melanoma is a significant world health problem with an increasing incidence ( 
Figure 1-3). Malignant melanoma affects people of all ages, sexes and ethnic groups and is 
one of the most common causes of cancer related deaths in young adults in the UK. 
Epidemiological data have recorded in excess of 230,000 new diagnoses of malignant 
melanoma worldwide (Organisation, 2015) with 2148 deaths from malignant melanoma 
documented in 2012 in the UK alone (Cancer Research UK, 2015). 
 
Figure 1-3: Cutaneous melanoma incidence trend in the UK 
Incidence trend of cutaneous melanoma. Melanoma incidence rates have increased overall for all of 
the broad age groups in the UK. www.cancerresearchuk.org (Cancer Research UK, 2015) 
Cutaneous malignant melanoma presents with different clinical characteristics and may arise 
either de novo or from a pre-existing naevus (Friedman and Rigel, 1985) and which is 
categorized according to anatomical location and histological characteristics (Figure 1-4). 
Clinically, melanoma presents as an irregular, growing and changing lesion which in the 
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majority of cases are pigment producing lesions but occasionally present as rare variants such 
as in the case of amelanotic melanomas (Cohen-Solal et al., 2002) and which can be 
challenging to diagnose both clinically and histologically. Certain criteria have been developed 
to help both patients and clinicians in the diagnosis of malignant melanoma. The most widely 
used is the ABCDE criteria (Asymmetry, Border irregularity, Colour variation, Diameter >6 mm, 
Evolution) which is a simple method to raise suspicion of a malignant lesion and urge patients 
to seek medical advice (Abbasi et al., 2004). Melanoma in situ is widely regarded as a pre-
malignant lesion in which the atypical proliferation of melanocytes is confined to the dermo-
epidermal junction without breaching the basement membrane (Tannous et al., 2000) 
whereas melanomas become invasive when atypical melanocytes proliferate in a vertical 
plane and therefore invade through the basement membrane to the dermis and subcutaneous 
fat (Smoller, 2006).  
 
Figure 1-4: Clinical subtypes of malignant melanoma 
Clinical subtypes of cutaneous malignant melanoma. a. cutaneous malignant melanoma, b. Lentigo 
maligna melanoma, c. subungual melanoma, d. mucosal melanoma 
Histologically, melanoma development is characterized by three distinct phases; an in situ, a 
radial and subsequent vertical growth phase. Transformed melanocytes are thought to first 
proliferate above the basement membrane, followed by invasion to the papillary dermis (in 
situ and invasive radial growth phases of melanoma) (Guerry et al., 1993). The radial growth 
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phase is characterized by enlargement of the tumour at its periphery. Subsequently cells 
proliferate in a vertical fashion, characterizing the vertical growth phase, initially reported as 
the development of a ‘new’ population of tumour cells within melanomas that grow in a 
perpendicular manor or radial growth phase (Clark et al., 1984; Rodrigo Arrangoiz, 2016) 
(Figure 1-5).  
 
 
 
 
 
 
 
 
 
 
Figure 1-5: Proposed growth phases of malignant melanoma 
Malignant melanoma develops from benign naevi through the accumulation of genetic mutation and 
the deregulation of cell signalling pathways. Initially tumour growth follows a radial growth phase, 
followed by a vertical growth phase before the detachment of malignant cells from the primary site 
and development of metastatic disease. (Rodrigo Arrangoiz, 2016) 
The observation that thicker tumours are associated with poor prognosis led to the 
development of stratification methods to assess the risk of developing systemic disease. The 
first attempt to correlate tumour thickness with risk of metastasis was made by Clark (Clark et 
al., 1969). Since then several studies (Barnhill et al., 1996; Schuchter et al., 1996) have 
highlighted Breslow thickness as a more sensitive prognostic biomarker for melanoma which 
remains an integral part of the current and generally accepted means of melanoma 
Vertical growth  
phase melanoma 
Metastatic 
melanoma 
Radial growth  
phase melanoma 
Dysplastic 
naevus 
Benign  
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classification according to the American Joint Committee on cancer (AJCC) staging criteria, 
further described in 1.2.3.  
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1.2.2 Melanoma risk factors 
 
A large number of potential determinants or risk factors for malignant melanoma have been 
proposed. The strongest association that has been proposed in a number of epidemiological 
studies is the association between melanoma development and UVR exposure both in 
childhood and during adult life (Richards et al., 2011; Lo and Fisher, 2014). Studies have 
suggested a consistent lower incidence of melanoma in residents of areas with low UV 
environment compared to residents in areas with high UV environment (Whiteman et al., 
2001). This could explain the significant higher incidence of malignant melanoma in the sub-
tropical areas like Australia, where a fair skinned population is subjected to high 
environmental UVR for the vast majority of the year, making UVR the most important 
environmental factor associated with melanoma development (Marks, 2002). As discussed 
above, the presence of light hair, eyes and skin type I-II (easy burning history and poor ability 
to tan in response to sunlight) is also positively correlated with melanoma development 
(Gandini et al., 2005). Other significant risk factors include the number of melanocytic naevi. 
The presence of >100 melanocytic lesions carries a relative risk of 7.6 compared to individuals 
with <10 melanocytic lesions with the distribution of actinic lentigines also associated with a 
higher incidence of malignant melanoma (Garbe et al., 1994).  In addition, a family history of 
melanoma increases the risk of developing malignant melanoma by almost 3 fold (Holman and 
Armstrong, 1984), reinforcing the theory of a potential genetic mediators in melanoma 
development. Again as discussed above, genetic signatures that have been associated with 
increased risk of familial melanoma include mutations in CDKN2A (Nobori et al., 1994) and the 
melanocortin-1receptor (MC1R) gene, (Taylor et al., 2015). Despite the recent increase in 
knowledge of melanoma identification and a significant increase in patient awareness about 
melanoma development and its association with UV exposure, melanoma however, remains 
the most deadly form of skin cancer and one of the major causes of death by cancer in young 
individuals (Cancer Research UK, 2015). 
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1.2.3 Prognosis and staging of malignant melanoma  
 
Malignant melanoma carries a variable prognosis, which differs significantly according to 
disease stage for which The American Joint Committee on cancer (AJCC) staging criteria 
(revised in 2009) is the most  universally accepted  means of melanoma categorization and 
which provides a prognostic indicator according to specific disease parameters (Balch et al., 
2009a) (Table 1.1). Such parameters include ‘Breslow’ depth, the presence of ulceration as 
well as the degree of tumour spread to regional or distant metastatic sites. Specifically, the 
Breslow depth described by Alexander Breslow is a measure of tumour thickness and invasion,  
(Breslow, 1970) which alone has been strongly correlated to disease progression. The 
presence of ulceration (the loss of epidermal integrity overlying a melanoma) in a resected 
primary melanoma provides additional prognostic information, adversely correlating with 
outcome (Balch et al., 2009a). However, it remains unclear whether ulceration represents the 
effect of an intrinsically more aggressive tumour on the epidermis, or whether any tumour 
that becomes ulcerated results in an increased likelihood of spread (Eggermont et al.). Primary 
melanoma proliferation as defined by the mitotic rate is also an independent prognostic 
biomarker incorporated into AJCC staging where an increased rate correlates with decreased 
survival and constitutes the second strongest predictor of survival following tumour thickness. 
A large number of mitotic cells indicates high metabolic cell activity and implies the ability of 
these tumours to enlarge and potentially metastasize (Francken et al., 2004) (Table 1-1).  
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Table 1-1: AJCC stage and associated prognosis (Adapted from Balch et al (Balch et al., 
2009b) 
 Histological characteristics of cutaneous melanomas according to the AJCC staging system and 
associated 5-year survival 
Taking into consideration the above points the AJCC staging criteria are thus divided into 
stages, where by stage I-II is characterized by histological features and tumour size in the 
absence of any loco-regional metastatic disease, whereas stage III is characterized by the 
presence of nodal metastases and stage IV by the presence of distant metastatic sites. Nodal 
metastatic burden is further stratified by the presence of micro metastases or macro 
metastases and the number of involved lymph nodes (Table 1-2). Collectively indicating that 
the metastatic nodal burden also has a prognostic impact on patient survival (White et al., 
2002).   
 
  
 
AJCC 
stage 
 
Disease characteristics 
 
5-year 
survival 
(%) 
IA Tumour ≤ 1mm, no ulceration 95 
IB Tumour ≤ 1mm, with ulceration or Tumour 1.01-2.0mm without ulceration 89-91 
IIA Tumour 1.01-2.0mm with ulceration or Tumour 2.01-4mm without ulceration 77-79 
IIB Tumour 2.01- 4.0mm with ulceration or tumour > 4mm without ulceration 63-67 
IIC Tumour > 4mm with ulceration 45 
IIIA 
Tumour of any thickness without ulceration and 1-3 positive lymph nodes with 
micrometastasis 
63-70 
IIIB 
Tumour of any thickness with ulceration and 1-3 positive lymph nodes with 
micrometastasis, or Tumour of any thickness without ulceration and 1-3 positive 
lymph nodes with macrometastasis 
46-59 
IIIC 
Tumour of any thickness with ulceration and 1-3 lymph nodes positive with 
macrometastasis, or tumour of any thickness and >4 involved lymph nodes 
24-29 
IV 
Presence of any distant metastasis regardless of tumour thickness or status of 
regional lymph nodes 
7-19 
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Table 1-2: Nodal classification of current AJCC staging system (Balch et al., 2009b) 
 
Metastatic disease is sub-categorised into M1a which describes metastatic loci in distant skin, 
subcutaneous or nodal metastases, M1b in lung metastases and M1c characterised by the 
presence of any other visceral metastases (Balch et al., 2009a). Finally, serum levels of lactate 
dehydrogenase (LDH) are also highlighted by the AJCC staging criteria, providing a surrogate 
marker of disease burden in patients with stage IV disease where elevated levels are 
correlated with reduced 1 and 2-year overall survival rates (Balch et al., 2009a). The 
histological characteristics of melanoma included in the AJCC staging criteria are able to 
capture a large proportion of high risk tumours, however, there is still a number of seemingly 
‘low’ risk tumours that still go on to metastasize and therefore combined efforts have 
concentrated in identifying novel mechanisms and biomarkers that can more accurately 
predict which tumours are innately more aggressive. As a result, the AJCC staging criteria for 
melanoma is under re-evaluation with the proposed 8th edition likely coming into clinical 
practice with effect from early 2018. The AJCC 8th edition will incorporate a significant change 
in melanoma staging which will include the classification of stage IA tumours if the tumour 
Breslow thickness is less than 0.8 mm (previously 1 mm in 7th AJCC edition, 2009) and with no 
ulceration whereas stage IB will be classified the tumours with Breslow thickness of 0.8-1.0 
mm or <0.8 mm with ulceration (Amin et al., 2017; Jeffrey E. Gershenwald, 2017). Additionally, 
the tumour mitotic rate will be removed from the classification of stage I tumours. Another 
 
N stage 
Number of metastatic nodes 
N0 0 
N1 1 
N2 2-3 
N3 
>4 metastatic nodes, or 
matted nodes, or in 
transit 
metastases/satellites 
with metastatic nodes 
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important change in the new AJCC staging criteria is the change in the nodal classification, in 
which 4 nodal classifications instead of 3 present are proposed. Additionally, the term micro 
metastasis will be replaced with the term ‘clinically occult disease as detected by sentinel 
lymph node biopsy (SLNB)’ (Jeffrey E. Gershenwald, 2017).  
Another potential determinant of a patients’ prognosis is the presence of lymph node 
metastases. Sentinel node biopsy is a minimally invasive staging procedure performed with 
the use of blue dye and radiolabelled particles and is used to identify the primary (i.e., sentinel) 
node or nodes containing melanoma cells and hence can be an early indicator of metastatic 
spread (Takeuchi and Kitagawa, 2012). Sentinel lymph node biopsy may give an early 
indication of melanoma metastases (Faries et al., 2017) but their use is controversial and is 
not universally adopted. 
Although the AJCC staging criteria provide a useful combination of both histological and 
clinical markers to inform prognosis, metastatic disease evolves with an extensive repertoire 
of deregulated cellular signalling and therefore further developments to aid stratification 
according to specific tumoural characteristics are of crucial importance to both improved 
prognosis and the development of more efficacious personalised therapies. 
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1.2.4 Oncogenic BRAF signalling 
 
Perhaps the best characterized deregulated cellular signalling mechanism linked to the 
development of melanoma is the constitutive activation of the mitogen-activated protein 
kinase (MAPK) signalling pathway mediated by hyper activating mutations NRAS or BRAF. The 
MAPK ( 
Figure 1-6) is an important cellular signalling pathway linking extracellular signals to promote 
cell growth, proliferation, differentiation, migration and apoptosis (Dhillon et al., 2007; 
Wellbrock and Arozarena, 2016). MAPK activation results from the stimulation of receptor 
tyrosine kinases (RTKs) activating the MAPK cascade in a multistep process. Several growth 
factors have been implicated into the activation of RTK like structures, such as membrane-
bound peptide/protein hormones including nerve growth factor (NGF), platelet-derived 
growth factor (PDGF), fibroIntroblast growth factor (FGF), epidermal growth factor (EGF), and 
insulin (Margolis and Skolnik, 1994). RTKs include epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptors, fibroblast growth factor receptors (FGFRs), vascular 
endothelial growth factor receptors (VEGF), Met (hepatocyte growth factor/scatter factor 
(HGF/SF) (Sebolt-Leopold and Herrera, 2004). G-protein coupled receptors, activated mainly 
by the epidermal growth factor receptor (EGFR), activate Ras by triggering guanosine 
triphosphate (GTP) loading of the Ras GTPase (Pierce et al., 2001). These then recruit Raf 
kinases to the plasma membrane, leading to sequential activation of MEK1/2 and 
phosphorylation of ERK1/2 (Dhillon et al., 2007) and the translocation of activated ERK to the 
nucleus which subsequently activate transcription factors and alter gene expression to 
promote cell growth, differentiation or proliferation (Zhang and Liu, 2002) (Figure 1-6).  
Activating mutations in NRAS are present in approximately 15-20% of cutaneous melanomas 
(Davies et al., 2002). The most common mutations are found in codon 61, with a substitution 
of glutamine for lycine (Q61K) which represents approximately 48% of all NRAS mutations and 
the substitution of glutamine for arginine (Q61R) in approximately 36% (Ellerhorst et al., 
2011). 
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The Raf family comprise of serine/theonine kinases (C-Raf, A-Raf and B-Raf) that 
phosphorylate and activate the MEK1 and MEK2 dual-specificity protein kinases initiating the 
MAPK cascade (Schreck and Rapp, 2006). Approximately 60% of all cutaneous melanomas 
harbour a mutation in BRAF which leads to the constitutive activation of MAPK signalling and 
thus enhanced tumour growth and proliferation. A number of BRAF mutations have been 
reported in melanoma and of those 90% of observed mutations are located at codon 600 
(Davies et al., 2002) with 90 % being of a single nucleotide mutation resulting in substitution 
of glutamic acid for valine (BRAFV600E: nucleotide 1799 T > A; codon GTG > GAG). The second 
commonest mutation is BRAFV600K substituting lysine for valine, that represents 5-6 % 
(GTG > AAG), followed BRAFV600D (GTG > GAT) (Forbes et al., 2001). 
 
Figure 1-6: Schematic representation of the MAPK pathway 
Activation of the MAPK pathway is a result of stimulation of receptor tyrosine kinases (RTK) activating 
a cascade of molecules leading to the final activation of ERK 1/2 and tumour cell growth and survival. 
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1.2.5 Current and novel treatment approaches for metastatic malignant 
melanoma 
Although surgical excision is the treatment of choice for primary localized melanoma, the 
successful treatment of patient with metastatic disease remain in consistent, likely linked to 
the extensive range of molecular defences against immunological and cytotoxic attack, 
exerted by such tumours that render them notoriously unresponsive to conventional 
chemotherapy and which has led to a large body of research focused on the development of 
more specific and more efficacious targeted therapies and immunomodulatory treatments.  
1.2.5.1 Chemotherapy 
 
Prior to the instigation of novel targeted therapies and immunotherapy, metastatic disease 
was traditionally treated with standard chemotherapies which included and still does, the use 
of dacarbazine (Lens and Eisen, 2003), temozolomide (Middleton et al., 2000), alone or in 
combination with other agents including cisplatin (Glover et al., 1987) or fotemustine (Avril et 
al., 2004). Limited response of 15% with the alkylating agent dacarbazine (Lui et al., 2007) with 
few long-term clinical responders have led to the use of temozolomide, the oral analogue of 
dacarbazine which reportedly better penetrates the blood-brain barrier. However, the 
objective response rate of temozolomide is limited to  14% with a median overall survival of 
only 7.7 months (Middleton et al., 2000) and hence other agents have been used to treat 
patients with metastatic melanoma including platinum analogues (cisplatin and carboplatin) 
(Glover et al., 1987) and antimicrotubular agents such as paclitaxel and vinblastine (Rao et al., 
2006), all of which have had limited success as single agents. Nevertheless despite numerous 
trials of such agents alone or in combination which have to date, have not shown any 
significant effect on over all patient survival (Del Prete et al., 1984; Glover et al., 1987; Legha 
et al., 1989; Margolin et al., 1998), these agents are still used to treat patients who have failed 
treatment with targeted therapies or immunotherapy.  
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1.2.5.2 Radiation therapy  
 
Radiation therapy (whole-brain irradiation and/or stereotactic radiosurgery) is also used in 
some metastatic melanoma treatment regimens and can be especially useful in patients with 
intracranial metastases, as most systemic therapies have limited penetration through the 
blood-brain barrier (Breneman et al., 1997) (Rades et al.). In particular, stereotactic 
radiosurgery (SRS) has significantly improved clinical outcomes in patients with limited brain 
metastases (1-4 lesions) (Soliman et al., 2016). However, in patients with extensive metastatic 
disease, WBRT is still used (Dyer et al., 2014).  
1.2.5.3 Immunotherapy 
 
While most chemotherapy has a cytotoxic anti-cancer effect through causing DNA damage or 
manipulation of cell cycle and apoptosis, immunotherapies rely on augmentation of immune 
responses that naturally target cancer cells (Tjin et al., 2011). Ipilimumab was the first 
immunotherapy to be FDA approved for the management of patients with metastatic 
melanoma (Mansh, 2011), which functions by targeting the Cytotoxic T-Lymphocyte Antigen 
4 (CTLA-4) receptor to enhance T-cell activity (Walunas et al., 1994). Shown to me more 
beneficial than the melanoma vaccine gp100 , with an associated improved effect on patient 
overall survival (Hodi et al., 2010), Ipilimumab has been used as first line treatment for 
patients with BRAFWT metastatic malignant melanoma with low volume disease until the 
recent introduction of anti-PD1 agents. PD-1 (programmed death-1) is an important immune 
checkpoint receptor present in activated T-cells. The associated PD-1 ligand (PDL-1) is 
expressed on the surface of cancer cells or stromal cells (Topalian et al., 2012a) and the 
interaction between PD-1 and PDL-1  (Figure 1-7) inhibits T cell function and promotes 
immunosuppression. Inhibition of this interaction has been reported to enhance immune 
responses to cancer cells and improve antitumor immune activity (Pardoll, 2012; Melero et 
al., 2013).  
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Figure 1-7: PD-1 and PDL-1 interaction (Taken from Pardoll et al) 
A.Oncogenic signalling can upregulate PDL1 which upon interaction with PDL-1 expressed in the 
surface of T-cells results in inhibition of local antitumour T cell-mediated responses. B. PDL-1 
expression can be induced by inflammatory signals, like interferon- γ (INF- γ) which is produced by 
tumour micro environmental factors like tumour infiltrating immune cells (Pardoll, 2012) 
 
Clinically, there is accumulating evidence to support the use of PD-1 and PDL-1 inhibitors in 
patients with advanced melanoma with the use of PD-1 inhibitors shown to be superior to the 
use of Ipilimumab alone (Postow et al.; Robert et al.; Topalian et al., 2012b; Hamid et al., 
2013). However, recent evidence suggests that combination immunotherapy with the PD-1 
inhibitor nivolumab and ipimilumab show superior effects with an objective response rate of 
61% in the combination group compared to 11% in patients treated with ipilimumab alone 
(Larkin et al., 2015). Nevertheless, combination immunotherapy is associated with a number 
of adverse effects, including life-threatening autoimmune colitis observed in 44% of patients 
(Larkin et al., 2015) and hepatitis in 17% of patients, which coupled with the observed 
development of acquired resistance in some patients limits clinical efficacy (Amaral and 
Garbe, 2016; Restifo et al., 2016) and  emphasises the continued need for more effective 
immunomodulatory therapies for metastatic melanoma. 
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1.2.5.4 Targeted therapies 
 
Perhaps, the greatest advance in the management of malignant melanoma over the past 
decade has been the development of inhibitors to constitutively activated MAPK signalling, 
either with BRAF specific inhibitors, targeting BRAFV600E or through the use of MEK specific 
inhibitors to inhibit downstream MAPK activation (Stadler et al., 2015),(Figure 1-8).  
 
Figure 1-8: Signalling pathways mediating tumour cell growth and targeted therapeutic 
targets 
Schematic representation of signalling pathways mediating melanoma cell growth and proliferation 
and potential targets. Taken from Stadler et al (Stadler et al., 2015). 
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Vemurafenib is a potent and effective inhibitor of mutant B-RAFV600E (Chapman et al., 2011; 
Sullivan and Flaherty, 2013; Menzies and Long, 2014), demonstrating for the first time 
enhanced overall and progression free survival for patients bearing BRAFV600E mutant 
melanomas (Chapman et al., 2011). Dabrafenib, another BRAF specific inhibitor, is a reversible 
and potent ATP-competitive inhibitor that selectively inhibits the BRAFV600E kinase (Laquerre 
et al., 2009) and like Vemurafenib has been shown to be efficacious in improving progression 
free survival (5.1 months in the dabrafenib group vs 2.7 months in dacarbazine group) 
(Hauschild et al., 2012) in patients with metastatic melanoma. However, although both 
vemurafenib and dabrafenib have revolutionized melanoma therapy, their efficacy is limited 
by the development of acquired resistance (Sosman et al., 2012), and the resultant 
reactivation of MAPK signaling. In an attempt to overcome this effect, down-stream MEK 
inhibitors have been developed including the MEK1/2 specific inhibitor trametinib, which have 
been used alone or in combination with BRAF inhibitors. The combination has shown an 
improved effect on progression free survival for patients with BRAF mutant melanoma over a 
BRAF inhibitor alone (Flaherty et al., 2012; Larkin et al., 2014; Long et al., 2014; Luke et al., 
2017). MEK inhibitors alone also target constitutively activated NRAS in patents with NRAS 
mutations. The combination of dabrafenib plus trametinib has been shown to provide a 
significant survival benefit in patients with BRAF mutant metastatic melanoma with 3 year 
overall survival of 44% in the combination group compared to 32% in the dabrafenib alone 
group (Long et al., 2014) and therefore these exciting data have triggered a fast-track adoption 
of the combination of dabrafenib plus trametinib in patients with BRAF mutant metastatic 
melanoma by NICE (NICE, 2016). However, accumulating evidence suggests that acquired 
resistance to combination targeted therapies, although later than monotherapy alone, is also 
a major reason for patient mortality (Welsh et al., 2016). The need for a greater understanding 
of the mechanisms that promote resistance to targeted therapies and the development of 
more efficacious therapeutic strategies is therefore of paramount importance.  
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1.2.5.5 Resistance mechanisms to targeted therapies 
 
Although BRAF/MEK specific inhibitors initially block tumour growth and tumour cell 
proliferation, paradoxical resistance may result in the acceleration of tumour growth. Several 
mechanisms mediating tumour resistance have bene proposed, broadly divided into two 
categories of intrinsic and acquired resistance (Luke and Hodi, 2012; Luke and Hodi, 2013) 
(Figure 1-9). 
 
 
Figure 1-9: Mechanisms of resistance to BRAF inhibitors 
A number of resistance mechanisms to BRAF inhibition have been described including 1. Secondary 
mutations in NRAS, 2. Overexpression of other kinases such as COT, 3. Secondary mutation in MEK, 4. 
Activation of upstream receptor tyrosine kinases, 5. Splice variants of BRAF, 6. Activation of HGF/cMET 
or 7. BARF amplification. Taken from Luke and Hodi (Luke and Hodi, 2013).  
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One of the first intrinsic mechanisms of BRAF/MEK inhibitor mediated-resistance described is 
the up regulation of cell cycle regulator levels like cyclin D. In vitro studies in melanoma cell 
lines with increased levels of cyclin D1 demonstrated resistance to BRAF inhibitors (Smalley et 
al., 2008). Interestingly, cyclin D1 amplification is present in 15-20% BRAF mutant melanomas, 
suggesting this mechanism is clinically relevant and may explain the observed resistance seen 
in patients treated with a BRAF inhibitor (Sauter et al., 2002). Loss of PTEN, a major regulator 
of the phosphotidylinositol-3-kinase (PI3K) (Sansal and Sellers, 2004) may also explain intrinsic 
resistance to BRAF/MEK inhibition. (Paraiso et al., 2011). Finally, recent evidence highlights 
the importance of the hepatocyte growth factor (HGF)-cMET axis in development of BRAF 
inhibitor acquired resistance indicating that the cross-talk amongst several receptor tyrosine 
kinases that are co-expressed in tumour cells could explain the development of both intrinsic 
and acquired resistance (Wilson et al., 2012). 
Acquired resistance to BRAF inhibition may also result from the development of secondary 
mutations in BRAF which block binding of BRAF inhibitors and thus allowing homo and 
heterodimerization with CRAF or ARAF and therefore paradoxical hyper-activation of the 
MAPK pathway (Hatzivassiliou et al., 2010) (Whittaker et al., 2010; Poulikakos et al., 2011; 
Sanchez-Laorden et al., 2014). Downstream activation of MEK and ERK could also result in the 
up regulation of non-MAPK pathways including COT, which can mediate activation of MEK 
independently of RAF (Johannessen et al., 2010b). Finally, the up regulation of other receptor 
tyrosine kinase receptor signalling pathways has been reported to play a role in acquired 
BRAF/ MEK inhibitor associated drug resistance. Up regulation of platelet derived growth 
factor receptor beta (PDGFRβ) and insulin-like growth factor 1 receptor (IGF-1R) in this context 
have been reported to activate the PI3K-AKT-mammalian target of rapamycin (mTOR) 
resulting in cell proliferation (Nazarian et al., 2010). 
Pertinent to the current study, accumulating evidence supports the concept that melanoma 
resistance to targeted therapies may be the result of emerging subpopulations within the 
heterogeneously populated tumours that emerge through resistance to both chemotherapy 
and targeted therapies and are defined by high phenotypic plasticity (Sztiller-Sikorska et al., 
2014) and referred to as cancer ‘stem-like cells’ (Shakhova and Sommer, 2013), multidrug 
resistance or induced drug tolerant cells (Ravindran Menon et al., 2014).  
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 Cancer stem cells 
 
Although the precise origin of melanoma remains unknown, recent evidence suggests the 
accumulation of genetic and epigenetic mutations in melanocytes enables the acquisition of 
stem cell-like capacities via somatic reprogramming (Shakhova and Sommer, 2013) . The 
cancer stem cell theory was first described in the context of acute myeloid leukaemia (AML) 
when it was suggested that isolated susceptible cells in the hematopoietic hierarchy were 
responsible for leukemic transformation (Bonnet and Dick, 1997). Since then there has been 
an ongoing debate about the origin and existence of cancer stem like cells in solid tumours. 
Two theories for tumour development have been proposed, the stochastic and the cancer 
stem cell theory. The stochastic theory proposes that every cell has the potential to initiate 
tumourigenesis, provided they accumulate tumorigenic genetic alterations (Michor et al., 
2004) while the cancer stem cell theory suggests that there is only a small subpopulation 
within solid tumours have the selective ability to maintain tumour growth via self-renewal and 
promoting tumour heterogeneity through maintaining differentiation (Reya et al., 2001) 
(Figure 1-10). The cancer stem cell model was first introduced in the context of malignant 
melanoma in 2005 with the identification of a subpopulation of melanoma cells able to 
differentiate under appropriate conditions into multiple cell lineages, including melanocytic, 
adipocytic, osteocytic, and chondrocytic lineages (Fang et al., 2005a). From a therapeutic 
perspective, the cancer stem cell concept has significant implications as the targeting of such 
subpopulations may be required to achieve long-term disease free survival (Visvader and 
Lindeman, 2008). The targeting of cancer stem cells has attempted by either directly targeting 
the expression of cell surface markers such as CD133 using small molecules or specific 
antibodies (Swaminathan et al., 2013) or by targeting signalling pathways cancer stem cells 
use to survive and promote tumour migration. (Der-Yang et al., 2013).  
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Figure 1-10: Proposed models for tumourigenesis  
a. Stochastic model of solid tumour development. Any cell is capable to produce and maintain tumour 
growth following genetic alterations. b. Only certain cells (CSC) are tumorigenic and have the ability to 
proliferate and maintain tumour growth. (Adapted from (Reya et al., 2001) 
 
The cancer stem cell (CSC) hypothesis provides an attractive cellular mechanism to account 
for the therapeutic resistance (Figure 1-11) and the aggressive behaviour of many tumours. 
The CSC theory hypothesizes that tumour relapse is a result of the existence of CSC that escape 
anti-cancer therapies. One explanation that has been proposed is that anti-cancer therapies 
only target differentiated tumour cells within the tumour bulk, while sparing the CSC 
subpopulations that are able to escape chemotherapy-induced death by down regulating 
tumour specific surface markers and reverting to a non-differentiated phenotype (Bose et al., 
2011; Abdullah and Chow, 2013) and therefore re-instating tumour bulk. Nevertheless, 
contrary to the AML stem cell cancer model, cancer stem cells in solid tumours are regarded 
as impure populations, reflected by the poor overlap between reported stem cell markers in 
pancreatic and breast cancer (Visvader and Lindeman, 2008) and with varying frequencies of 
expression within the same tumour type, making cancer stem cell research a controversial and 
difficult area to research.  
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Figure 1-11: Proposed model for tumour chemo resistance 
Both traditional chemotherapeutics and targeted therapies are effective in targeting the non-cancer 
stem-like cells. As a result, the tumour bulk is initially reduced but when resistance develops, the 
tumour bulk is reconstituted by differentiation and proliferation of tumour cells that have stem-like 
capabilities. 
 
1.3.1 Cancer stem-like cell surface marker expression 
 
The increased expression of several surface markers has been associated with increased 
tumourigenic potential and resistance to both standard chemotherapeutics and targeted 
therapies as well as a cancer stem cell phenotype. The expression of ABCB5 (ATP-binding 
cassette subfamily B member 5) which acts as an ATP-dependent pump to transport 
compounds out of the cell (Frank et al., 2003) has been associated with the development of 
chemo resistant melanoma cells when cultured in the presence of both standard 
chemotherapeutics such as doxorubicin (Frank et al., 2005a) or targeted agents including BRAF 
inhibitors (Chartrain et al., 2012). Interestingly, ABCB5 +ve melanoma subpopulations isolated 
from patient derived tissue and xenotransplanted into NOD/SCID mice ABCB5 +ve melanoma 
cells demonstrated greater tumorigenic capacity compared to the ABCB5 -ve subpopulations 
with greater ability to re-establish tumour heterogeneity (Schatton et al., 2008). Additionally, 
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immunohistochemical analysis of ABCB5 expression in benign naevi, primary melanomas and 
melanoma metastases demonstrated ABCB5 expression is higher in primary and metastatic 
MMs compared with benign melanocytic naevi, with increased expression in thick primary 
compared to thin primary melanomas also noted and collectively suggesting ABCB5 as a 
molecular marker of neoplastic disease progression (Frank et al., 2005b; Gambichler et al., 
2016). 
CD133 has also been described as a putative cancer stem cell marker in both melanoma and 
neurological malignancies (Singh et al., 2004). Higher CD133 expression has been observed in 
malignant melanomas compared to benign naevi (Klein et al., 2006) with reports of CD133 +ve 
cells also being resistant to Caffeic acid phenethyl ester (CAPE)-mediated by up regulation of 
ABCB5 expression (El-Khattouti et al., 2015). 
Nestin, a class VI intermediate filament protein, was one of the first neural crest stem cell 
markers to be described (Lendahl et al., 1990). Nestin expression is variable in malignant 
melanoma but a stepwise increase in immunohistochemical expression has been associated 
with increasing AJCC disease stage progression (Akiyama et al., 2013c). Interestingly, the 
presence and isolation of circulating melanoma cells that express Nestin has also been 
associated with poor prognosis (Fusi et al., 2011) while knockdown of nestin in melanoma cell 
lines inhibits tumour cell migration and invasion (Akiyama et al., 2013b), collectively indicating 
that Nestin plays an important role in melanoma progression and invasion. 
SOX10 is a transcription factor important for the development of neural crest derived tissues 
and melanocytes (Harris et al., 2010) also seems to play a crucial role in melanoma cell 
proliferation and survival where expression inversely correlates with both tumour thickness 
and disease stage (Agnarsdottir et al., 2010). SOX10 expression also serves as a reliable marker 
melanoma metastases in sentinel lymph node samples (Willis et al., 2015). Moreover, SOX10 
inhibition in melanoma cell lines results in reduced proliferation and increased cell death 
through binding to the Melanoma Inhibitory Activity (MIA) promoter and therefore resulting 
in reduced MIA expression, considered responsible for the invasion-promoting role of SOX10 
(Graf et al., 2014b). Finally, the downregulation of SOX10 has also been associated with 
activation of TGF-b signalling, leading to upregulation of EGFR and platelet-derived growth 
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factor receptor-β (PDGFRB) and the resistance of melanoma cells to the cytotoxic effects of 
BRAF and MEK inhibitors (Sun et al., 2014).  
More recently JARID1B melanoma subpopulations with stem-like properties have been 
identified. JARID1B (KDM5B/PLU-1/RBP2-H1 is a member of the highly conserved family of 
jumonji/ARID1 (JARID1) histone 3 K4 (H3K4) (Roesch et al., 2005) and although JARID1B is 
minimally expressed in normal tissue, in cancer cells it functions as a transcriptional regulator 
of oncogenes (Scibetta et al., 2007; Roesch et al., 2010). Specifically in melanoma, JARID1B, 
has been shown to display increased self-renewal capacity, without having any significant 
effect on tumour initiation. Interestingly, knock-down of JARID1B leads to an initial 
acceleration of tumor growth, suggesting JARID1B-positive subpopulations are crucial for 
tumor growth. Expression of JARID1B however, does not follow a cancer stem cell model as 
JARID1B-negative cells can become positive, and irrespective of selection are tumorigenic 
(Roesch et al., 2010). JARID1B positive cells are also reported to emerge as multidrug tolerant 
cells, for which blockade of the mitochondrial respiratory chain in drug resistant JARID1B 
expressing cells has been shown to overcome intrinsic drug resistance in melanoma (Roesch 
et al., 2013) and collectively suggesting that JARID1B expression in melanoma is possibly more 
associated with drug resistance rather than tumour initiation and is therefore unlikely a true 
cancer stem cell marker.  
Finally CD271 has also been described as a stem cell marker (Boiko et al., 2010a; Cheli et al., 
2014a), the expression of which has also been linked to MEK or BRAF-inhibitor induced 
resistance in melanoma (Ravindran Menon et al., 2014; Gray et al., 2015)  
 
1.3.2 CD271 expression in normal tissue 
CD271 (p75NTR), a member of the tumour necrosis factor (TNF) receptor superfamily is a 
transmembrane protein that binds to the nerve growth factor (NFG) (Johnson et al., 1986) 
which plays a key role in a number of different biological systems, including the immune, 
vascular and nervous systems (Liepinsh et al., 1997a). CD271 has been extensively described 
in the neuroscience literature where variable expression is found throughout normal life but 
whose expression is increased during developmental periods and with dramatic reduction 
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during adulthood (Gall and Isackson, 1989; Chen et al., 2009). Associated with different signal 
transduction pathways including cell survival and apoptosis, CD271 through interaction with 
the TrK (tyrosine receptor kinase) receptor (Lad et al., 2003) results in the enhancement of 
NGF mediated neurite growth and in neuronal cell survival (Lad et al., 2003). Downstream 
mechanisms involved in CD271 signalling in neuronal cells also include extracellular signal-
regulated kinase (ERK), nuclear factor-kappa B (NF-κB) and Jun N-terminal kinase (JNK) (Carter 
et al., 1996; Xue et al., 2000; Yeiser et al., 2004). CD271 acts as a signal transducer to either 
induce or inhibit apoptosis via activation of different signalling pathways ( 
 
Figure 1-12). Upon binding of NGF to CD271 recruited cytoplasmic adaptor proteins recruit 
the tumor necrosis factor receptor member TRAF6 which can in turn activate the inhibitor of 
the kappaB kinase (IKK) and thus the canonical NF-Kb signalling (Khursigara et al., 1999) 
pathway. Alternatively, this interaction can activate c-Jun N-terminal kinase (JNK) 
(Casademunt et al., 1999) which phosphorylates the transcription factor c-Jun which 
subsequently mediates apoptosis by upregulating the expression of pro-apoptotic genes. 
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Figure 1-12: CD271 (p75NTR) can induce or inhibit apoptosis in normal cells 
CD271 can promote cell survival via activation of the NF-kB pathway or promote apoptosis through 
activation of JNK in normal cells. (Adapted from Demir et al (Demir et al., 2016) 
  
P75NTR P75NTR 
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1.3.2 CD271 subpopulations in melanoma 
 
CD271 expressing melanoma cells have been proposed as a tumourigenic and chemo resistant 
subpopulation. Isolation of CD271 +ve and –ve melanoma cells from metastatic patient 
derived tumours and xenotransplantation into T, B, and NK deficient Rag2−/− γc−/− mice (RG) 
mice, results in the engraftment of 70% of CD271+ cells compared to 7% of CD271− ve 
subpopulations (Boiko et al., 2010b). However, other studies highlight the unstable nature of 
CD271 in vitro and the inconsistency in the tumourigenic potential of CD271 positive cells 
(Boyle et al., 2016). In addition, literature has reported the emergence of CD271 +ve 
subpopulations in line with the development of acquired resistance to both targeted therapies 
and standard chemotherapy (Civenni et al., 2011; Ravindran Menon et al., 2014; Redmer et 
al., 2014b). CD271 expression in vivo is also associated with poor melanoma patient survival 
(Beretti et al., 2015). Furthermore, increased CD271 expression is observed in metastatic 
melanoma deposits to the brain (Guo et al., 2014b) indicating that CD271 expression may 
serve not only as a marker of resistance to treatment but also as a predictive biomarker. 
However, recent evidence supports the hypothesis that there are different subpopulations 
within CD271 +ve melanoma expressing cells with different capabilities and tumourigenic 
potential; although there is a transient slow-growing population within CD271 +ve melanoma 
cells that are highly tumorigenic, a fast growing/ CD271 +ve population exhibits poor 
tumorigenic ability (Cheli et al., 2014b). Interestingly, melanoma subpopulations expressing 
CD271 exhibit lower surface expression of melanoma specific antigens such as TYR, MART and 
MAGE (Boiko et al., 2010b) possibly indicating a de-differentiated phenotype and supporting 
the hypothesis that CD271 +ve melanoma subpopulations have a stem-like phenotype. This 
ability of CD271 +ve melanoma subpopulations to down regulate expression of melanoma 
antigens (Furuta et al., 2014) could also  potentially explain the resistance of melanomas to 
immune mediated death using standard and newer immunotherapies (Robert et al., 2015b). 
The fact that the process of autophagy has been reported to be required for the maintenance 
of stem cell and tumourigenicity of breast cancer stem like cells (Gong et al., 2013) suggests 
however that this mechanism may also be key to the survival and chemo resistance of 
melanoma specific subpopulations with stem like properties. 
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1.3.3 Targeting cancer stem cells as a therapeutic approach for cancer therapy 
 
The identification of cancer stem cells has introduced the concept of targeting these specific 
subpopulations to overcome resistance to chemotherapy and targeted therapies. The cancer 
stem cell model comprises an attractive framework to explain acquired resistance through the 
emergence of cancer stem like subpopulations that harness different pathways to escape the 
effects of chemotherapy and targeted agents (Figure 1-13).  
 
Figure 1-13: Mechanisms of survival of cancer stem cells to chemotherapy 
Combination of standard therapy (green) with targeted cancer stem cell therapy targeting specific 
pathways (purple). Taken from Vidal et al (Vidal et al., 2014). 
 
Targeting cancer stem cells has been an attractive research field and two different approaches 
have been adopted; either targeting the cancer stem cells directly or targeting the signalling 
pathways key to the survival of such subpopulations.  
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Targeting cancer stem cell surface markers with either monoclonal antibodies or small 
molecule inhibitors in combination with standard chemotherapy agents has been shown to 
be beneficial in head and neck squamous cell carcinomas (Chen et al., 2017) or prostate cancer 
by targeting CD44 (Liu et al., 2011). Interestingly, targeting signalling pathways crucial to stem 
cell maintenance and survival such as the Wnt pathway (Zhao et al., 2007), Notch pathway 
(Hovinga et al., 2010) or the Hedgehog signalling pathway (Zhao et al., 2009) have also all been 
associated with a reduction in cancer stem cell survival proposing further new avenues for 
combinatorial therapeutic options that may improve current strategies targeting generic 
mechanisms of rapid cell growth and survival. 
However, it is still not clear which approach is likely to be the most beneficial in the clinical 
setting and given melanoma is a very heterogeneous cancer, targeting one subpopulation may 
not be sufficient to overcome acquired resistance that likely equally allows for the emergence 
of other subpopulations expressing differential stem cell surface markers supported by 
differential signalling mechanism, such as autophagy.  
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 Autophagy 
 
Autophagy represents the principal catabolic process for the lysosomal mediated degradation 
and recycling of damaged organelles and excess proteins (Roy and Debnath, 2010) which plays 
a crucial role in the maintenance of cellular homeostasis. To date, three major types of 
autophagy have been described: macro autophagy, micro autophagy and chaperone-
mediated autophagy (Boya et al., 2013). Macro autophagy involves the sequestration of 
unwanted products within cytosolic compartment into double-membrane vesicles with the 
formation of the double-membrane bound phagophore and autophagosome (Feng et al., 
2014), while micro autophagy involves the degradation of unwanted products though flap like 
lysosomal projections and protrusions that facilitate sequestration by direct interlysosomal 
engulfment of cytosolic material (Mijaljica et al., 2011). On the other hand chaperone 
mediated autophagy involves the direct transfer of targeted molecules into the lysosomal 
lumen through a dedicated protein translocation complex and chaperone proteins present on 
either side of the lysosomal membrane (Cuervo and Wong, 2014). Collectively these processes 
function to maintain correct degradation and recycling of damaged organelles and proteins, 
promoting cellular homeostasis and energy. Sensitive to changes in the nutrient environment 
macroautophagy (from here on referred to as autophagy) is activated under situations of 
nutrient or oxidative stress (Figure 1-14). 
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Figure 1-14: Schematic representation of the autophagic process (Professor Penny Lovat) 
Autophagy induction is regulated by mTOR and activation leads to a cascade of events including 
formation of the isolation membrane around cytoplasmic material to be degraded, elongation, 
autophagosome formation, maturation and finally fusion with the lysosome to form an autolysosome. 
This process is regulated by key proteins, protein kinase complexes and conjugation systems: mTOR a 
central regulator of autophagy which is sensitive to changes in nutrient availability, the ULK1/2 and 
beclin-1 complex and the Atg 12-5-16L and LC3 conjugation systems key to the expansion of the 
isolation membrane and the recruitment of proteins and organelles to be degraded. Image supplied 
by Professor Penny Lovat 
 
Activation initiates a cascade of events  characterized by an induction phase involving the 
development of a double isolation membrane or phagophore, followed by maturation of the 
autophagosome containing cytoplasmic material to be degraded and finally  completion of the 
process characterized by fusion of the autophagosome with a lysosome and the lysosomal 
degradation/recycling of cytoplasmic material (Tooze and Yoshimori, 2010). 
 
1.4.1 Autophagy regulation  
 
A number of signalling pathways are involved in the regulation and induction of autophagy. 
Primarily, autophagy induction is regulated through the mammalian target of rapamycin 
complex 1 (mTORC1) which coordinates the activation of a cascade of key complexes and 
events (Jung et al., 2009). Upon autophagy induction, the activation of the ULK1/2 complex 
mediates the initial nucleation phase followed by activation of the Beclin-1 complex 
(comprising Beclin-1/Atg 6, Ambra-1 and Vps34) controlled by Vps34, a class III PI3 kinase 
mTOR 
p62 
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leading to the formation of a pre-autophagosomal structure. The elongation of the isolation 
membrane is regulated by the Atg12-Atg5 complex then recruits additional membranes (Kuma 
et al., 2002) by further interacting with ATG16L in order to expand the isolation membrane. 
Once the autophagosome has been formed, these autophagy regulatory proteins are released 
back to the cytoplasm (Mizushima et al., 1999) with the lipidation of LC3 (Atg8) (Ichimura et 
al., 2000) enabling the recruitment of proteins and organelles to the growing autophagosome 
(Burman and Ktistakis, 2010). The final maturation step is regulated by the Vps34/ Beclin-1/ 
UV irradiation resistance-associated gene (UVRAG) complex (Itakura et al., 2008), allowing the 
fusion of the autophagosome with a lysosome, forming the autolysosome and allowing the 
enzymatic degradation of the cytosolic content. Key events associated with autophagy 
induction include the degradation of p62 (also known as sequestosome-1/SQSTM1). P62 is a 
multidomain adaptor protein which interacts with both ubiquitinated proteins and LC3, 
allowing for its inclusion within the autophagosome (Moscat and Diaz-Meco, 2009), followed 
by its degradation after formation of the autophagolysosome. 
 
1.4.2 Autophagy and cancer 
 
The role of autophagy in cancer is complex. While the removal of unwanted organelles and 
proteins is key to the prevention of tumourigenesis, the accumulation of damaged organelles 
or excess proteins is genotoxic thereby promoting tumourigenesis. So although autophagy is 
predominately accepted as a survival mechanism, in the context of cancer, autophagy can 
both suppress and drive tumourigenesis; the so called “autophagy paradox” (White et al., 
2010). Several studies have shown autophagy to be impaired or inhibited in cancer, mediated 
for example by loss of beclin-1 expression which has been described in the context of a 
number of human cancers (Ahn et al., 2007; Cai et al., 2014; Rohatgi et al., 2015). Supporting 
autophagy deregulation in cancer, specific studies of Beclin 1 loss have shown knockdown in 
murine models increases tumourogenicity (Qu et al., 2003) whereas Beclin 1 overexpression 
prevents tumour development (Liang et al., 1999).  However, paradoxically autophagy may 
also aid and promote tumour survival at later disease stages through the recycling of cellular 
components to produce essential nutrients and sustain cellular energy (Ma et al., 2011; 
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Sandilands et al., 2012) collectively indicating that deregulated autophagy leads to tumour 
development, whereas in already established cancers autophagy provides an important 
source of energy though the recycling of cellular components to maintain and promote 
tumour survival in times of nutrient stress. 
AMPK is a major cellular energy sensor activated by ATP and nutrient depletion to maintain 
energy homeostasis, directly activates autophagy (Hardie, 2011) and has been shown to be a 
key event in autophagy m52- ediated survival of lung (William et al., 2012) and colorectal 
(Baba et al., 2010). There is also increasing evidence in the literature to suggest AMPK 
activated by glucose starvation or ATP depletion to sustain the metabolic and energetic 
cellular demands in the micro environment may provide the link to the activation of 
autophagy (Cantó et al., 2009) though inactivation of m-TORCH1 (Hardie, 2011) or direct 
phosphorylation of ULK1 (Kim et al., 2011a). 
Accumulating evidence suggests that autophagy is also deregulated in melanoma. 
Immunohistochemical expression of LC3-II is increased in malignant melanoma compared to 
benign naevi (Lazova et al., 2010; Lazova et al., 2012). Further evidence also suggests that the 
down regulation of ATG5 contributes to melanomagenesis (Liu et al., 2013b), while down 
regulation of ATG6/Beclin-1 has been associated with melanoma progression (Sivridis et al., 
2011). More recently, the immunohistochemical expression of p62 also appears to reflect the 
paradoxical role of autophagy in melanoma where increased expression was consistent with 
autophagy being blocked in early stage disease, while its reduction in late stage disease was 
consistent with autophagy reactivation (Ellis et al., 2014b). 
 
1.4.3 Autophagy and stem-like cells 
 
Stem cells have several capabilities including self-renewal, longevity and differentiation. These 
processes require a strict regulation of cellular homeostasis and remodelling and there is 
accumulating evidence that autophagy plays a crucial role in stem cell survival. The role of 
autophagy in embryonic stem cells has been investigated in detail and is essential for the very 
early stages of embryogenesis. Knockdown of ATG5 in fertilized oocytes results in their failure 
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to divide beyond the 4- to 8-cell stages if fertilized by Atg5-null sperm, and therefore failure 
to undergo more advanced stages of the differentiation processes (Tsukamoto et al., 2008). 
Autophagy seems to also play a role in differentiation and pluripotency of haematopoietic 
stem cells (Orford and Scadden, 2008) and neuronal stem cells (Zhang et al., 2008) . 
Interestingly, autophagy also seems to play a crucial role in the maintenance and survival of 
cancer stem-like cells (CSC). CSCs consist of specific subpopulation of cancer cells that may 
exhibit some characteristics of stem cells, being capable of self-renewal and differentiation 
that is responsible for the heterogeneity in bulk tumours (Magee et al., 2012). The effects of 
autophagy in cancer stem-like cells may be related to characteristic micro environmental 
factors affecting the growth and development of cancer cells and which include hypoxia and 
nutrient deprivation. The ability of certain subpopulations within tumours to survive under 
these micro environmental stresses may lead to specific expansion of CSC subpopulations in 
favour of non-CSC tumour cells. This theory is supported by evidence suggesting that 
inhibition of autophagy with the lysosomal inhibitor chloroquine is sufficient to suppress the 
development of breast cancer stem like cell spheroid formation and ex vivo invasion into 
autologous breast stroma (Espina and Liotta, 2011) indicating that subpopulations of cancer 
stem-like cells lose their ability to survive upon inhibition of autophagy. In addition, autophagy 
seems to play a crucial role in the tumourigenicity of breast cancer stem like cells (Gong et al., 
2013) and invasion in glioblastoma stem like cells (Galavotti et al., 2013). 
Finally, autophagy plays a role not only in the maintenance and invasion of stem like cells but 
also contributes to chemo resistance in certain tumour types. During chemotherapy, cancer 
cell clones are subjected to stressful environmental factors allowing the survival of only some 
cell populations. As described above, autophagy seems to be an important mechanism in the 
ability of selected cell clones to evade the effects of chemotherapeutic and targeted agents, 
making autophagy inhibition an attractive therapeutic strategy to potentiate the effects of 
chemotherapy. To this aim, combination treatments of standard therapies with lysosomal 
inhibitors like chloroquine, able to indirectly inhibit autophagy have shown considerable 
promise for a number of tumours including hepatocellular cancer (Guo et al., 2012), 
pancreatic cancer (Yang et al., 2011), breast cancer (Zarzynska, 2014) and CML (Yu et al., 2012) 
as well as melanoma (Amaravadi et al., 2011; Molenaar et al., 2017).  
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1.4.4 Targeting autophagy in cancer therapy 
 
Given the pivotal role of autophagy in resistance to chemotherapy and targeted therapies, there is 
increasing evidence to support the targeting of autophagy to enhance therapeutic response to 
cytotoxic agents. Chloroquine and hydroxychloroquine have been used to treat malaria for many 
years before the effects on autophagy were fully established. Chloroquine acts via inhibiting 
lysosome acidification, therefore blocking the late stages of autophagy (Geng et al., 2010) wit 
it use documented in a number of clinical trials in combination with chemotherapy to 
overcome acquired drug resistance (Schmukler et al., 2014), including in combination with 5-
fluouracil in gallbladder carcinomas (Liang et al., 2014), erlotinib in non-small cell lung cancer 
(Zou et al., 2013) or imatinib ( a TKI) in the case of chronic myeloid leukaemia (Bellodi et al., 
2009). Inhibition of autophagy has also been shown to be beneficial in combination with 
radiation therapy. In gliomas, glioma stem-like cells expressing CD133 associated with 
resistance to radiation therapy demonstrate higher levels of autophagic activity (Lomonaco et 
al., 2009), where combined autophagy inhibition revealed  more extensive DNA double-strand 
breaks in such radio- resistant sub populations compared to cells that have been treated with 
radiation therapy alone (Ito H, 2005). Similarly, blocking autophagy in vitro with 3MA, which 
blocks the formation of the autophagosome (Wu et al., 2010), or genetically using an siRNA 
approach results in radio sensitization of a number of human cancer cell lines (Apel et al., 
2008). However, chloroquine is not a specific autophagy inhibitor, leading to the recent 
development of more specific inhibitors including those targeting the Vps34 complex, 
currently in clinical trials in combination with mTOR inhibitors for patients with renal cell 
carcinoma (Pasquier, 2015). 
Interestingly, although autophagy inhibition may increase the efficacy of cytotoxic agents, the 
induction of cytotoxic autophagy represents a promising alternative (Josset et al., 2013; Ren 
et al., 2013), including the use of cannabinoids such as D(9)-tetrahydrocannabinol (THC), 
recently shown to promote autophagy mediated apoptosis in melanoma in vitro and in in vivo 
melanoma mouse models (Salazar et al., 2009; Armstrong et al., 2015b; Giglio et al., 2015; 
Velasco et al., 2016b). THC derived from Cannabis sativa exerts a variety of biological effects 
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by mimicking endogenous substances, the endocannabinoids, which function via activation of 
the cannabinoid receptors CB1 and CB2 (Howlett et al., 2002), the engagement of which leads 
to  a cascade of events including the induction of pro-apoptotic sphingolipid ceramide and 
reduced tumour cell proliferation in vitro (Velasco et al., 2016b). Clinical trials of THC have also 
shown promising results in advanced glioma (Guzmán et al., 2006), while in melanoma, pre-
clinical data suggest that THC equally promotes autophagy mediated apoptosis  (Armstrong 
et al., 2015b), further supporting the concept of harnessing autophagy exacerbation with THC 
might as a viable therapeutic option for patients with advanced cancer.  
 Models of melanoma metastasis 
 
1.5.1 Murine models for melanoma metastasis 
 
Molecular heterogeneity in human melanoma has impaired efforts to efficiency and 
consistently target melanoma cells and improve patient survival. Although clinical 
characteristics of melanoma provide an indication for the identification of high risk individuals, 
many of the mechanisms mediating tumour initiation, progression and metastasis remain 
unknown. While molecularly targeted therapies show great promise for melanoma patients, 
the development of acquired resistance has highlighted the need for more efficacious 
treatment strategies. To evaluate the effect of such treatment approaches, establishing 
accurate animal models that recapitulate human cutaneous melanoma progression is of 
crucial importance. To further reinforce findings deriving from in vitro data, in vivo models 
have been developed to provide clinically relevant information about tumour dissemination 
and metastasis as well as efficacy of treatments for localised and metastatic disease. In 
melanoma research, murine models have been extensively used to model metastasis and 
assess response to different agents. However, murine models of metastatic melanoma require 
the recipient’s innate immune system to be severely compromised. The most commonly used 
murine model for melanoma metastasis is the nude, NOD (non-obese diabetic), SCID (severe 
combined immunodeficiency) and RAG (recombination activating gene) strains, which 
harbour single or multiple genetic mutations and exhibit varying degrees of innate and 
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adaptive immune deficiencies (Kuzu et al., 2015). However, the use of these models are 
limited by a low metastatic burden and the fact that this degree of immunodeficiency is not a 
true representation of the human immune system (Vandamme, 2014). Thus, there is an urgent 
need for the development of effective and efficient in vivo model systems that recapitulate 
human melanomas so that improve our understanding of the biology of melanoma.  
 
1.5.2 Zebrafish model for melanoma metastasis 
 
As a result, to address the need for clinically relevant in vivo models that better recapitulate 
the metastatic process, alternative in vivo models have been developed including the use of a 
zebrafish model of metastasis. The use of an in vivo zebrafish model of metastasis has the 
advantage of small number of cells required for transplantation, easy tracking of transplanted 
cells because of the transparency of zebrafish embryos allows for real-time observation of the 
migration of tumour cells and formation of secondary metastatic deposits as well as the 
possibility to perform large scale experiments with high reproducibility (Marques et al., 2009; 
Eguiara et al., 2011; Zhao et al., 2011). As a result, zebrafish models have become increasingly 
popular in cancer research. Zebrafish models have been used to model a number human 
cancers including haematological malignancies (Langenau et al., 2003) and solid tumours such 
as melanoma (Dovey et al., 2009) or rhabdomyosarcoma (Ignatius et al., 2012). Future 
directions in the zebrafish field include the simultaneous manipulation of a number of genes 
which can contribute to cancer heterogeneity by using sophisticated gene editing techniques 
such as Crisp/Cas9 which would allow for the assessment of hundreds of candidate genes 
which cannot be achieved in mouse models (Jao et al., 2013). Additionally, zebrafish can allow 
for large scale chemical screening and also allow for the more accurate recapitulation of 
cancer metastasis. Finally zebrafish can be used to study the epigenetic contribution to cancer 
development and metastasis by rapid large-scale trans-genesis which will be a key method to 
determine the temporal dynamics of such changes, which will differ from purely genetic 
changes seen in many tumour types(Ceol etal.,2011) 
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 Hypothesis, aims and objectives  
 
Given the evidence for the presence of CD271 expressing sub-populations and their 
contribution to melanoma survival or the emergence of CD271 expressing sub populations as 
a potential key mechanism mediating the resistance of NRAS/BRAF mutant melanoma to 
BRAF/MEK inhibitor therapy and the likely contribution of key survival signalling mechanisms 
such as autophagy, this leads to the central hypothesis of the present thesis that:  
 
Autophagy plays a crucial role in the survival and invasion of CD271 expressing melanoma 
subpopulations and the promotion of tumour progression. 
 
To test this hypothesis the principle objectives were to  
• Define the association between constitutive CD271 expression by melanoma cells and 
autophagy 
• Define the association between MEK inhibitor-induced CD271 expression in drug 
resistant melanoma subpopulations and autophagy 
• Evaluate potential therapeutic approaches to inhibit CD271 or autophagy as a means 
through which to re-sensitize BRAF mutant melanoma to the cytotoxic effects of 
trametinib. 
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Chapter 2 Materials and Methods 
 Cohort of primary cutaneous melanomas and metastatic lymph 
nodes 
 
Full ethical permission for the use of patient tissue in these studies, including benign naevi, 
primary cutaneous melanomas or metastatic lymph nodes was obtained from Newcastle and 
Tyneside 1 research ethics committee (reference: NRES 08/H0906/95+5_Lovat). 
A retrospective cohort of 22 formalin-fixed paraffin-embedded (FFPE) malignant melanomas 
of eventual American Joint Committee on Cancer (AJCC) stage I, II or III at the time of analysis 
and 5 benign naevi were obtained from the Histopathology department at the Royal Victoria 
Infirmary, Newcastle upon Tyne.  
A second cohort of 9 formalin-fixed paraffin-embedded (FFPE) primary cutaneous melanomas 
and patient matched FFPE metastatic lymph nodes (7 matched eventual AJCC stage III 
melanomas and patient matched lymph node melanoma metastases), or 2 normal lymph 
nodes (used for experimental purposes as controls) was obtained in collaboration with Mr 
Jong Kim (department of Plastic surgery, University Hospital of North Durham), and Dr Paul 
Barrett (Department of Pathology, University Hospital of North Durham, Durham, UK) from 
the histopathology department at the University Hospital of North Durham.  
A third cohort of 11 formalin-fixed paraffin-embedded (FFPE) metastatic melanoma lymph 
nodes was also obtained from the Histopathology department at the Royal Victoria Infirmary, 
Newcastle upon Tyne. 
 Growth and Maintenance of Human Cutaneous Melanoma Cell 
Lines, genetically modified melanoma cell lines and melanocytes  
 
Cutaneous human metastatic cell lines WM35 (a generous gift from Professor Meenhard 
Herlyn, The Wistar Institute, Philadelphia, USA), A375 (American Type Culture Collection 
(ATCC), Manassas, USA), SK-mel-28, (ATCC) WM164 (ATCC) (all B-RAF V600E mutant), 
WM266-4 (ATCC) (BRAFV600D mutant), SK-mel-23, CHL-1, C8161 (a generous gift from Professor 
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Meenhard Herlyn, The Wistar Institute, Philadelphia, USA), Mel 505 (ATCC) (BRAF Wild Type) 
and WM-1361 (NRAS mutant) were grown and maintained in Dulbecco’s modified Eagles 
Medium (DMEM, Lonza, Vervies, Belgium) supplemented with 10% foetal calf serum (FCS, 
Sigma, St Louis, U.S.A) and 5% penicillin streptomycin (P/S, Lonza, Vervies, Belgium) (complete 
media) at 37oC in a humidified atmosphere of 5% CO2 in air. Cell line mutational status 
information was obtained from the ATCC website and the Wistar Institute. A summary table 
of all known mutation is presented in Table 1 ( 
Table 2-1).  All cell lines were cultured for up to a maximum of 50 passages (at which point 
fresh cells were taken from frozen stocks stored in 90% FCS/10% DMSO in liquid N2) and 
passaged by detaching cells with trypsin/EDTA (Lonza, Vervies, Belgium) as previously 
described (Armstrong et al., 2015a). Cell lines were used at approximately 70% confluency for 
all experimental procedures. The authentication of all cell lines was verified by the assessment 
of BRAF and NRAS mutational status using  commercial Single Nucleotide Polymorphism (SNP) 
genotyping assays  (TaqMan SNP genotyping assays, Applera, Europe BV, UK) for the presence 
of the most frequent mutations observed in melanomas;  NRASG61L, NRASG61A, BRAFV600E or 
BRafV600D mutation as previously described (Hiscutt et al., 2010). In addition, to confirm  
melanocytic lineage, all cell lines were evaluated for the expression (using 
immunofluorescence or western blot analysis) of the melanocyte differentiation marker 
Melan A, again as previously described  (Hiscutt et al., 2010). Experiments using BRAF or MEK 
inhibitor treatment of melanoma cells were performed in BRAF mutant cell lines (A375, 
WM35, SK-mel-28 or WM266-4). 
Genetically modified human cutaneous melanoma cell lines (all previously modified in the 
Lovat lab or modified as part of the current study as described below); WM266-4 RFP-GFP-
LC3B, A375 histone 2B RFP, WM35 histone 2B RFP, A375 stably overexpressing CD271 or 
WM35 stably overexpressing CD271, were grown and maintained using Dulbecco’s modified 
Eagles Medium supplemented with 10% foetal calf serum and 5% penicillin streptomycin, at 
37oC in a humidified atmosphere of 5% CO2 in air, again for up to a maximum of 50 passages.  
Human primary melanocytes were derived from redundant foreskin supplied by the 
Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK and processed and 
supplied by colleagues in dermatological sciences, Institute of Cellular Medicine, Newcastle 
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University as previously described (PhD thesis Dr Ashleigh McConnell 2016). Full ethical 
permission for the use of surplus human skin tissue was obtained (NRES, Newcastle and 
Tyneside 1 REC reference 08/H0906/95). Isolated primary melanocytes were subsequently 
grown and maintained in melanocyte 254 medium (Life Technologies, Paisley, U.K), 
supplemented with human melanocyte growth supplement (Life Technologies, Paisley, U.K) 
containing  bovine pituitary extract (BPE) (0.2% v/v), fetal bovine serum (0.5% v/v), 
recombinant human insulin-like growth factor-I (1 µg/ml), bovine transferrin (5 µg/ml)basic 
fibroblast growth factor (3 ng/ml),Hydrocortisone (0.18 µg/ml) and Heparin (3 µg/ml) Phorbol 
12-myristate 13-acetate (PMA) (10 ng/ml), for up to a maximum of 5 passages before being 
used either for experimental purposes or stored for future use in 90% FCS (Sigma) and 10% 
Dimethyl sulfoxide (DMSO) in a liquid nitrogen storage facility. 
 
Table 2-1: Summary of all known mutations in melanoma cell lines used  
Summary of the most common mutations found in melanoma cell lines for all cell lines used in this 
Thesis. Information obtained from the ATCC website and The Wistar’s institute website. 
 
 Chemical and Drug treatment of Cutaneous Melanoma Cell lines 
in vitro 
 
PLX4720 (Plexxikon Inc., Berkeley, U.S.A) is a selective small molecule inhibitor of BRAFV600E 
which selectively blocks the ATP-binding site of oncogenic B-RAFV600E (Sievert et al., 2013). 
PLX4720 was diluted to a stock concentration of in 10 mM in DMSO and stored at -20oC with 
further dilution in culture media to given final concentrations for treatment of melanoma cells 
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in vitro at given time periods. For experiments in which melanoma cells were treated for 9 
days with 3 μM of PLX4720, the media was changed every 3 days, each time replacing with 
fresh media containing 3 μM of PLX4720 prior to the assessment of cell viability or effect on 
differential protein expression by Western Blotting.  
Trametinib (GSK 112021B, GSK, Brentford, UK) is a reversible, allosteric inhibitor of mitogen-
activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation (Borthakur et al., 
2016). Trametinib was dissolved in DMSO at a concentration of 10 mM and stored in aliquots 
at -80°C, prior to further dilution in cell culture medium and use at final concentrations of 16 
or 32 nM to treat melanoma cells in vitro for 3, 6, 9, 12, 24 or 42 days. For experimental 
procedures exceeding 3 days, the media was replaced every subsequent 3 days, with fresh 
complete media containing the appropriate given concentration of trametinib. For in vivo 
experiments in a zebra fish xenograft of human metastatic melanoma, trametinib was added 
directly to the water environment (E3 media) in which fish were maintained in a final 
concentration of 16 nM at 33oC  in an atmosphere of 5% O2, 5% CO2 for 72 hours.  
Chloroquine (CQ, Sigma-Aldrich, Poole, UK) a lysosomal inhibitor, was diluted to a stock 
concentration of 10 mM in distilled water, filter sterilized and stored at room temperature 
protected from light. Chloroquine was added to melanoma cell cultures at a final 
concentration of 10 μM, either continuously for 24/48 hours to cultures pre-exposed to 
trametinib or PLX4720 for up to 9-days and prior to the assessment of cell viability or 
clonogenic potential or for the final 2 hours of given experiments prior to the assessment of 
LC3 I-II autophagic flux by western blotting.  
Vps34 inhibitor PIK-III (Stratech, Suffolk, UK) is a selective inhibitor of  VPS34 that inhibits 
autophagy and de novo lipidation of LC3 binding to that binds a unique hydrophobic pocket 
not present in related kinases such as PI (3)Kα (Dowdle et al., 2014). PIK-III was dissolved in 
DMSO to stock concentrations of 10 mM and stored at -20oC. For experimental purposes PIK-
III was further diluted in complete culture media and used to treat melanoma cells in vitro at 
final concentrations of 1, 5 or 10 μM for 24 or 48 hours. For in vivo experiments in a zebra fish 
xenograft of human metastatic melanoma, PIK III was added directly to the water environment 
(E3 media) in which fish were maintained at a final concentration of 5 μM at 33oC  in an 
atmosphere of 5% O2, 5% CO2 for 72 hours.  
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Tetrahydrocannabinol (THC) (kindly supplied by Dr Guillermo Velasco, Complutense University 
of  Madrid, Spain) was dissolved in DMSO to a final concentration of 100 mM and stored at -
20oC. THC was added to melanoma cell cultures in vitro at final concentrations of 4.5 or 5 μM 
in low serum (0.5% FCS) DMEM for 24 hours  as previously described (Armstrong et al., 2015b) 
before analysis of effects on cell proliferation or protein expression by western blotting. 
The CD271 inhibitor TAT-PEP5 (Merk Millipore, Massachusetts, USA) is a small molecule 
inhibitor which inhibits the interaction of p75NTR with Rho-GDI in vitro. TAT-PEP5 was 
dissolved in DMSO and stock concentrations of 1 mM, stored in -80oC. For treatment of 
melanoma cells, TAT-PEP5 was further diluted in complete DMEM culture medium and added 
to cultures at final concentrations of 0.01, 0.1,1,5 or 10 μM for 72 hours.  
The CD271 inhibitor, Ro 08-2750 (Tocris Bioscience, Bristol, UK) is a small molecule which 
inhibits the binding of NGF to p75NTR (Niederhauser et al., 2000). Ro 08-2750 was dissolved 
in DMSO to stock concentrations of 10 mM and stored at -20oC before being subsequently 
further diluted into fresh media to a final concentration of 1, 5 or 10 μM for 72 hours.  
Recombinant human Nerve growth factor b (b-NGF, Peprotech, New Jersey, USA) is a 
neurotrophic factor that plays a crucial role in the development and preservation of nervous 
system (Söderström et al., 1990), used in the present studies to investigate the contribution 
of exogenous NGF in trametinib-induced CD271 expressing melanoma subpopulation 
proliferation and invasive potential. NGF was reconstituted in filter sterilized 0.1% Bovine 
Serum Albumin (BSA, Alpha Diagnostic, Texas, USA) to a concentration of 200 μg/ml and 
stored at -20oC . For experimental treatment purposes, NGF stock solutions were further 
diluted in complete culture media and added to melanoma cell cultures at final concentrations 
of 0.01 ng/ml- 1mg/ml for 72 hours.  
Dorsomorphin (Dorsomorphin (Compound C), Stratech Scientific Limited, Newmarket, Suffolk, 
UK), a potent, reversible, selective AMPK inhibitor (Dai et al., 2013) was dissolved in DMSO to 
stock concentrations of 5 mM and stored at -80oC. Compound C was subsequently diluted in 
complete culture medium and added to melanoma cell cultures at final concentrations of 5 
μM for given incubation times. 
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 Isolation of CD271+ve and –ve subpopulations using M. Biotec 
magnetic columns 
 
CD271 positive and negative subpopulations were isolated from 1×107 primary WM35 or 
metastatic A375 or SK-Mel-28 melanoma cells using M. Biotec magnetic columns (Miltenyi 
Biotec Ltd, Auburn, USA). Fresh wash/suspension buffer, (2 mM Ethylenediaminetetraacetic 
acid (EDTA), 0.5% Bovine serum albumin (BSA) in PBS) was prepared for each separation and 
kept on ice for the duration of the experiment. Following centrifugation of melanoma cells at 
310 g for 5 minutes at room temperature and aspiration of the cell supernatant, cell pellets 
were resuspended in 10mls of sterile PBS in a biosafety cabinet and passed through a 30 μm 
CellTrics mesh (Miltenyi Biotec Pre-Separation Filters) to achieve a single cell suspension. Cells 
were then centrifuged again for 5 minutes at 310 g before re-suspension in 80 μl of fresh ice-
cold wash/resuspension buffer containing 10 μl of human FcR blocking reagent (Miltenyi 
Biotec Ltd). 10 μl of CD271-PE antibody (Miltenyi Biotec Ltd) was then added to the suspension 
prior to incubation for 10 minutes at 4°C. 1 ml of fresh wash/resuspension ice-cold buffer was 
subsequently added to each cell suspension before further centrifugation at 310 g or 5 
minutes, re-suspension in 70 μl of fresh ice-cold buffer and the addition of 10 μl of FcR blocking 
reagent and 20 μl of anti-PE microbeads (Miltenyi Biotec, Auburn, USA). The cell suspension 
was then incubated for another 15 minutes at 4°C before 1 ml of fresh ice-cold wash/re-
suspension buffer was added to the suspension and further centrifugation at 310 g for 5 
minutes. A separation magnet (MiniMACS Separator Miltenyi Biotec) was assembled in a 
biosafety cabinet and magnetic separation columns (MS Columns Miltenyi Biotec) attached to 
the magnetic stand. Magnetic columns were pre-prepared by application of 500 μl of fresh 
ice-cold wash/re-suspension buffer, allowed to pass through the magnet into a 15 ml falcon 
centrifugation/ test tube (SuperClear™ Ultra-High Performance Centrifuge Tube, VWR 
International LLC, Radnor, USA) which was then discarded. The cell suspension was then 
added directly to the magnetic column and CD271 –ve subpopulations collected into a fresh 
15 ml falcon tube with 3×500 μl of fresh ice-cold wash/resuspension buffer. Following removal 
of the magnetic column CD271 positive subpopulations were finally eluted with 1ml of fresh 
buffer with the application of a column plunger to expel CD271 +ve cells into a fresh 15 ml 
falcon centrifuge tube. At the end of the process, parental or isolated CD271 +ve or -ve cells 
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were used directly or following culture for 3-9 days in complete DMEM, to derive cell lysates 
for Western Blotting, or fresh cell pellets were processed by the Histopathology department 
at the Royal Victoria Infirmary to derive formalin fixed and paraffin embedded cell blocks. 
 
 Flow Cytometry 
2.5.1 Flow cytometry of Annexin V or Propidum Iodide (PI) labelled melanoma 
cells as a measure of apoptosis 
 
The induction of apoptosis was confirmed using an Annexin V- Fluoroscein (FITC)/ Propidium 
iodide (PI) detection kit (ab14085, Abcam, Cambridge, UK). Upon initiation of apoptosis, 
phosphatidylserine translocates from the cell plasma membrane to the cell surface. 
Fluorescent antibodies to Annexin V can selectively conjugate to phosphatidylserine thereby 
allowing the quantification of the levels of apoptosis (Logue et al., 2009). Counter staining 
with propidium iodide (PI, which binds to the fragmented DNA of apoptotic cells (Riccardi and 
Nicoletti, 2006) was performed to detect the number of viable cells.  
A375 cells were seeded at a density of 2×105 well in tissue culture grade flat bottomed 6 well 
plates (Corning Incorporated, New York, USA) in a final volume of 3 mls of complete culture 
medium (DMEM/10% FCS/1%P/S) and allowed to attach overnight at 37oC. The media was 
subsequently aspirated and replaced with either fresh complete culture media or media 
containing 16 nM trametinib and incubation continued for 3, 6, 9, 14, 28 or 42 days. Cells were 
then detached with trypsin/EDTA (as described in section 2.2) before centrifugation at 310 g 
for 5 minutes,  followed by a washing step in 1 ml PBS and further centrifugation at 310 g for 
another 5 minutes. The supernatant was then aspirated and the cell pellet resuspended in 500 
µl of 1 × Binding buffer from the Annexin V/PI kit with the addition of 5 µl Annexin V-FITC and 
5 μl of propidium iodide prior to continued incubation at room temperature for 5 minutes in 
the dark. Annexin V binding and PI staining were detected using a FACS-Canto II (8 Colour) 
flow cytometer (BD biosciences, San Jose, USA) and data analysed using FlowJo analysis 
software for flow cytometry (FlowJo, Ashland, Oregon, USA). Viable cells with intact cell 
membrane are impermeable to PI whereas dead and dying cells are permeable to PI. 
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Therefore viable cells are both Annexin V and PI negative, whereas early apoptotic cells are 
Annexin V positive and PI negative and dead cells are both Annexin V and PI positive.  
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2.5.2 Flow cytometry sorting of melanoma cells overexpressing red fluorescent 
protein (RFP) 
 
A375 and WM35 cells were stably transfected to express Histone H2B monomeric red 
fluorescent protein or RFP tagged CD271 as described in section 2.10. Transfected cells were 
cultured in complete DMEM in the presence of G418 at a concentration of 500 µg/ml to 
maintain selection of transfected cells. Following detachment with trypsin/EDTA, 1×106 cells 
were pelleted by centrifugation at 310 g for 5 minutes followed by washing in 1 ml PBS and 
further centrifugation at 310 g for 5 minutes. Cells were then resuspended in 1 ml FCS and 
passed through a 30 μm CellTrics mesh (Miltenyi Biotec Pre-Separation Filters) to achieve a 
single cell suspension before transfer to a FACS round bottom tube and incubation on ice prior 
to sorting RFP positive cells using a FACS-Aria (BD biosciences, San Jose, USA) flow sorting flow 
cytometer with the help of Dr Andrew Filby (Flow Cytometry Core Facility, Institute of Cellular 
Medicine, Newcastle University). Auto fluorescence was compensated for using untransfected 
WM35 or A375 cells respectively. Flow sorted RFP expressing cells were collected into a sterile 
tube and then returned to culture in complete DMEM for given time periods. 
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 Real time reverse transcriptase polymerase chain reaction (qPCR) 
 
qPCR was used to quantify CD271 mRNA expression in primary melanocytes, human 
metastatic cutaneous melanoma cell lines WM35, A375, WM266-4, SK-mel-28, WM164, SK-
mel-23, CHL-1, C8161, WM-1361 and Mel 505. qPCR was also used to verify siRNA mediated 
knockdown of CD271 in WM35 human metastatic melanoma cells. All cell lines were seeded 
at a density of 2x105 cells per well in 3 mls of complete DMEM per well, in 6 well flat bottom 
cell culture plates for 24 hours. Cells were then washed with ice cold PBS prior to RNA 
extraction using a ReliaPrep™ RNA Cell Miniprep System (Promega, Madison, Wisconsin, 
U.S.A) as per the manufacturer’s instructions. The extracted RNA was quantified using a 
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific, Waltham, USA) and stored at 
-80oC. mRNA was then converted to single-stranded cDNA using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Vilnius, Lithuania) as per manufacturer’s instructions 
(Table 2-2).  Transcription reactions in a total volume of 20 µl/sample were subsequently 
subjected to reverse transcription using a Gene Amp PCR system 9700 thermal cycler (Applied 
Biosystems, California, USA) with cycles of 10 minutes at 25 oC, 120 minutes at 37 oC, 5 minutes 
at 85 oC then 4 oC ∞). cDNA was then stored at 4 oC for short term periods of up to two weeks 
or at -20 oC for longer term storage. 
Table 2-2: Constituents of a Single Reverse Transcription Reaction 
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Following cDNA conversion, qPCR was then performed to determine the relative expression 
levels of CD271 mRNA, relative to 18s mRNA, used as a house keeping control. PCR reaction 
mixes were prepared using TaqMan Universal PCR Master Mix (Applied Biosystems, 
Warrington, UK), and pre-designed Gene Expression Assays for CD271 (NGFR human 
Hs00609976_m1, TaqMan, ThermoFischer Sienctific, Waltham, USA) (Table 2-3) or 18s as a 
housekeeping control gene (Integrated DNA Technologies, Leuven, Belgium) ( 
Table 2-4). 
 
Table 2-3: Constituents of a single PCR reaction using CD271 (NGFR) TaqMan® Gene 
Expression Assay 
 
 
Table 2-4: Constituents of a single PCR reaction using 18s TaqMan® Gene Expression Assay 
 
2 µl cDNA was added to 8 µl of PCR reaction mix in each well of a 96 well MicroAmp Fast 
Optical Reaction Plate (Applied Biosystems, California, USA). All samples were added in 
duplicate including a non-template control (H2O only). Plates were then sealed with optical 
film and centrifuged at 161G for 30 seconds before qPCR analysis using a StepOne Plus Real-
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Time PCR instrument (Applied Biosytems, California USA) with 40 cycles of: 2 minutes at 50oC 
hold, 10 minutes at 95oC hold, 15 seconds at 95oC denature, and 1 minute 60oC anneal/extend. 
mRNA expression analysis was performed using the StepOne Soft wear V2.3 (Applied 
Biosystems, California, U.S.A). Data analysis was performed using a comparative CT method 
(2−ΔΔCT) as previously described (Schmittgen and Livak, 2008). 
 
 Immunohistochemistry for CD271 and p62 expression in Formalin 
Fixed Paraffin Embedded melanoma cell pellets and primary 
melanoma tissue  
 
5 µM formalin fixed and paraffin embedded tissue sections derived from cell pellets of human 
primary cutaneous melanoma cell line WM35 cultured in the presence or absence of 16 nM 
Trametinib for 9 days were used to optimise the immunohistochemical expression of CD271 
according to standard methodology (Ellis et al., 2014c). Optimal antigen retrieval (10 mM Tris-
HCl (pH 9) and primary antibody concentrations (1:50 in PBS/2%BSA) were pre-determined 
and then used to determine semi quantitative expression of CD271 in a cohort of 47 FFPE 
primary naevi/melanomas (5 benign naevi, 5 AJCC stage I, 16 AJCC stage II, 9 AJCC stage III and 
patient matched metastatic melanoma lymph nodes and an additional cohort of 12 metastatic 
melanoma lymph nodes) and correlation with autophagy status as determined by IHC of p62 
expression as previously described (Ellis et al., 2014d).  
5 µm FFPE sections were initially baked onto X-tra microscope slides (Leica Microsystems, 
Milton Keynes, UK) at 60°C overnight. Sections were then de-paraffinised in Histo-Clear (Fisher 
Scientific, Loughborough, UK) for 20 minutes at room temperature before dehydration 
through 100%, 75%, and 50% ethanol and washing in distilled water, each for 5 seconds. To 
optimise antigen retrieval, sections were immersed in 10 mM Tris-HCl (pH 7.6), 10 mM Tris-
HCl (pH 9) or 10 mM Sodium Citrate (pH 6) pre-heated in a microwave at full power for 12 
minutes before being allowed to cool for 20 minutes at room temperature. Tissue was then 
marked using an ImmEdge hydrophobic pen (Vector Laboratories Inc., Burlingame, USA. 
Sections were then rehydrated in PBS containing 0.05% Tween20 (TWEEN® 20, Sigma-Aldrich 
Co. LLC, U.S.A, PBS/T) for 3 minutes and subsequently incubated in 0.2% Triton X-100 (Sigma, 
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St. Louis, USA) in PBS/T for 10 minutes at room temperature. Endogenous peroxidase was 
then blocked by immersion in 3% H2O2 in water for 10 minutes, followed by a washing step in 
PBS/T. Protein blocking was  performed by incubation in 2% goat serum in PBS/T (2 drops in 5 
ml) from a Vectastain Elite kit (Vector, Peterborough, UK), before a further wash in PBS/T, and 
subsequent incubation with primary anti-human CD271 monoclonal antibody (Abcam 
Biochemicals, Cambridge, UK; ab31251); diluted 1:50 in 2% BSA/PBS, or primary anti-p62 
antibody (Santa Cruz Biotechnology, USA;SQSTM1 Antibody (D-3): sc-28359) diluted 1:50 in 
2% BSA/PBS overnight at 4oC. Sections were then washed three times with PBS/T and 
incubated with anti-mouse 2° antibody diluted 1:200 in 2% serum/PBS/T from a Vectastain 
Elite kit for 30 minutes at room temperature. Following three washes with PBS/T sections 
were then incubated with ABC reagent from a Vectastain Elite kit (pre-mixed 30 minutes prior 
to use) at room temperature for 30 minutes, again washed three times in PBS/T, and then 
incubated with VIP solution (Vector Laboratories Inc., Burlingame, USA) for 10 minutes at 
room temperature prior to counterstaining with haematoxylin (Thermo Fisher Scientific, UK) 
for 2 minutes, and rinsing in tap water for 10 minutes.  Sections were finally dehydrated 
through 75% and 100% ethanol for 5 seconds and incubated in histoclear for 2 minutes, before 
air drying and mounting with a coverslip and DPX mounting medium (VWR International Ltd., 
Poole, UK). Sections were then imaged by light microscopy and representative images 
captured using a Zeiss Axio Imager microscope (Carl Zeiss Microscopy New York, U.S.A). 
Sections following CD271 or p62 staining were digitally imaged using an automated slide 
scanner (Leica SCN400 digital slide scanner (Leica Biosystems, Milton Keynes, UK)), Newcastle 
University Biobank. CD271 or p62 staining intensity was calculated using the Leica digital slide 
scanner at ×20 magnification using a semi quantitative calculation of percentage staining 
intensity of 10 representative areas and statistical comparison using a one-way ANOVA test 
with Tukey’s multiple comparison test.  
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 Immunofluorescence for the expression of CD271 and p62 in 
Cutaneous Human Melanoma Cell lines 
 
Melanoma cells were seeded onto glass cover slips (22x22 mm) at a density of 5x104 cells /well 
of 6 well tissue culture plates (Corning Incorporated, New York, USA), covered with 3 mls of 
complete culture medium and allowed to attach overnight before the culture medium was 
aspirated and adherent cells washed twice in PBS for 5 minutes and subsequently fixed with 
ice-cold paraformaldehyde (4%) in PBS for 15 minutes on ice. Cells were then washed three 
times with PBS and subsequently incubated in 0.2% Triton X-100 (Sigma, St. Louis, USA) in 
PBS/T for 10 minutes before a blocking step with 2% goat serum (Sigma, Dorset, UK) in PBS/T 
for 30 minutes at room temperature. Coverslips were then transferred onto a glass slide and 
marked using an ImmEdge hydrophobic pen (Vector Laboratories Inc., Burlingame, USA). 
Slides were incubated with 100 µl of a primary anti-human CD271 monoclonal antibody 
(Abcam Biochemicals, Cambridge, UK; ab31251) or anti-p62 (Santa Cruz Biotechnology Inc. 
USA) all diluted 1:50 in 2% BSA and 2% goat serum (Sigma, Dorset, UK) in PBS or in PBS/T alone 
as a negative control at 4°C overnight. Cells were then washed in PBS/T three times before 
incubation with a fluorescent secondary antibody Alexa Fluor® 488 Goat Anti-Mouse IgG (Life 
Technologies, Eugene, Oregon USA) or Alexa Fluor® 568 Goat Anti-Mouse IgG (Life 
Technologies, Eugene, Oregon USA) to detect primary CD271 and p62 binding. All fluorescent 
secondary antibodies were diluted 1:250 in 2% BSA and 2% goat serum in PBS with the 
addition of diamidino-2-phenylindole dye (DAPI, Thermo Fisher Scientific, Thermo Fisher 
Scientific, Illinois, U.S.A) diluted 1:1000 prior to1 hour incubation at room temperature. 
Finally, cells were washed with PBS/T three times before mounting with a cover slip using hard 
set anti-fade mounting medium (Vector labs, Burlingame, California, USA). Fluorescent 
intensity was visualised and representative images captured using a Leica TCS SP2 UV confocal 
microscope and analysis with LC2 2.61 software (Leica Microsystems GmbH Heidelberg). 
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 Western Blotting 
 
Western blotting was carried out using standardized methodology (Armstrong et al., 2015a). 
Briefly, following trypsinisation of melanoma cells and collection of cells and the entire 
supernatant (to ensure any detached cells following drug treatment were also captured) cells 
were washed in PBS and pelleted by centrifugation into microfuge tubes before the addition 
of  50-500 μl of ice cold cell lysis buffer (0.1 M Tris-HCl pH 7.4, 25 mM NaF, 0.1 M NaCl, 2 mM 
EDTA (pH 8), 1 mM benzamidine, , 0.1% Triton-X100 and 0.1 mM sodium orthoVanadate) for 
approximately 50,000 to 2 X 106 cells, containing 150 µl/ml of freshly added protease inhibitor 
cocktail (Promega, Southampton, UK).  Protein was extracted by sonication with a probe 
sonicator (Soniprep 150, MSE, UK) for 2 pulses of 5 seconds each at amplitude of 7 microns. 
Protein concentration was then determined using a Bradford protein quantification assay 
(Pierce Biotech, Rockford, USA) according to the manufacturers specifications with protein 
absorbance measured at 595 nm using a SpectraMAX 250 plate reader (Molecular Devices Ltd. 
UK). 10 µg of protein lysate was diluted at a ratio of 1:3 in 4x sample buffer (250 mM Tris HCL 
(pH 8), 8% sodium dodecyl sulphate (SDS), 40% glycerol, 10% β-mercaptoethanol and 
bromophenol blue). Samples were then denaturated at 95oC for 10 minutes on a heat block. 
Protein separation was performed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) with 4-20% tris-glycine gels (Bio-Rad, UK) in a (SDS) running buffer 
(25 mM Tris base,190 mM glycine 0.1% SDS) and incorporating Bench MarkTM Prestained 
Protein Ladders (Invitrogen, Paisley, UK; 10748-010). Proteins were then transferred onto a 
PVDF membrane (Bio-rad, UK) using a Bio-rad Turbo-blotter (1.3A, 25V; Bio-Rad, UK) for 15 
minutes before membranes were blocked with 5% non-fat milk (OXOID ltd, Baisingstoke, UK) 
in Tris-buffered saline (Tris base and NaCl in Millipore water, pH 7.6;TBS) for 1 hour at room 
temperature. Membranes were then incubated with primary antibodies (Table 2-5) over night 
at 4oC, before washing three times in TBS with 0.05%Tween 20 (TBS/T) for 15 minutes each 
and incubation with relevant secondary antibodies; anti-rabbit (Vector Laboratories, 
Burlingame, USA) for the detection of CD271, LC3 I/II, cleaved caspase 3, cleaved PARP, 
ERK1/2, phospho ERK1/2, phospho AMPKa, total AMPK, GAPDH and Nestin or anti-mouse 
secondary antibody (Vector Laboratories, Burlingame, USA) to detect p62, ABCB5, Jarid-1B, 
SOX10 and β-actin. All secondary antibodies were diluted 1:5000 in 5% non-fat milk in TBS/T. 
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Membranes were then again washed in TBS/T three times for 15 minutes each before protein 
expression was visualized using the ECL-plus system (Clarity Western ECL-Substarte, Bio-Rad, 
USA) and either photographic film (Super RX-N, Fujifilm) or Odyssey FC Image studio soft-wear 
(Li-cor Biosciences, Lincoln, Nebraska, U.S.A). Photographic film was developed using a 
developer (MINIMED90 X-Ray film processor; photon imaging systems, AFP imaging corp., 
Elmsford, NY, U.S.A). 
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Table 2-5: List of primary antibodies used for western blot analysis 
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 Lentiviral transduction of human melanoma cell lines with 
histone 2B-RFP construct or over expression of CD271 
 
The Histone H2B monomeric red fluorescent protein lentiviral vector (pHIV-H2BmRFP, 
Addgene plasmid # 18982) was transformed into competent E.Coli (One Shot® TOP10 
Chemically Competent E. coli, Invitrogen) following a standard recommended heat shock 
procedure as per the manufacturer instructions (Moore et al., 2010). Bacterial colonies grown 
on Lysogeny broth (LB) agar plates containing 50 μg/ml ampicillin (Sigma Aldridge, Poole, UK) 
were selected and expanded in LB broth (Life Technologies, Paisley, UK). Plasmid DNA was 
purified using maxi Prep kits (QIAGEN Kit, Venlo, Limburg, Netherlands) according to the 
manufacturer’s specifications. 20 μg of lentiviral plasmid DNA was then co-transfected with 
5 μg of an expression plasmid for the viral envelope (pMD2.G) and 15 μg packaging plasmid 
(pCMVdelta8.91) into HEK293T cells at 80% confluency by standard calcium precipitation 
(Armstrong et al., 2015a) method.  The following day the transfection media was removed 
and cells washed with PBS before the addition of fresh complete culture media and incubation 
at 37°C continued for 72 hours. Lentiviral containing supernatant was then harvested and 
centrifuged at 310 g for 15 minutes before filter sterilization through 0.45 μm filters and 
storage at -80oC prior to use. Human melanoma cell lines (5×104 cells/well of a 6 well plate) 
were spin transduced with 2 mls of the viral supernatant supplemented with polybrene (4 
μg ml−1) at 310 g for 90 minutes. The viral supernatant was then removed, cells washed with 
PBS before returning to culture in normal growth culture media (DMEM, 10% FCS, PS). Flow 
cytometry was used to select for RFP expression using a FACS Aria cell sorter and 
representative images captured using a confocal microscope (Leica TCS SP2 confocal 
microscope, Leica microsystems) as described in section 2.5.2. 
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For stable overexpression of CD271, a mammalian vector with C-terminal tRFP tagFP (pCMV6-
AC plasmid vector containing RFP tagged CD271, Origene PS100034, Rockville, Maryland, USA) 
(Figure 2-1) was transformed into competent E.Coli (One Shot® TOP10 Chemically Competent 
E. coli, Invitrogen) following a standard recommended heat shock procedure as per the 
manufacturer instructions (Moore et al., 2010). Bacterial colonies grown on Lysogeny broth 
(LB) agar plates containing 50 μg/ml ampicillin (Sigma Aldridge, Poole, UK) were selected and 
expanded in LB broth (Life Technologies, Paisley, UK). Plasmid DNA was purified using maxi 
Prep (QIAGEN Kit, Venlo, Limburg, Netherlands) according to the manufacturer’s 
specifications. 
 
Figure 2-1: Map of pCMV6-AC plasmid vector.  
To assess the effect of CD271 overexpression, melanoma cells were transfected with a CD271 
overexpressing construct tagged with a C-terminal tRFP tag. 
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Following DNA purification, a reverse transfection approach was adopted using LTX 
Lipofectamine (Lipofectamine® LTX with Plus™ Reagent, Thermo Fischer Scientific, Waltham, 
USA). A tranfection mixture was prepared by mixing 1 µg of DNA with 500 µl DMEM (10% FCS 
but without antibiotics) in a 1.5 ml Eppendorf tube. 5 µl of PLUS reagent was then added to 
the mixture followed by a 5-minute incubation at room temperature before the addition of 
10 µl of Lipofectamine LTX and a further 30-minute incubation at room temperature. The 
transfection mixture was then dispersed in one well of a flat bottomed 6 well plate (Corning 
Incorporated, New York, USA). A cell suspension of 3.5×105 A375 or WM35 cells was then 
added dropwise to the transfection mixture before continued incubation at 37oC for 6-8 hours. 
The transfection was then terminated by carefully aspirating the transfection mixture and 
replacing with complete DMEM before again continued incubation for a further 48 hours. 
Transfected cells were then continuously selected through neomycin resistance by the 
addition of 500 µg/ml G418. RFP expressing clones were verified by visualization with a Leica 
TCS SP2 UV confocal microscope and LC2 2.61 analysis software. This technique however 
resulted in low transfection efficiency and therefore an alternative overexpression approach 
was used using Xfect Transfection Reagent (Clontech, Mountain View, California, USA).  
For CD271 over expression using Xfect,  A375 or WM35 cells were seeded at a density of 2×105 
cells per well of a flat bottom 6 well plate before allowing cells to attach overnight prior to 
replacing the media with 1 ml of fresh complete media and the addition of pre mixed 
transfection mixtures for 4 hours. Pre prepared transfection mixtures for each transfection 
comprised 0.4 µl of Xfect polymer transfection reaction buffer, 2 µg of cDNA and Xfect reaction 
buffer to a total volume of 100 µl, which was premixed and incubated for 10 minutes at room 
temperature before brief centrifugation and dropwise addition to cell cultures. The 
transfection reaction was subsequently terminated by gentle aspiration of the transfection 
mixture and the addition of 2 mls of fresh complete media to each well. Transfected cells were 
then continuously selected by the addition of 500 µg/ml G418 prior to confirmation of RFP 
expression by visualization using a Leica TCS SP2 UV confocal microscope and LC2 2.61 
software. 
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 Stable (ShRNA) and Transient knockdown (SiRNA) of CD271 in 
human melanoma cell lines  
 
Silencing mediated knockdown of CD271 was performed using either a short hairpin RNA 
(shRNA) or Small Interfering RNA (siRNA) approach. The incorporation of shRNA into host cells 
through lentiviral infection allows for stable integration of shRNA and long-term knockdown 
of the targeted gene (Taxman et al., 2010). However, an alternative approach of using 
silencing RNA, which functions by oligonucleotides interfering with the expression of target 
genes by degradation of the mRNA and therefore preventing translation of the target gene 
(Rao et al., 2009) was also used.   
2.11.1 ShRNA- mediated knockdown of CD271 
 
ShRNA-mediated knockdown of CD271 in melanoma cells was performed in collaboration with 
Dr Paola Giglio and Dr Marco Corazzari, University of Rome ‘Tor Vergata’, Italy using lentiviral 
transduction of a shRNA targeting CD271 with five different clones targeting different regions 
of CD271 (SHCLNG-NM_002507, NGFR MISSION shRNA Bacterial Glycerol Stock nerve growth 
factor receptor, Sigma Aldrich, St Louis, USA, Table 2-6).  
Table 2-6: Sequences of five differing ShRNA’s targeting CD271. 
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Plasmid vectors ShRNA to CD271 or scrambled control sequence vectors were transformed 
into competent E.Coli following a standard recommended heat shock procedure as per the 
manufacturer instructions. Bacterial colonies grown on Lysogeny broth (LB) agar plates 
containing 50 μg/ml ampicillin (Sigma Aldridge, Poole, UK) were selected and expanded in LB 
broth (Life Technologies, Paisley, UK). Plasmid DNA was purified using maxi Prep (QIAGEN Kit, 
Venlo, Limburg, Netherlands) according to the manufacturer’s specifications. 10 μg of 
lentiviral plasmid vector (shRNA-pLKP ERp57, Sigma Aldrich, St. Louis, Missouri, USA) was then 
co-transfected with 2.5 μg of an expression plasmid for the vesicular stomatitis virus G protein 
and psPAX2 plasmid, containing gag, pol and rev genes  into HEK293T cells at 80% confluency 
by standard calcium precipitation (Armstrong et al., 2015a) method. The following day the 
transfection media was removed and cells washed with PBS before the addition of fresh 
complete culture media and continued culture at 37°C for 48 hours. The lentiviral particle 
containing supernatant was then harvested and centrifuged at 310 g for 15 minutes before 
filter sterilization through 0.45 μm filters and storage at -80o. A375 cells (2×105 cells in 10cm 
tissue culture dish) were transduced with 5mls of the viral supernatant supplemented with 
polybrene (4 μg ml−1) for 6- 8 hours, before aspiration of the lentiviral supernatant, the 
addition of fresh complete DMEM media and further culture for 48 hours prior to confirmation 
of CD271 knockdown by qPCR as described in section 2.6. 
 
2.11.2 SiRNA- mediated knockdown of CD271 
 
A375 or WM35 cells were seeded at a density of 1.5x105 cells/well, in 6 well culture plates in 
3ml of complete culture medium and allowed to attach overnight at 37oC. Three transfection 
mixtures were prepared, one containing  2.5 µl of lipofectamine RNAiMax reagent (Invitrogen, 
Carlsbad, California, U.S.A) in 125 µl Opti-MEM 1x reduced serum medium (life technologies, 
New York, U.S.A)/ well of a six well plate, one containing  pre-siRNA mixtures consisting of 2.5 
µl  of ON-TARGETplus Human NGFR siRNA (SMART pool siRNA, Dharmacon, GE lifesciences, 
Lafayette, Colorado, U.S.A) and one containing Stealth RNAi™ siRNA Negative Control (none 
target) (Invitrogen, Carlsbad, California, U.S.A) in 125 µl Opti-MEM1x reduced serum medium 
(Life technologies, U.S.A). Following incubation for 30 minutes, lipofectamine and siRNA 
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mixtures in OPTIMEM were combined and incubation at room temperature continued for a 
further 15 minutes.  
Following removal of the media from the adhered cells to be transfected and a brief wash in 
PBS, the media was replaced with 1 ml Opti-MEM1x reduced serum medium and 250 µl of 
each respective siRNA/ lipofectamine mixture (added dropwise) and incubation at 37oC 
continued for 6 hours.  The transfection was then terminated by replacing the transfection 
solution with 3 mls of fresh complete DMEM media and transfection efficiency and CD271 
knockdown verified by qPCR or western blotting after 24, 48 or 72 hours as described in 
section 2.6 and 2.9 respectively. 
 Cell Viability Assays 
All melanoma cell lines were seeded in complete culture media at a density of 5 or 2.5×103 
cells/well in a volume of 100 μl per well of a 96-flat well plate (Corning Incorporated, New 
York, U.S.A), with at least four replicates per experimental condition, prior to being allowed 
to attach overnight at 37oC. The cell culture media was then replaced with 100 µl of fresh 
media containing a given drug/drug combination before incubation was continued for a 
further 24 or 48 hours.  Cell viability was assessed by the addition of 20 µl of Aqueous 
NonRadioactive Cell Proliferation Assay (3- (4,5- dimethylthiazol- 2- yl)- 5-(3-
carboxymethoxyphenyl )-2-(4-sulfophenyl)-2H tetrazolium, inner salt; MTS, CellTitre 96, 
Promega, Southampton, UK) to each well (including blank wells containing just media) for 4 
hours and colorimetric detection by measuring absorbance at 490 nm using a Spectra Max 
250 plate reader (Molecular Devices). 
Alternatively to assess cell viability using MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma-
Aldrich, St Louis, USA) melanoma cells were seeded at a density of 5×104 cells per well in a 12-
flat well tissue culture plate (Corning Inc, Corning, NY, USA) and allowed to adhere overnight, 
prior to drug treatment for given times and the assessment of cell viability by the addition of 
100 μL of Thiazolyl Blue Tetrazolium Bromide at a concentration of 5 mg/ml and continued 
incubation for 4-hours before aspiration and replacement with  300 μL of Isoproplanol/ 
Hydrochloric acid (HCL) solution (5 ml HCL in 500 ml Isopropranol) for 5 minutes and the 
measurement of absorbance at 570 nm using a Spectra Max 250 plate reader (Molecular 
Devices).  
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 Colony forming Assay 
 
To assess the ability of melanoma cells to undergo division and develop colonies following 
treatment with either trametinib, chloroquine, PIK-III or combined treatment with trametinib 
with either chloroquine or PIK-III, a colony forming assay was performed. A375 or Sk-mel-28 
cells were initially treated with trametinib (16 nM) for 9 days before subsequent treatment 
for 48 hours with either trametinib alone, chloroquine (10 μM) alone, PIK-III (5 μM) alone or 
combination of trametinib with chloroquine or PIK-III. Drug treated or control untreated cells 
were then detached with trypsin EDTA before three replicates of 100, 250, 500 or 1000 cells 
in 7 mls of fresh complete media were subsequently seeded into a 10 cm tissue culture dish 
(Corning Inc., Corning, USA), dispersed evenly and incubated at 37oC for 2 weeks. At the end 
of the 2 week period, the cell culture media was aspirated and colonies were gently washed 
in PBS before fixing in 5mls Carnoy’s fixative (100 mls acetic acid in 300 mls methanol) for 5 
minutes. The Carnoy’s fixative was then aspirated and plates were washed in PBS before the 
addition of 5 mls of 0.4% Crystal Violet (1% Crystal Violet V5265, Sigma Aldrich, St Louis, USA) 
for 5 minutes. The excess crystal violet was then washed off by careful use of a fine flow of 
tap water to prevent disturbance of the colonies. The number of colonies were then counted 
using a colony counter (ColCountTM Oxford Optronics, Abingdon, UK) and the colony efficiency 
and percentage of cell survival calculated using Equation 2.1 and Equation 2.2  as below: 
%	$%&'(')	*++($(*'$, = .$&%&'(*/	$&0'1*2$*%%/	/**2*2 34100 Equation 2.1 
 
%	/078(89% = .270)	17*91*2	$*%%	$%&'(')	*++($(*'$,$&'17&%	$*%%	*++($(*'$, 34100 Equation 2.2 
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 Collagen Invasion Assay 
 
Collagen Invasion assays were used to model melanoma cell invasion in vitro (De Wever et al., 
2014) and specifically the invasive capacity of the human BRAF mutant melanoma cell line, 
WM35 following long exposure to Trametinib (16 nM) for 9 days and subsequent drug 
treatment. The wells of 96 well TC grade plates (Corning Incorporated, New York, USA) were 
pre-coated with 100 µl/well 1.5% low melting point agarose (Agarose, low gelling 
temperature, A-9414, Sigma-Aldrich Co. LLC, USA), dissolved in PBS by microwave heating for 
follow 1-3 minutes) for 2 hours, prior to the addition of 5×103 control or trametinib treated 
WM35 cells to each well is a volume of 200 µl/well and culture for 72 hours.  
Collagen mix was prepared (Table 2-7) by pre-mixing collagen (Collagen I Bovine Protein 
(A1064401, Thermo Fisher Scientific, Paisley, UK)), H2O, Modified Eagle’s Medium (EMEM 12-
684F, Lonza, Vervies, Belgium) and L-Glutamine (200 mM L-Glutamine solution G7513, Sigma-
Aldrich Co. LLC, U.S.A) on ice followed by the addition of 7.5% NaHCO3 and FCS. 200 µl of 
resulting collagen mix was then added to each well of a 24 well plate and allowed to set at 
37oC for 5 minutes.  
 
Table 2-7: Constituents of collagen mix for collagen invasion assay for 4 wells of a 24 well 
plate 
 
Spheroids were then visualised using a stereomicroscope and 3 spheroids per condition were 
harvested using a 1 ml pipette tip into a 1.5 ml Eppendorf tube (Eppendorf UK Limited, 
Stevenage, UK) and allowed to settle by gravity.  The excess media was then carefully aspirated 
before spheroids were resuspended in 300 µl of the collagen mix and carefully transferred 
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onto the collagen coated wells with continued incubation at 37oC for 15 minutes.  1 ml of 
complete DMEM containing trametinib, TAT-PEP5, RO-08, NGF or PIK III (Vps34 inhibitor) was 
then added to each well. Spheroids were visualised using a Nikon A1R confocal microscope 
and images were captured after 0, 2, 4 and 7 days continued incubation.  Spheroid invasion 
was analysed using Volocity 3D Image Analysis Software (Volocity 6.3, High performance 3D 
imaging software, PerkinElmer, Waltham, Massachusetts, USA). 
 
 CellTiter-Glo® Luminescent Cell Viability Assay 
 
A commercial CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, USA) was 
used to measure cellular ATP release and therefore estimate the number of viable cells cell 
viability in WM35 and A375 cells subjected to treatment with trametinib. ATP released from 
cells is a recognized marker of viable cells. Once cells lose their membrane integrity, the 
cellular ability of ATP synthesis quickly diminishes and endogenous ATPases degrade any 
remaining cytoplasmic ATP (Kleijn et al., 2016). Untreated control or WM35 and A375 
melanoma cells pre-treated with 16 nM trametinib for 8 days were seeded at a density of 
5×103 cells/well in a volume of 100 μl per well of an opaque walled 96 flat well plate (Corning® 
opaque 96 well plates, Sigma-Aldrich Co. LLC, U.S.A), with at least four replicates per 
experimental condition and four replicates to be used as a positive control, prior to culture 
overnight at 37oC, to allow cell attachment. Cell culture media was then replaced with 100 µl 
of fresh media ± 16 nM Trametinib before incubation was continued for a further 24 hours. 
ATP release was assessed by the addition of 100μl of CellTiter-Glo reagent per well (including 
to some wells containing media alone, to measure the background luminescence). For 
induction of ATP release in the positive control cells, cells were additionally treated with 10 µl 
of 10% sodium dodecyl sulphate (SDS) (sodium dodecyl sulphate, 436143, Sigma Aldrich, St 
Louis, USA) in de-ionized water for 2 minutes at room temperature on an orbital shaker before 
the luminescence measured as light intensity of the rate of catalysis by luciferase was 
recorded using a luminometer (GloMax® Explorer, Promega, Wisconsin, USA).  
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 Enzyme-linked immunosorbent assay (ELISA) to detect 
endogenous levels of phosphorylated AMPKα  
 
Cutaneous melanoma cell lines, A375 and WM35 were initially seeded in 7 mls of complete 
media in 10 cm tissue culture dishes at a density of 2×106 in case of trametinib treatment or 2 
x105 in the case of untreated controls in duplicate conditions. Following overnight attachment 
of cells at 37o C, the cell media was replaced with fresh complete culture media in the presence 
or absence of 16 nM of trametinib and culture continued for 9 days, changing the media ± 
trametinib every 3 days. Following 9 days the media of untreated cells was aspirated and 
replaced with fresh media containing 10 mM hydrogen peroxide (H2O2) (30% Hydrogen 
peroxide solution in H2O, Sigma Aldrich, St Louis, USA) before continued culture for 10 minutes 
at which point the media was aspirated from all conditions (untreated control, untreated 
control plus H2O2 for 10 minutes or 9 day trametinib treatment) and cells subsequently 
washed in ice cold PBS. The tissue culture dishes were then placed on ice prior to the addition 
of  800 μL in case of untreated control +/- H2O2 cells or 500 μL of ice cold Elisa Lysis buffer 
(PathScan Sandwich ELIZA lysis buffer, Cell Signalling, Danvers, Massachusetts, USA) and the 
detachment of cells using cell scrapers (25 cm cell scraper, Sarstedt, Newton, USA). Cell lysates 
were then incubated on ice for 30 minutes before protein concentration was determined 
using a commercial Bradford assay as described in section 2.9. 10 µg of protein from each 
sample was then used to determine the level of endogenous pAMPKa.  
A commercial sandwich enzyme-linked immunosorbent assay (ELISA), PathScan® Phospho-
AMPKα (Thr172) Sandwich ELISA Kit #7959 (Cell Signalling, Danvers, USA) was used to detect 
pAMPKa secretion as per manufacturer’s specifications.  Absorbance was measured at 450 nm 
using a Spectra Max 250 plate reader (Molecular Devices, Workingham, UK) as previously 
described. In vitro pAMPKa secretion by cell lines was expressed as a mean of three individual 
experiments for cell lines and analysed by two-way ANOVA analysis of variance with Tukey’s 
post hoc correction.  
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 Use of a zebra Fish xenograft model of human metastatic 
melanoma to study melanoma invasion in vivo. 
 
To evaluate the potential efficacy of autophagy inhibition on the prevention of systemic 
invasion on trametinib-induced resistant melanoma cells in vivo, a zebrafish model of human 
metastatic melanoma was developed in collaboration with Dr Bill Chaudhry (Institute of 
Genetic Medicine, Newcastle University) and Dr David Hill (Institute of Cellular Medicine, 
Newcastle University). Although murine models have been extensively used to monitor 
systemic melanoma invasion, zebrafish models are increasingly used to model cancer 
development and dissemination (Lieschke and Currie, 2007), with advantages including the 
ability to follow developing pathologies using real time imaging (Santoriello and Zon, 2012).   
Transparent transgenic Casper (flk1:GFP) tagged zebrafish embryos, which lack skin pigment 
and express green fluorescent tagged vasculature were used throughout the present studies.  
Studies describing how the optimal environmental temperature and oxygen conditions were 
derived for the growth and monitoring of melanoma invasion in vivo using the described zebra 
fish xenograft are further described in chapter 5.  
Adult zebrafish colonies were maintained in a dedicated fish facility at the Institute of Genetic 
Medicine, Newcastle University with approximately 30 adult fish/tank. Zebrafish were paired 
for breeding before the eggs were collected 24 hours later, cleaned and incubated in 1×E3 
media (50x E3 medium: 5.0 mM NaCl (14.6g), 0.17 mM KCl (0.65g), 0.33 mM CaCl (2.20 g), 
0.33 mM MgSO4 (4.05 g) in 1 lt H2O) at 28.5oC, 21% O2 and 0.04% CO2  for 48 hours. 
 
2.17.1 Preparation and DiI labelling of melanoma cells for inoculation into 
zebra fish embryos 
 
A375 cells were cultured in a T75 tissue culture flask (Corning® 75 cm² U-shape cell culture 
flask, canted neck, Corning, New York, USA)  in 10 mls of complete DMEM or DMEM containing 
16 nM trametinib for 9 or 42 days before the media was aspirated and replaced with 5 mls of 
complete DMEM media containing 25 µl 1,1'-Dioctadecyl-3,3,3',3'-
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Tetramethylindocarbocyanine Perchlorate (DiI) dye (Dil Stain (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate ('DiI'; DiIC18(3), D282, Invitrogen, California, USA) 
for 20 minutes at 37oC . The media was then aspirated and cells washed three times with warm 
complete DMED for 10 minutes before detaching with trypsin/EDTA as previously described. 
500 µl of 15 µm Fluorospheres (FluoSpheres® Polystyrene Microspheres, 15 µm, blue 
fluorescent (365/415), Thermo Fischer Scientific, Massachusetts, USA) were transferred into 
a 15 ml sterile plastic centrifuge tube before the addition of 10 mls sterile PBS and 
centrifugation at 310 g for 5 minutes. The supernatant was then aspirated and mixed with the 
detached melanoma cells before the combined cell/ fluorosphere mix was centrifuged again 
at 310 g for 5 minutes and the pellet finally resuspended in 100 µl complete DMEM, prior to  
inoculation into zebra fish embryos as described below.  
 
2.17.2 Injection of human melanoma cells in the yolk sac of 2 day post 
fertilisation zebrafish embryos 
 
Viable two-day post fertilization zebrafish embryos were selected, transferred into a 10 cm 
petri dish and anaesthetized in an E3/tricaine containing solution (46 mls E3 media / 4 mls 
tricaine (Stock: 400 mg tricaine (Ethyl 3-aminobenzoate methanesulfonate, Sigma Aldrich, 
Missouri, USA), 0.26 g Tris, 100 ml E3. pH 7) and prior to embedding the embryos in a mix of 
E3 media and low melting point agarose prepared as follows: 250 mg of low melting point 
agarose (Sigma-Aldrich, USA) was dissolved in 25 mls of E3 media by microwave heating and 
cooled to 35oC before the addition of 1 ml of tricaine and transfer to the lid of a 10 cm petri 
dish and embedding of the anaesthetized zebrafish embryos. To facilitate embedding, the 
excess agarose/tricaine was removed to allow zebrafish to be embedded into a thin layer of 
agarose. Microinjection needles (Glass capillaries made of borosilicate glass 3.3, with filament, 
Hilgenberg, Malsfeld, Germany) were initially pulled with a needle puller (Sutter instruments 
Co - Model P-97 micropipette puller) at a setting of Heat=638, Pull=100, Velocity=80, 
Delay=200 before attachment to a pump injector (Nanoliter 2000, Microprocessor controlled 
nanoliter injection system, World Precision Instruments, Hertfordshire, UK) and the needle 
being broken to a diameter of 30-40 µm. Dil labelled cells/ fluorospheres were then aspirated 
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into the microinjection needle prior to injection of  20 nl of cell/flourosphere solution into the 
inferior part of the yolk sac of anaesthetized zebrafish embryos ( 
Figure 2-2) 
 
Figure 2-2: Two day post fertilization Tg(flk1:GFP) zebrafish embryo. 
Marked injection site (red circle) in the inferior part of the yolk sac. 
 
Following injection, fish were examined for the presence of melanoma cells within the yolk 
sac using a fluorescent stereo Leica M165 FC microscope (Leica, Wetzlar, Germany) through a 
dsRed filter. Fish with cells outside the injection site, at multiple sites or without cells were 
discarded and suitable fish were carefully taken out of the agarose/tricaine solution and 
placed individually into one well of a 24 well plate containing 1 ml of E3 media ± 16 nM 
trametinib, 5 µM PIK III or combined trametinib/PIK III and incubation at 33oC, in an 
atmosphere of 5%O2, 5% CO2 for 72 hours.  
 
2.17.3 Confocal microscopy imaging zebrafish xenografts 
 
To monitor tumour invasion and dissemination, Zebrafish were then carefully removed and 
transferred into a glass bottomed Wilko dish in a small amount of agarose/tricaine solution 
and orientated with the injection site facing towards the bottom of a Wilko glass bottomed 
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dish (35 mm glass bottom culture dish, 10 mm glass window, MatTek Corporation, Ashland, 
USA). The surrounding agarose was allowed to solidify before the addition of 3-5 mls of E3 
media containing tricaine and images captured using an inverted Nikon A1R confocal 
microscope at 460 nm (blue beads), 488 nm (green blood vessels) and 564 nm (red cells) and 
analysed using Velocity 3D Image Analysis Software (Velocity 6.3, High performance 3D 
imaging software, PerkinElmer, Waltham, Massachusetts, USA). 
 
 Statistics 
 
Throughout this thesis data were analysed using Statistical software Graph Pad Prism 7 (Graph 
Pad Prism version 7, Graph Pad, San Diego, CA USA). All data were assessed for normality using 
a Shapiro-Wilk Test. In datasets where there were not enough data points to use a Shapiro-
Wilk Test, normality was not assumed and non-parametric tests were applied. P values of P< 
0.05 *, P< 0.01 **, P< 0.001 ***, P<0.0001 **** were regarded as statistically significant 
throughout the thesis and values P > 0.05 were regarded non-significant (ns). 
In vitro protein expression data was acquired using Odyssey FC Image studio soft-wear (Li-
cord) and expression intensity normalized to the corresponding loading control (β-actin or 
GAPDH). Densitometry expression data for each protein analysed were presented as the mean 
of three individual replicate experiments and analysed by one-way analysis of variance 
(ANOVA) with Tukey’s post hoc correlation relative to the experimental control condition set 
to 1 in chapters 3 and 4, or relative to the mean of all experimental conditions in chapter 5. 
Data deriving from all MTS, MTT and ATP release proliferation assays were reported as the 
mean of a minimum of four replicates over 3 individual experiments using a one-way ANOVA 
with Tukey’s multiple comparison tests.  Results from MTS cell viability assay in isolated CD271 
+ve and –ve subpopulations treated for 24 hours with either vehicle control, chloroquine 10 
μM or the Vps34 inhibitor PIK III 5 μM were analysed using a Mann Whitney U non-parametric 
T test.  
To quantify basal CD271 mRNA in vitro across a panel of cell lines and primary melanocytes as 
well as CD271 mRNA expression following Si RNA and ShRNA –mediated knockdown of CD271, 
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CD271 mRNA expression was determined by q PCR as described in section 2.6. Mean CD271 
Ct values were normalized to 18S control Ct value data were analysed by one-way ANOVA 
with Tukey’s post hoc correlation. Normalized CD271 mRNA expression between CD271 siRNA 
and non-target siRNA were compared by Students T-Test.  
In vitro immunofluorescent expression of CD271 in WM266-4 cells expressing dual tagged LC3 
RFP/GFP was compared to a null primary negative control and mean fluorescent intensity 
analysis derived using ImageJ image analysis software. Immunofluorescent expression was 
expressed as mean fluorescence per cell (relative to DAPI) and compared using Mann-Whitney 
U test. 
In vitro immunohistochemical expression of CD271 and p62 in primary melanomas of different 
AJCC stage, benign naevi and metastatic melanoma lymph nodes were assessed using an 
automated slide scanner (Leica SCN400 digital slide scanner) and staining intensity calculated 
using the Leica digital slide scanner at ×20 magnification and expressed semi quantitatively as 
the mean percentage staining intensity of 10 representative areas. Results were compared 
using one way ANOVA test with Tukey’s multiple comparison test.  
Spheroid collagen invasion of WM35 control or trametinib treated or A375 trametinib 
resistant cells was analysed using Volocity 3D Image Analysis Software. The maximum 
diameter of the spheroid was measured and compared to the respective control for each time 
point. Results were expressed as the mean (± SD) of the absolute increase in spheroid 
diameter at each time point compared to the respective untreated control. Results compared 
by two-way ANOVA test with Sidak multiple comparison test.
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Chapter 3 Constitutive expression of CD271 in melanoma is 
associated with an increase in pro-survival basal 
autophagy 
 Introduction 
 
The recent identification of melanoma subpopulations that are involved in tumour 
progression, metastasis and resistance to targeted therapies has significantly changed the way 
melanoma biology is considered. Malignant melanoma is a very heterogeneous cancer with 
complex tumour biology and with diverse survival mechanisms that orchestrate a cascade of 
events leading to tumour resistance to therapies and escape from immune-mediated death.   
Over a decade ago Herlyn et al first described the observation that some melanoma cells grow 
in specialized stem cell growth media as melanospheres and isolated cells deriving from these 
melanospheres could be differentiated under appropriate conditions into multiple cell 
lineages, such as melanocytic, adipocytic, osteocytic, and chondrocytic, implicating a direct 
stem cell heritage of a subpopulation of melanoma cells (Fang et al., 2005b) and therefore 
paving the way for the investigation of melanoma cells with stem like properties. 
Melanoma cells expressing stem cell markers such as ABCB5, CD271, SOX10 and Jarid-1B have 
recently been described to be involved in melanoma progression and resistance to targeted 
therapies. However, there is also increasing controversy about the importance of these 
subpopulations in tumour initiation and their contribution to tumour resistance. 
CD271 (p75 NTR) is a low-affinity p75 neurotrophin receptor that has the ability to bind to the 
nerve growth factor (NGF) (Liepinsh et al., 1997b). Although the role of CD271 in neural crest 
development is well understood, in the skin, CD271 interacts with several ligands and co-
receptors to mediate a variety of cellular functions and the direct role of CD271 in this context 
is still to be fully elucidated (Pincelli, 2017). 
The role of CD271 in neural crest cell development and the neural crest origin of melanocytes 
and melanoma cells has prompted the investigation of CD271 in human cutaneous melanoma. 
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The tumorigenic potential of CD271 expressing melanoma cells has been explored in several 
studies. Boiko et al first explored the hypothesis that highly expressing CD271 melanoma cells 
are more tumorigenic in vivo by isolating CD271 +ve and  –ve melanoma cells from patient 
samples and transplanting them into T, B, and NK deficient Rag2−/− γc−/− mice (RG) mice. 
Results  demonstrated the increased tumorigenic potential of isolated CD271 +ve cells 
compared to CD271 –ve cells indicating that CD271 expression per se demonstrates increased 
tumourigenicity in vivo (Boiko et al., 2010a). However, subsequent studies have not been able 
to reproduce these findings and recent work by Quintana et al demonstrated that patient 
derived CD271 +ve and CD271 -ve cells exhibited similar tumorigenic potential once engrafted 
as single cells in nude mice (Quintana et al., 2010), with additional studies demonstrating 
CD271 +ve and –ve cells derived from patient tumour and transplanted into patient derived 
xenografts assays revealed similar ability to for either subset to initiate tumour development. 
However, genetic studies have highlighted the significant change in CD271 expression in 
secondary tumours derived from either CD271 +ve or –ve subpopulations indicating a rapid 
re-equilibration of marker-defined cell populations in these tumours and highlighting the 
unstable nature of CD271 expressing populations in this context (Boyle et al., 2016). 
Further evidence for an association between CD271 expression and melanoma progression is 
supported by studies of the immunohistochemical expression of CD271, demonstrating 
expression levels as high as 60% in advanced melanomas, correlated with high risk clinical and 
dermoscopic characteristics (Beretti et al., 2015) and thus indicating CD271 expression in 
primary melanomas is associated with poor prognosis. Interestingly, CD271 expression is also 
increased in melanoma associated cerebral metastases and other visceral metastases further 
indicating that constitutive CD271 expression may indeed play a role in melanoma progression 
(Guo et al., 2014a). 
These conflicting results highlight the complexity of CD271 expression and interactions, the 
possible unstable nature of CD271 de novo expression in melanoma but also indicate the 
potential association of CD271 expression with melanoma progression and metastasis. 
However, the mechanisms mediating the survival of these subpopulations and their ability to 
promote tumour migration, progression and metastasis remains poorly defined. The possible 
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interplay between autophagy and tumour cell survival (Lei et al.) in constitutively expressed 
CD271 positive melanoma subpopulations leads to the aims of the current chapter; to define 
the interplay between constitutive expression of CD271 in primary cutaneous melanomas in 
vivo and metastatic melanoma cells lines in vitro with autophagy, whether or not CD271 
expression is related to the expression of other neuroectodermal stem cell markers and to 
investigate the effect of autophagy inhibition in the survival of CD271 +ve expressing 
melanoma subpopulations. 
  
  Constitutive expression of CD271 in melanoma is associated with an increase in pro-survival 
basal autophagy 
 
 
 
88 
 
 Results 
3.2.1 CD271 expression is increased in advanced stage in primary cutaneous 
melanoma and is associated with active autophagy  
 
To confirm previously published data suggesting increased CD271 expression in advanced 
melanomas and further assess any potential correlation with autophagic activity, the 
immunohistochemical expression of CD271 was determined in a cohort of 5 benign naevi, 34 
metastatic cutaneous malignant melanomas (5 AJCC stage I, 15 AJCC stage II, 7 AJCC stage III) 
and 7 melanoma lymph node metastases. Initial experiments focused on the optimization of 
antigen retrieval and primary antibody conditions to reveal CD271 expression in formalin fixed 
and paraffin embedded tissue (FFPE). Since previous studies reported relatively low levels of 
CD271 expression in primary melanomas (Gray et al., 2015), immunohistochemical expression 
was pre-optimised using FFPE cell blocks derived from WM35 cells treated with 16 nM  
trametinib for 9 days (Figure 3-1: Optimization of an Immunohistochemical assay to detect 
CD271 expression in FFPE melanoma cell pellets (Figure 3-1).  Results demonstrated enhanced 
expression of CD271 in FFPE WM35 cells following treatment with trametinib compared to 
untreated control cells. Noteworthy also was the presence of positive CD271 staining in WM35 
parental cells, in line with the presence of small numbers of these subpopulations within the 
parental phenotype prior to trametinib treatment (Figure 3-1). Antigen retrieval optimisation 
was carried out using sodium citrate (10 mM, pH 6), Tris HCL pH7.6 and Tris HCL pH9, in which, 
as shown by Figure 3-1, revealed a clear difference in staining intensity between CD271 
expression in cell pellets derived from WM35 control cells and the increased staining intensity 
of CD271 positive cells following treatment with trametinib and revealed using Tris HCL pH 9 
as the antigen retrieval buffer and an antibody dilution of 1:100. However, in subsequent 
analysis of FFPE melanoma tissue primary antibody dilutions of 1:100 failed to detect CD271 
expression and hence a more concentrated dilution of 1:50 was adopted for subsequent 
analysis of expression in primary tissue (Figure 3-2). 
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Figure 3-1: Optimization of an Immunohistochemical assay to detect CD271 expression in FFPE melanoma cell pellets  
Representative photomicrographs for the immunohistochemical expression of CD271 (abcam, ab3125) in FFPE WM35 cells (WM35 control) or in FFPE WM35 cells 
following 9 days treatment with 16 nM trametinib (WM35 trametinib) to induce CD271 expression and revealed by antigen retrieval performed in Na Citrate (10 
mM, pH 6) (Na Citrate), Tris HCL pH 7.6 or pH 9 and using three different primary CD271 antibody concentrations: 1.100 (A.), 1.250 (B.) and 1.500 (C). Images were 
acquired at x20 magnification. Scale bar = 50 µM  
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Figure 3-2: 1:50 is the optimal CD271 antibody dilution for the detection of CD271 expression 
in FFPE melanoma tissue  
Representative photomicrographs for the immunohistochemical expression of CD271 (abcam, ab3125) 
in advanced stage IV melanoma (M045) at 1:50 antibody dilution (A) (M045 1:50), 1:100 antibody 
dilutions (B) (M045 1:100), null primary staining (C) (Null primary) or in FFPE WM35 cell pellet following 
9 days treatment with 16 nM trametinib (D) (Positive control) using Tris HCL pH 9 as antigen retrieval. 
Images were acquired at x20 magnification. Scale bar = 50 µM  
 
Using optimized conditions for immunohistochemical CD271 detection, subsequent 
experiments demonstrated increased expression of CD271 in primary cutaneous stage III 
melanomas compared to benign nevi (Figure 3-3), with analysis in 5 benign naevi and 27 
primary cutaneous melanomas of differing AJCC stages (5 AJCC stage I, 15 AJCC stage II and 7 
AJCC stage III) consistently revealing low levels of CD271 expression in benign naevi, and AJCC 
stage I and II melanomas compared to significantly increased expression in advanced stage 
melanomas (One way ANOVA test with Tukey’s multiple comparison test, **P<.0.01, 
***P<0.001, ****P<0.0001 (Figure 3-4). These findings were in line with previously published 
studies highlighting increased CD271 expression in advanced melanomas and the association 
with more aggressive disease (Ellis et al., 2014a; Beretti et al., 2015). 
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Figure 3-3: CD271 expression is increased in stage III malignant melanomas compared to 
benign naevi 
Representative photomicrographs for the immunohistochemical expression of CD271 (ab3125, diluted 
1:50 in A) a primary melanoma (with eventual AJCC stage IV disease) or B) a benign naevus. A i and B i 
x10 magnification, A ii and B ii x20 magnification. Scale bar = 50 µm (A I and B i) or 100 µm (A ii and B 
ii). 
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Figure 3-4: Immunohistochemical expression of CD271 is increased in stage III melanomas 
Representative photomicrographs for the immunohistochemical expression of CD271 in a benign 
naevus (i), an AJCC stage I (ii), stage II (ii) or stage III melanoma (iv). B. Mean % CD271 expression is 5 
naevi, 5 AJCC stage I, 17 AJCC stage II and 7 AJCC stage III melanomas. I, ii, iii, iv a: x 10magnification, 
scale bar = 100 µm. I, ii, iii, iv b: x 20magnification, scale bar = 50 µm.   Each point is the mean CD271 
expression of a minimum of 5 fields of vision. Horizontal lines represent median CD271 expression. 
**P<.0.01, ***P<0.001, ****P<0.0001  
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To evaluate a potential association between CD271 expression in vivo and autophagic activity, 
the expression of CD271 in 5 benign naevi and 27 primary cutaneous melanomas of differing 
AJCC stages (5 AJCC stage I, 16 AJCC stage II and 6 AJCC stage III) was correlated with the 
immunohistochemical expression of p62, determined using pre-standardized methodology 
(Ellis et al., 2014a). Results demonstrated the bi phasic expression of p62, with consistently 
low levels detected in benign naevi and AJCC stage I primary melanomas while expression 
significantly increased in AJCC stage II melanomas (One way ANOVA with Tukey’s post hoc 
correlation) for the comparison of median p62 expression in benign naevi or AJCC stage I 
primary melanomas with median expression in primary AJCC stage II melanomas, ** P < 0.01 
(Figure 3-5). Expression of p62 in AJCC stage III melanomas was however, significantly reduced 
compared to expression in AJCC stage II primary melanomas (One way ANOVA with Tukey’s 
multiple comparison test for the comparison of mean p62 expression in AJCC stage II primary 
melanomas with mean expression in primary AJCC stage III melanomas, *P<0.05 , Figure 3-5), 
consistent with the paradoxical role of autophagy in cancer and suggesting AJCC stage III 
melanomas in which CD271 expression was increased are associated with an increase in basal 
autophagy (as reflected by reduced levels of p62 (Figure 3-5B). 
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Figure 3-5: p62 expression in primary melanomas is increased in stage II melanomas and 
decreases in stage III melanomas 
A.Representative photomicrographs for the immunohistochemical expression of p62 in a benign 
naevus (i), a primary AJCC stage I (ii), stage II (iii) or stage III (iv) melanoma. B. Mean % p62 expression 
in 5 benign naevi, 5 AJCC stage I, 17 AJCC stage II and 7 AJCC stage III (iv) primary melanomas. Each 
point is the mean % p62 expression of a minimum of 5 fields of vision. Horizontal lines represent 
median expression levels of CD271 expression. * P< 0.05** P < 0.01.   
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Further analysis revealed a significant correlation between decreased CD271 and increased 
p62 expression in primary AJCC stage II melanomas (Spearman correlation coefficient R2: 
0.0569, P= 0.04, Figure 3-6A). However, although a trend for a correlation between reduced 
p62 and increased CD271 expression was evident in AJCC stage III melanomas, this was not in 
fact significant (Spearman correlation coefficient R2: 0.0135, P= 0.49, Figure 3-6B). 
Nevertheless, collectively these data highlight a relationship between increased CD271 
expression and an increase in basal autophagic activity in more advanced primary melanomas 
in vivo. 
 
Figure 3-6: Increased CD271 expression in stage II primary melanomas is associated with 
decreased p62 expression   
Scatter plots of mean % CD271 and p62 expression in AJCC stage II (A.) or stage III (B.) melanomas. 
Each point represents the mean % CD271/p62 expression in an individual primary melanoma derived 
from 10 representative fields of vision P= 0.04, Spearman correlation coefficient R2: 0.0569, P=0.49, 
Spearman correlation coefficient R2: 0.0135) 
To further evaluate the relationship between constitutive CD271 expression and autophagy 
status in melanoma, studies of CD271 expression were further undertaken in a panel of 
primary melanocytes and human melanoma cell lines derived from both primary and 
metastatic tumours, as well as in isolated CD271 +ve and –ve subpopulations derived from the 
metastatic melanoma cell lines WM35 and SK-mel-28 with additional correlative studies of 
CD271 expression in melanoma in vitro with autophagy status as determined by p62 or LC3-II 
expression.  
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3.2.2 Basal CD271 mRNA and protein expression is variable in human 
melanoma cell lines and primary melanocytes 
 
Analysis of both basal CD271 protein and mRNA expression levels in primary melanocytes 
derived from two independent donors and a cohort of 10 melanoma cell lines revealed 
variable expression with no particular trend for any change in expression between melanoma 
cell lines bearing a BRAF mutation (WM35, A375, SK-mel-28, WM164 (all BRAFV600E mutant), 
WM266-4 (BRAFV600D mutant), an NRAS mutation (WM-1361), or those wild-type for BRAF/ 
NRAS (SK-mel-23, CHL-1, C8161, Mel 50) (Figure 3-7). 
Furthermore, CD271 mRNA expression levels did not correlate with levels of protein 
expression, with higher levels of CD271 mRNA observed for example, in WM266-4 and CHL-1 
cells, indicating CD271 mRNA may not be translated and highlighting the potential for complex 
post translational modifications, consistent with reported literature (Vogel and Marcotte, 
2012). 
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Figure 3-7: Expression of CD271 mRNA and protein varies in human primary melanocytes 
and melanoma cell lines.  
A.Representative western blot for basal CD271 expression (75kDa) and b actin (42kDa) in three primary 
melanocyte samples (M1058F, M1054F and M880F) and BRAF mutant cell lines (WM35, A375 and SK-
mel-28). B. Representative western blot for basal CD271 expression (75kDa) and b actin (42kDa) in 
included WM35, A375, SK-mel-28, WM164 (all BRAF mutant), WM266-4 (BRAF V600D mutant), SK-mel-
23, CHL-1, C8161, Mel 505 (all BRAF Wild Type) and WM-1361 (NRAS mutant) cell lines. C. Relative 
mRNA expression of CD271 (relative to 18S loading control). Each bar is the mean of three replicate 
experiments in all cell lines/melanocytes. 
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3.2.3 Constitutive CD271 expression in isolated CD271 expressing melanoma 
cells in vitro is associated with increased autophagic activity but is not 
associated with the expression of other neuro ectodermal stem cell 
markers 
 
To further delineate a potential association between constitutive CD271 expression and 
autophagy, CD271 positive and negative subpopulations were initially isolated from either 
WM35 or SK-mel-28 melanoma cells using Miltenyi Biotec magnetic columns prior to the 
analysis of CD271 expression by western blotting (Figure 3-8) or associated expression of LC3II 
or p62 as standard markers of autophagic activity (Figure 3-9). Results demonstrated the 
increased expression of CD271 in isolated subpopulations from either cell line, although 
expression of CD271 was only consistently significant in CD271 +ve subpopulations derived 
from WM35 cells (One way ANOVA with Tukey’s multiple comparison test **P<0.01, (Figure 
3-8A).  
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Figure 3-8: Isolation of CD271 subpopulations from melanoma cell lines confirmed by 
constitutive expression of CD271    
Representative western blot for CD271 expression in WM35 (A) and SK-mel-28 (B) subpopulations 
following isolation using magnetic microbead-tagged CD271 antibodies and columns, and relative 
CD271 expression in CD271 positive and negative subpopulations derived from WM35 (A) or SK-mel-
28 (B) cells. Each bar represents the mean of 3 replicate experiments relative to b actin loading control. 
**P<0.01 
Furthermore, the expression of CD271 in CD271 +ve isolated subpopulations derived from 
WM35 cells was associated with a significant reduction in p62 expression (One way ANOVA 
with Tukey’s multiple comparison test, **P< 0.01, (Figure 3-9 Ai and iii) and a non-significant 
trend for the expression of LC3-II compared to a reduction in expression in CD271 –ve 
subpopulations (Figure 3-9 Ai and ii). Similarly, in isolated CD271 positive subpopulations 
derived from SK-mel-28 cells, there was a trend for an associated increase in LC3 II and a 
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decrease in p62 expression, although this was not statistically significant (Figure 3-9B). 
Conversely, there was no significant change in either LC3 II or p62 expression in CD271 
negative subpopulations compared to expression in wild type SK-mel-28 cells (Figure 3-9B). 
Although suggesting a potential association of increased autophagic activity with constitutive 
CD271 expression, experiments using chloroquine (added to given treatment conditions for 
the final 2 hours) to block autophagic flux were undertaken to confirm any association.  
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Figure 3-9: Constitutive expression of CD271 is associated with decreased p62 expression  
Ai and Bi, Representative western blots for CD271 (75kDa), LC3 I/II (16-18kDa), p62 (62kDa) and b actin 
(loading control, 42kDa) expression or relative LC3 II (A and B ii) or p62 (A and B iii) expression in wild-
type (control), CD271 positive (CD271 +) or CD271 negative (CD271 -) subpopulations isolated from 
WM35 (A) or SK-mel-28 (B) cells. A/B ii or iii; Each bar represents the mean of 3 replicate experiments 
expressed relative to the mean of each individual experiment (mean ± SD, N = 3) **P<0.01 
Previous studies have shown that the expression of CD271 in vitro is unstable (Boyle et al., 
2016). The potential for the rapid re-equilibration of isolated CD271 expressing melanoma 
subpopulations may thus be a potential limiting factor in subsequent functional studies of 
such subpopulations with further culture or use in xenograft models in vivo. To investigate the 
stability of CD271 expression in isolated melanoma subpopulations, isolated subpopulations 
derived from WM35 cells were cultured for 3 or 6 days under standard conditions (37oC, 21% 
O2 and 5% CO2) prior to the analysis of CD271 expression as well as LC3 I/II expression, to 
correlate any impact on basal autophagy status. Results demonstrated the significant increase 
in CD271 expression (One way ANOVA test with Tukey’s multiple comparison test, ** P<0.01), 
( 
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Figure 3-10A)  immediately following magnetic micro bead selection but which was reduced 
following 3 days of culture and further declined after day 6 continued culture ( 
Figure 3-10).  LC3 II expression on the other hand was increased in CD271 positive WM35 
subpopulations compared to CD271 negative subpopulations immediately following isolation 
and remained at a similar level in CD271 positive subpopulations after 3 and 6 days of 
continued culture ( 
Figure 3-10). 
Collectively these data thus confirmed the unstable nature of CD271 expression after 3 days 
culture but interestingly the continued increase in basal autophagic activity over 6 days in 
isolated CD271 positive melanoma sub populations despite the gradual decline in CD271 
expression. Nevertheless, since CD271 expression in isolated melanoma subpopulations was 
stable for at least 3 days, this enabled subsequent experiments to investigate the invasive 
potential of such subpopulations (described in Figure 3-13, section 3.2.5) within this time 
frame. To investigate the functional impact of CD271 expression over longer time periods, for 
example, on tumour invasive potential, CD271 was over expressed in human melanoma cell 
lines and these studies are described in chapter 4.  
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Figure 3-10:  CD271 expression in isolated CD271 positive subpopulations declines over time 
A.Representative western blot of CD271 (75 kDa), LC3 I/II (16-18 kDa), b actin (42 kDa, loading control) 
in WM35 melanoma cells (control) or in CD271 +ve and –ve subpopulations   following magnetic 
microbead selection and continued culture for 0, 3 or 6 days. B. Relative CD271 (i) and LC3 II (ii) protein 
expression in isolated WM35 CD271 +ve or –ve subpopulations following 0 (D0), 3 (D3), or 6 (D6) days 
continued culture, relative to b actin protein expression. Each bar represents the mean of 3 replicates 
for each cell line, normalized to b actin and expressed relative to the mean control of each individual 
experiment (mean ± SD, N = 3) (*p<0.05, **p<0.01) 
 
To further investigate the potential correlation between CD271 expression and increased 
autophagic activity, CD271 positive and CD271 negative subpopulations isolated from WM35 
cells, stably expressing red fluorescent protein were grown as 3D spheroids prior to 
incorporation into collagen gels and the analysis of CD271 and p62 expression by 
immunofluorescence. Results revealed by day 7, CD271 negative subpopulations acquired 
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CD271 expression in the centre of the spheroid while p62 expression was observed only at the 
periphery of the spheroid where its expression was increased compared to expression in the 
centre (Figure 3-11) indicating active autophagy in the nutrient deprived core of the spheroid 
where CD271 expression is acquired. Conversely, CD271 expression was retained in CD271 
positive subpopulations where in this case there was no observable distinct pattern of p62 
expression indicating similar autophagic activity throughout these spheroids (Figure 3-11).  
Taken together these data highlight the dynamic regulation of CD271 expression and a 
correlation with reduced p62 expression, further supporting observations of increased 
autophagic activity within CD271 positive melanoma subpopulations.  
 
Figure 3-11  CD271 expression in melanoma spheroids is associated with reduced p62 
expression in the centre of spheroid 
Immunofluorescence images for the expression of CD271 and p62 expression (green 
fluorescence) in CD271 positive and negative WM35 spheroids stably expressing red 
fluorescent protein. Scale bar 100 μm.  
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3.2.4 Constitutive CD271 expression is not associated with the expression of 
other neuro ectodermal stem cell markers 
 
Recent published literature highlights CD271 as a putative stem cell marker and its associated 
expression with other neuroectodermal stem cell markers (Roesch et al., 2010; Cheli et al., 
2014a; Ladstein et al., 2014; Zhang and Herlyn, 2014). However, there is conflicting evidence 
as to whether CD271 in melanoma serves as a stem cell marker or whether its expression is 
more associated with the emergence of chemo resistance to targeted therapies and 
conventional chemotherapy (Chartrain et al., 2012; Ravindran Menon et al., 2014). To 
investigate the potential association and overlap between the expression of CD271 in isolated 
CD271 positive and negative subpopulations derived from WM35 cells and the expression of 
other stem cell markers, expression of SOX10, Jarid-1B and Nestin in selected subpopulations 
were determined by Western blotting. Results demonstrated poor overlap and no significant 
correlation between CD271 expression in enriched CD271 subpopulations with either Nestin, 
Jarid-1B or SOX 10 expression (Figure 3-12) with in fact, a trend for increased Nestin 
expression in CD271 negative sub populations (Figure 3-12), suggesting CD271 expression is 
isolated melanoma subpopulations may not be a marker of stem ness or a stem cell 
phenotype. 
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Figure 3-12: CD271 expression in isolated melanoma subpopulations is not associated with 
the expression of neuroectodermal stem cell markers.  
A.Representative western blot for the expression of Nestin (177 kDa), Jarid-1B (190 kDa), SOX 10 (37 
kDa) or GAPDH (37 kDa) in WM35 cells (control) or CD271 positive (CD271 +ve) and negative (CD271 –
ve) subpopulations selected from WM35 cells. B. Relative Nestin, Jarid-1B or SOX10 expression in 
CD271 positive and negative WM35 subpopulations, relative to GAPDH expression. Each bar is the 
mean of 3 biological replicates for each cell line, expressed relative to the mean control of each 
individual experiment (mean ± SD, N = 3)  
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3.2.5 Constitutive expression of CD271 is associated with reduced spheroid 
expansion in vitro 
 
In addition to the ongoing debate about the role of CD271 expressing melanoma 
subpopulations in melanoma initiation, the role of CD271 expression in tumour invasion and 
metastasis is also poorly defined. Several recent publications highlight the presence of distinct 
subpopulations within the CD271 expressing melanoma subpopulations that exhibit 
tumourigenic and invasive properties in contrast to the bulk of the CD271 positive 
subpopulation that remains less invasive compared to CD271 negative subpopulations (Cheli 
et al., 2014a).  
To investigate the spheroid expansion of constitutive CD271 expression in cutaneous 
melanoma, isolated CD271 positive and negative subpopulations derived from WM35 or SK-
mel-28 cells (stably expressing RFP) were grown as 3D spheroids prior to incorporation into 
collagen gels and the monitoring of spheroid expansion over 96 hours. Results demonstrated 
a significant reduction in spheroid expansion of both WM35 and SK-mel-28 CD271 positive 
(CD271 +ve) compared to CD271 negative (CD271 -ve) subpopulations after 96 hours (Two-
way ANOVA with Sidak multiple comparison test, ****p<0.0001) (Figure 3-13) suggesting, in 
line with published literature, that constitutive CD271 expression does not necessarily confer 
a more invasive phenotype (Saltari et al., 2016) and that the role of CD271 is possibly more 
associated with chemo resistance to targeted therapies/chemotherapy. 
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Figure 3-13: Spheroid derived from CD271 positive melanoma subpopulations exhibit 
reduced collagen expansion compared to CD271 negative subpopulations  
Representative immunofluorescence images of spheroids derived from WM35 RFP (A i) or Sk-mel-28 
(B i) CD271 negative (CD271 –ve) or positive (CD271+ve) subpopulations in collagen gels. Scale bar + 
or Images were acquired as a total magnification of X20.  A and B ii; Relative spheroid size (µm) of 
WM35 (A ii) or SK-mel-28 (B ii) CD271 negative (red line) or positive (green line) spheroids (relative to 
initial spheroid size at time 0 hours) over 96 hours.  Each bar is the mean of 3 replicate experiments ± 
SD. ****P<0.0001  
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3.2.6 Chemical inhibition of autophagy with chloroquine or selective Vps34 
inhibitors inhibit the viability of isolated CD271 positive melanoma 
subpopulations in vitro 
 
Data presented above highlight the association between constitutive CD271 expression and 
increased autophagy. To further investigate this link and whether autophagy in this context 
plays a pro-survival role, contributing to the survival of CD271 positive melanoma 
subpopulations, autophagic activity in selected/isolated melanoma subpopulations was 
blocked either by treatment with the lysosomal inhibitor chloroquine of with a specific Vps34 
inhibitor, PIK III. 
 Treatment of isolated CD271 positive and negative subpopulations from WM35, SK-mel-28 
or A375 BRAF mutant melanoma cells with 10 µM of chloroquine for 24 hours resulted in the 
significant inhibition of cell viability in CD271 positive with little or no effect on the cell viability 
of CD271 negative subpopulations derived from either cell line (One-way ANOVA, Tukey’s 
multiple comparison test, **P<0.01, ****P<0.0001 (Figure 3-14). 
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Figure 3-14: Chloroquine inhibits the cell viability of melanoma CD271 expressing 
subpopulations 
Relative cell viability of WM35 (A), SK-mel-28 (B), A375 (C) isolated CD271 positive or negative 
subpopulations in the presence or absence of treatment with 10 µM chloroquine for 24 hours (relative 
to control untreated CD271 positive or negative cell viability). Each bar is the mean cell viability of 12 
replicates from 3 independent experiments + SD. **P<0.01, *****P<0.0001. 
 
To further define whether the observed effect on cell viability was a dose dependent effect of 
chloroquine on the isolated cells rather than a direct effect of autophagy inhibition, further 
dose response studies of chloroquine were performed over clinically achievable 
concentrations. Results demonstrated isolated CD271 positive WM35 and A375  
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subpopulations treated with 1, 5 or 10 µM chloroquine for 24 hours resulted in consistently 
inhibited cell viability, again with little or no effect observed in CD271 negative subpopulations 
form either cell line in response to treatment with chloroquine at any dose (one way ANOVA 
with Tukey’s multiple comparison test *P<0.05, **P<0.01) ( 
Figure 3-15). Taken together these data thus further support a pro-survival role for autophagy 
in melanoma subpopulations constitutively expressing CD271. 
 
Figure 3-15 Chloroquine selectively inhibits cell viability of CD271 expressing melanoma 
subpopulations 
Relative cell viability of WM35 (A) or A375 (B) isolated CD271 positive or negative subpopulations 
(relative to control untreated CD271 positive or negative cell viability) following treatment for 24 hrs 
in the presence or absence of 1, 5 or 10 µM chloroquine. Each bar is the mean cell viability of 12 
replicates from 3 independent experiments + SD. *P<0.05, **P<0.01. 
To confirm chloroquine-mediated inhibition of CD271 expressing melanoma subpopulation 
cell viability was specific to autophagy inhibition, isolated CD271 positive or negative WM35 
or A375 melanoma subpopulations were treated in the presence of PIK III, a selective and 
novel inhibitor of Vps34 enzymatic function, essential for the lipidation of LC3 and degradation 
of autophagy substrates such as p62 and mitochondria (Dowdle et al., 2014). Control wild-
type WM35 or A375 melanoma cells were first treated for 24 hours in the presence or absence 
of dose reducing concentrations of PIK III; 10, 5, 1 µM or 100 or 10 nM for 24 hrs prior to the 
assessment of cell viability. Results demonstrated the significant inhibition of cell viability in 
both cell lines following 24-hour treatment with higher concentrations of 10 µM PIK III (one-
way ANOVA analysis of variance with Tukey’s multiple comparison test, **P<0.01 for the 
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inhibition of WM35 and ****P<0.0001 for the inhibition of A375 cell viability, Figure 3.16). 
However, at concentrations of 5 µM and below PIK III had no significant effect on the inhibition 
of the cell viability in either cell line (Figure 3-16). 
 
Figure 3-16: Dose-dependent inhibition of melanoma cell viability in vitro by the Vps34 
inhibitor PIK III  
Relative cell viability of WM35 (A) or A375 (B) in the absence (control) or presence of treatment for 24 
hrs with 10, 5 or 1 µM or 100, 10 nM PIK III (relative to DMSO vehicle control treated cells). Each bar 
is the mean cell viability of 12 replicates from 3 independent experiments + SD. **P<0.01, 
****P<0.0001. 
To evaluate the potential for Vps34 inhibition to inhibit basal autophagy in wild-type WM35 
or A375 melanoma cells, each cell line was treated in the presence or absence of 5 µM of PIK 
III for up to 24 hours, prior to western blotting for p62 and LC3 /II expression. In WM35 cells, 
results demonstrated a significant decrease in basal LC3 II expression following treatment with 
PIK III for 2 or 4 hours (One way ANOVA with Tukey’s multiple comparison test, *P <0.05, 
***P<0.001) which then increased after 24 hours continuous treatment (Figure 3-17 A i and 
ii). Similar effects were also observed in A375 cells (Figure 3.17 B i and ii) although PIK III-
induced inhibition of LC3 II was only significant after 2 hours treatment. PIK III-induced p62 
expression on the other hand revealed a trend for increased expression in a time dependent 
manner in both WM35 and A375 cells, although induction was only significant in WM35 cells 
following 24 hrs treatment with PIK III (One way ANOVA with Tukey’s multiple comparison 
test, *P <0.05, ***P<0.001, Figure 3-17 A iii). Interestingly it has been reported that PIK III 
inhibits the formation of autolysosomes and the lipidation of LC3 and therefore basal levels of 
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either LC3 I or II may appear increased (Dowdle et al., 2014) likely due to continued LC3 
transcription, and noteworthy in the present study this was corroborated by  the apparent 
increase in LC3 I expression, particularly in WM35 cells following treatment with PIK II for 2-
24 hrs (Figure 3-17 Ai), as well as in A375 cells (Figure 3-17 Bi). Collectively nevertheless, these 
data suggest that concentrations of 5 µM PIK III inhibit autophagy at 24 hours.  
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Figure 3-17: PIK III inhibits basal autophagy in melanoma cells in vitro in a time dependent 
manner    
Representative western blots for the expression of p62 (kDa size), LC3 I/II (kDa sizes), or β-actin loading 
control (kDa sizes) in WM35 (Ai) or A375 (Bi) melanoma cells (control) or following treatment with 5 
µM PIK III for 2, 4 or 24 hours. A or B I or ii; Relative LC3 II (A/B ii) or p62 expression (A/B iii, relative to 
b actin protein expression) in WM35 (A) or A375 (B) melanoma cells (control) or following 2, 6 or 24 hr 
treatment with 5 µM PIK III. Each bar is the mean of 3 biological replicates for each cell line, and 
expressed relative to the mean control of each individual experiment (mean ± SD, N = 3, *P<0.05, 
***P<0.001  
  Constitutive expression of CD271 in melanoma is associated with an increase in pro-survival 
basal autophagy 
 
 
 
115 
 
Finally, to assess the effect of specific autophagy inhibition on the cell viability of isolated 
CD271 positive and negative melanoma subpopulations in vitro, CD271 positive and negative 
subpopulations derived from either WM35 or A375 cells were treated in the presence or 
absence of 5 µM PIK III for 24 hours prior to the assessment of cell viability. Results 
demonstrated PIK III induced inhibition of both CD271 positive and negative subpopulations 
derived from either cell line (Figure 3-18), however, a significant reduction in the cell viability 
of CD271 positive cells compared to CD271 negative cells was observed in both WM35 and 
A375 subpopulations (one-way ANOVA analysis of variance with Tukey’s multiple comparison 
test **P<0.01 for A375, ***P<0.001 for WM35) (Figure 3-18). Collectively these data thus 
highlight the intimate relationship between constitutive expression of CD271 by melanoma 
subpopulations and increased basal autophagy and suggest CD271 positive subpopulations 
depend on pro-survival autophagy for survival. 
 
Figure 3-18: Autophagy blockade by Vps34 specific inhibition inhibits the cell viability of 
CD271 expressing melanoma subpopulations 
Relative cell viability of WM35 (A) or A375 (B) isolated CD271 positive and negative subpopulations 
following treatment for 24 hrs with 5 µM PIK III (data expressed relative to control untreated cells). 
Each bar is the mean cell viability of 12 replicates from 3 independent experiments ± SD. **P<0.01, 
***P<0.001. 
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 Discussion 
3.3.1 Constitutive expression of CD271 in vitro and in vivo, a marker of an 
aggressive melanoma phenotype? 
 
To date, the only well-established predictors for melanoma progression and metastasis are 
those included in current AJCC staging, namely tumour Breslow thickness, ulceration and the 
presence of mitoses (Charles et al., 2009). However, these markers do not capture all high-
risk melanomas and occasionally melanomas with indolent tumoural characteristics still go on 
to develop metastatic disease with associated poor prognosis, thereby emphasizing the acute 
need for credible biomarkers able to identify high risk tumour subsets.  Recent literature 
highlights the presence of subpopulations within melanomas that exhibit a more aggressive 
phenotype and express neural crest stem cell markers. A number of these melanoma 
subpopulations have been described including those expressing neuroectodermal stem cell 
markers such as Nestin, SOX10, Jarid-1B and ABCB5 (Roesch et al., 2010; Chartrain et al., 2012; 
Ladstein et al., 2014; Zhang and Herlyn, 2014), while expression of the neural crest stem cell 
marker CD271 has been linked to both melanoma progression as well as resistance to targeted 
therapies (Ravindran Menon et al., 2014; Beretti et al., 2015). The observations of high levels 
of constitutive CD271 expression in metastatic melanoma tissue compared to expression 
observed in early AJCC stage primary melanomas that did not progress in the present study, 
are thus consistent with the association of such subpopulations with metastasis. These data 
therefore highlight constitutive CD271 expression as a marker of advanced, stage III 
melanomas. However, as CD271 expression was very low in benign naevi, stage I and stage II 
melanomas, the expression of CD271 could not serve as an early prognostic biomarker but the 
presence of increased CD271 expression could signify more advanced and aggressive 
melanomas.  
Data form the present study additionally highlighted the variable expression of CD271 
expression in primary melanocytes, primary and metastatic melanoma cell lines in vitro, 
consistent with previous findings reporting a diverse range in CD271 expression from 3-70% 
and a cell line dependent effect (Gray et al., 2015). Interestingly, current data also 
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demonstrated the disproportionate expression of CD271 at the mRNA and protein level, a 
phenomenon previously linked to  protein translation efficiency, protein half-life and protein 
turnover (Vogel and Marcotte, 2012) and factors which perhaps explain the current mismatch 
between protein and mRNA expression observed between many cell lines. Phenomenon 
which was particularly pronounced in WM164 cells demonstrating high expression of CD271 
at the protein level but which was not accompanied by increased expression at the mRNA 
level or in CHL-1 cells where high levels of CD271 mRNA level were not translated at the 
protein level.   
As mentioned, recent literature suggests CD271 as a putative stem cell marker in melanoma 
(Boiko et al., 2010a), although there is conflicting evidence for an association between CD271 
expression and other stem cell markers and the significance of such an association if any, in 
melanomagenesis (Boiko et al., 2010a; Quintana et al., 2010) and melanoma progression 
(Beretti et al., 2015). A recent publication by Redmer et al suggests only a fraction of CD271 
positive cells are present in melanoma tumours in vivo which co-express the associated gene 
and stem cell marker, CD133 (Redmer et al., 2014a). Nevertheless, Redmer et al reported the 
constitutive expression of CD271 prevented melanoma cell differentiation and hence these 
studies support CD271 expression by melanomas as a stem like marker. Another study by Cheli 
et al also highlighted the poor overlap between the expression of CD271 in vitro and in vivo 
and the co- expression of another neuroectodermal stem cell marker,  ABCB5 (Cheli et al., 
2014a). Interestingly, this group also confirmed the association of CD271 expression with an 
increase in the expression of other markers of ‘stem ness’, including expression of CD271 per 
se by melanoma cells is associated with a stem –like phenotype. Other stem like markers that 
have been described to be associated with melanoma progression and resistance to 
chemotherapy and targeted therapies include Nestin, a marker neural progenitor cells 
important for the development of the central nervous system and which is associated with 
more aggressive cutaneous melanomas (Ladstein et al., 2014). Jarid-1B, a member of the 
highly conserved family of jumonji/ARID1 (JARID1) histone 3 K4 (H3K4) demethylases is also 
associated with a chemo resistant slow cycling melanoma subpopulation (Roesch et al., 2010). 
However, co-expression of CD271 with either of these stem cell markers still remains 
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inconclusive controversial. Data reported in the present chapter however, demonstrated a 
poor association between CD271 expression and the co-expression of other stem cell markers; 
Jarid-1b, nestin and SOX10, suggesting constitutive CD271 expression may not in fact be linked 
to a melanoma stem like phenotype. Nevertheless, since the present study did not evaluate 
the co-expression of CD271 with these markers at a single cell level, the derived results should 
be interpreted with some caution as a mixed population may have been present in vitro and 
studies within isolated CD271 positive and negative melanoma subpopulations in vitro 
skewing the derived data. Thus, the correlation between constitutive CD271 expression by 
melanoma with a stem cell phenotype remains somewhat enigmatic.  
Concerning a link between constitutive CD271 expression by melanoma subpopulations and 
the contribution or role of such subpopulations to melanoma invasion and tumourigenicity, 
data derived from the present chapter suggest melanoma cells constitutively expressing 
CD271 exhibit reduced spheroid expansion in vitro compared to their CD271 negative 
counterparts. These data are consistent with recent reports demonstrating CD271 negative 
cells are more invasive in vitro in collagen based invasion assays as well as in skin equivalent 
models and in vivo in a zebrafish xenograft model (Saltari et al., 2016). However, additional 
studies by Cheli et al add further complexity to the role of CD271 in melanoma 
tumourigenecity, describing alternative subcategorization of CD271 positive and negative 
melanoma and the existence of a sub sets expressing high levels of CD271 and which are 
characterized by their slow growth but highly tumorigenic potential or subpopulations which 
express low levels of CD271 but which display a high proliferation rate with low tumorigenic 
potential (Cheli et al., 2014a).  
Having made the association between constitutive CD271 expression and a more aggressive 
but less invasive melanoma phenotype, and in line with previous studies suggesting a pro-
survival role of autophagy in cancer stem cell  (Maycotte et al., 2015b) (Yang et al., 2015b) 
survival, few studies however have investigated the potential association, if any, between 
constitutive CD271 expression and autophagy. 
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3.3.2 Linking constitutive CD271 expression with autophagy 
 
Previous data from the Lovat group has shown the biphasic expression of p62 is consistent 
with the paradoxical role of autophagy in cancer (Ellis et al., 2014a). Autophagy functions to 
remove degraded cellular debris; failure to execute this function results in the accumulation 
of toxic cellular waste, thereby driving tumourigenesis (Mathew et al., 2007) while autophagy 
activation in the hypoxic environment of solid tumours such as melanoma serves to promote 
tumour survival and metastatic development (Ma et al., 2014). Consistent with the studies by 
Ellis et al (Ellis et al., 2014a), data derived from the present study revealed expression of p62 
in naevi and primary AJCC stage I melanomas was reduced compared to expression in AJCC 
stage II and III. These observations thus support a potential association between the 
constitutive expression of CD271 by some melanoma subpopulations within a more aggressive 
melanoma and increased autophagic activity. However, in the present study this correlation 
was only statistically significant in AJCC stage II tumours and not in stage III. The lack of 
statistical significance in this context however, may reflect the small sample size of stage III 
tumours accessed and therefore further studies in an expanded cohort of AJCC stage III 
melanomas are required to provide a clear and more representative analysis and the 
validation of a potential correlation between constitutive CD271 expression and increased 
autophagic activity in vivo.  
Breast and pancreatic cancer stem cell research has additionally highlighted the pivotal role 
of autophagy in the survival of breast (Maycotte et al., 2015b) and pancreatic (Yang et al., 
2015b) cancer stem cells. Although results from the present study demonstrated a trend for 
increased basal autophagic activity in isolated CD271 positive compared to negative 
subpopulations in vitro, this association was not in fact significant. It should be noted however, 
that studies to support associated increased LC3-II expression in isolated CD271 melanoma 
subpopulations in vitro were performed in the absence of the addition of chloroquine to block 
autophagic flux (Loos et al., 2014) and hence the incorporation of such experiments in future 
studies is required to more definitively validate the association between constitutive CD271 
expression and the apparent increase in basal autophagy in such subpopulations in vitro. As 
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well as reporting a potential association between CD271 expression and increased basal 
autophagy in isolated melanoma subpopulations, the present study also revealed the 
plasticity and instability of CD271 expression in melanoma was more pronounced in 3D 
spheroids culture in which CD271 negative subpopulations acquired CD271 expression in the 
centre of the spheroid while p62 expression was observed only at the periphery of the 
spheroid, indicating active autophagy in the nutrient deprived core of the spheroid where 
CD271 expression is acquired. Conversely, CD271 expression was retained in CD271 positive 
subpopulations in which there was no observable distinct pattern of p62 expression and 
indicating similar autophagic activity throughout these spheroids. Collectively these data thus 
further support the notion that constitutive CD271 expression by melanoma cells in vitro is 
associated with increased autophagic activity. However, there is increasing evidence to 
support the influence of micro environmental factors on stem cell development and 
metastatic potential (Scott et al., 2014). A recent paper by Menon et al, investigating the role 
of micro environmental variables such as hypoxia and nutrient deprivation on CD271 
expression (Ravindran Menon et al., 2014) demonstrated the induction of CD271 expression 
in response to pronounced hypoxia (5 or 1% O2) as well as glucose deprivation indicating an 
early stress response to hostile micro environmental factors. Results from the present studies 
highlight the unstable nature of CD271 expression, and hence stability may depend on the 
hypoxic environment and nutrient availability additionally shown in other studies to influence 
the induction of CD271 expression (Ravindran Menon et al., 2014).  
There is increasing evidence associating cancer stem cells with the activation of pro-survival 
autophagy (Mowers et al., 2017). However, there is little evidence to suggest the blockade of 
autophagy in melanoma stem like cells may present a viable approach to prevent the survival 
of such subpopulations or influence melanomagenesis. Data from the present study 
demonstrated blocking autophagy in isolated CD271 positive melanoma subpopulations in 
vitro with the lysosomal inhibitor chloroquine, resulted in the consistent inhibition of cell 
viability of such subpopulations derived from multiple cell lines, thereby supporting the notion 
that CD271 positive subpopulations, which as discussed above may not represent a true stem 
like subpopulation, nevertheless use autophagy to maintain survival. However, chloroquine is 
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not a specific autophagy inhibitor and hence additional studies of autophagy inhibition in 
melanoma subpopulations constitutively expressing CD271 were undertaken using a selective 
inhibitor of the Vps34 complex. Results demonstrated the Vps34 inhibitor, PIK III blocked both 
autophagy and the cell viability of wild-type WM35 and A375 melanoma cells as well as CD271 
positive subpopulations derived from either cell line compared to CD271 negative 
subpopulations, collectively further supporting the hypothesis that melanoma cell 
subpopulations constitutively expressing CD271 use autophagy as a pro-survival mechanism.  
Collectively results from this chapter highlight the association of CD271 expression with more 
aggressive melanomas and the correlation of CD271 expression with increased autophagic 
activity both in vitro and in vivo. Contrary to the original hypothesis of the present study it 
seems collectively however, that constitutive expression of CD271 expression by melanoma 
subpopulations is associated with reduced spheroid expansion, raising the question as to 
whether drug-induced CD271 melanoma subpopulations represent an inherently different 
phenotype which play a differing role in melanoma invasion and progression. These questions 
are addressed in the following chapters to the present thesis.  
  
  Constitutive expression of CD271 in melanoma is associated with an increase in pro-survival 
basal autophagy 
 
 
 
122 
 
 Summary 
 
• Constitutive expression of CD271 is increased in advanced primary AJCC stage III 
melanomas compared to AJCC stage I, II or benign naevi  
 
• Constitutive expression of CD271 in AJCC stage II melanomas is inversely correlated 
with p62 expression indicating CD271 expression in vivo is associated with increased 
basal autophagy  
 
• Primary melanocytes, primary and metastatic melanoma cell lines display variable 
CD271 mRNA and protein expression 
 
• CD271 positive melanoma subpopulations isolated from metastatic melanoma cell 
lines in vitro display increased basal autophagy  
 
• Constitutive expression of CD271 by melanoma cells in vitro does not correlate with 
the expression of other neuroectodermal stem cell markers 
 
• Spheroid derived from CD271 positive melanoma subpopulations isolated from 
metastatic melanoma cell lines in vitro exhibit reduced spheroid expansion in collagen 
gels than their CD271 negative counterparts  
 
• Inhibition of autophagy with chloroquine or a specific inhibitor of Vps34 results in 
significant reduction in cell viability of CD271 positive compared to CD271 negative 
melanoma subpopulations isolated from melanoma cell lines in vitro. 
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Chapter 4 Drug-induced or overexpression of CD271 in 
melanoma is associated with increased pro-survival 
autophagy and reduced collagen expansion 
 Introduction 
 
Although the prognosis for early AJCC stage melanomas is excellent, for patients with 
malignant AJCC stage IV disease, prognosis remains very poor with continued 5 year survival 
rates of 10-20% (http://www.cancerresearchuk.org/about-cancer/melanoma/survival, 2016). 
The recent identification of driver mutations in BRAF, present in approximately 60% of all 
melanomas (Ascierto et al., 2012) has unveiled a new era in targeted therapy for patients with 
advanced BRAF mutant melanoma. BRAF and subsequently MEK inhibitors have been 
developed to target activated MAPK signalling, showing significant benefit in progression free 
and overall survival for patients with stage IV metastatic melanoma (Chapman et al., 2011; 
Long et al., 2014). However, the early development of acquired resistance to BRAF inhibitors 
(usually established after 6-9 months of treatment initiation (Shi et al., 2014) which although 
may delayed by up to 12 months through combined therapy with novel generation MEK 
specific inhibitors (Welsh et al., 2016), contributes to disease progression and impacts on 
patient survival. Much research has focused on mechanisms mediating the resistance of 
melanoma to BRAF/MEK inhibition and novel approaches through which to overcome such 
acquired resistance (Aplin et al., 2011) and given the complexity of a heterogeneous cancer 
type with different histological and biological characteristics, it is therefore perhaps not 
surprising that multiple mechanisms have been proposed, including the secondary 
upregulation of N-RAS (Nazarian et al., 2010), activation of receptor tyrosine kinases (RTK) 
such as IGF-1R (Villanueva et al., 2011) and the emergence of chemo resistant subpopulations 
expressing stem cell surface markers such as CD271 (Ravindran Menon et al., 2014), ABCB5 
(Chartrain et al., 2012) and Jarid-1B (Roesch et al., 2013). 
Recently CD271 expressing melanoma subpopulations have emerged as one of the major 
subpopulations associated with the resistance of melanoma to BRAF and MEK inhibition 
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(Ravindran Menon et al., 2014). CD271 is a neurotrophin receptor expressed in normal tissues 
and involved in neuronal development (Dechant and Barde, 2002), however, the precise role 
of CD271 expression in the drug-induced resistance of melanoma is not fully understood. As 
revealed in chapter 3, constitutive CD271 expression by melanoma cell lines is associated with 
an increase in autophagic activity and accumulating evidence further highlights CD271 
expressing melanoma subpopulations as an early drug-induced tolerant population that 
emerges under stressful micro environmental conditions such as hypoxia and nutrient 
deprivation (Ravindran Menon et al., 2014), key factors in autophagy activation and 
suggesting autophagy may also play an integral role in the survival of drug resistant CD271 
expressing melanoma subpopulations (Pursiheimo et al., 2008), (Young et al., 2009). As a 
major cellular energy sensor activated by ATP and nutrient depletion to maintain energy 
homeostasis, AMPK may directly activate autophagy (Hardie, 2011), shown to be a key event 
in autophagy mediated survival of lung (William et al., 2012) and colorectal (Baba et al., 2010) 
cancer and hence raises the question as to whether AMPK activation may also initiate pro-
survival autophagy in drug-resistant CD271 expressing melanoma subpopulations. 
Results reported in the previous chapter further highlighted the reduced invasive capacity of 
constitutively CD271 expressing melanoma subpopulations. It is well known that CD271 as a 
nerve growth factor receptor is stimulated by NGF to promote neuronal cell survival in vivo 
(Johnson et al., 1986) and increasing evidence supports the role for NGF in tumour cell 
proliferation and invasion. In pancreatic cancer cells, over expression of NGF is associated with 
increased perineural cancer invasion  (Zhu et al., 2002) while in vitro exogenous NGF 
treatment of melanoma increases tumour cell invasion in a dose dependent manner 
(Herrmann et al., 1993). It is therefore possible that the invasive capacity of CD271 drug 
resistant subpopulations is supported by NGF or other factors independently of autophagy. 
Nevertheless, given the association of constitutive CD271 expression by melanoma cells with 
increased basal autophagy activity and recent literature describing the association of 
increased autophagy with BRAF/MEK inhibitor-induced CD271, autophagy is clearly linked to 
the emergence of drug resistant CD271 expressing melanoma subpopulations. Whether 
autophagy is activated as a consequence of drug-induced CD271 expression (or by over 
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expression of CD271) in melanoma or whether its activation leads to the induction of CD271 
expression in BRAF/MEK inhibitor drug-resistant subpopulations is unclear and leads to the 
aims of the present chapter of defining the association between autophagy activation and 
CD271 induction in melanoma cells in the presence or absence of BRAF or MEK inhibition, and 
the cascade of events and relative contribution of autophagy to the survival and invasive 
potential of CD271 expressing melanoma subpopulations. 
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 Results 
4.2.1 Drug-induced resistance of melanoma to BRAF and MEK inhibition in 
vitro is associated with an increase in CD271 expression and basal 
autophagy 
 
To confirm the association between BRAF and MEK inhibitor-induced CD271 (Ravindran 
Menon et al., 2014; Lehraiki et al., 2015; Fallahi-Sichani et al., 2017) and an increase in basal 
autophagy BRAF mutant melanoma cells, WM35, SK-mel-28 or A375 cells were treated 
continuously over a long-term period of 9 days with 3 µM PLX4720 (BRAF inhibitor) or 16 nM 
trametinib (MEK inhibitor), prior to western blot analysis of CD271, p62 and LC3 I/II 
expression. Initial pilot experiments of PLX4720 in SK-mel-28 cells revealed the dose 
dependent induction of CD271 paralleled by the induction of LC3 I/II ( 
 
 
 
 
 
 
 
Figure 4-1). 
 
 
 
 
 
 
 
CD271 
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Figure 4-1: PLX4720 increases CD271 and LC3 I/II in BRAF mutant SK-mel-28 cells in a dose-
dependent manner.  
Representative Immunoblot for the expression of CD271 (75 kDa), LC3I/II (16-18 kDa) or β actin loading 
control (45 kDa) in SK-mel-28 cells (control) or in SK-mel-28 cells following treatment with 2-6 µM PLX 
4720 for 9 days (n=1) 
Given treatment with 3 µM PLX4720 induced maximal CD271 and LC3 I/II expression following 
9 days treatment, this concentration was used in subsequent experiments to establish the 
optimal time point for BRAF inhibitor- induced CD271 induction and associated changes in 
autophagic activity. Experiments performed by Dr David Hill using BRAF mutant A375 cells 
treated with 3 µM PLX4720 for 3, 6, 9 or 12 days prior to western blot analysis of CD271or p62 
expression. Results demonstrated a time-dependent increase in CD271 expression by PLX4720 
which peaked at 12 days ( 
Figure 4-2 which was again paralleled by an increase in autophagic activity as evidenced by a 
reduction in p62 expression ( 
Figure 4-2).  
 
 
Figure 4-2: PLX4720 induces a time dependent increase in CD271 and decrease in p62 in BRAF 
mutant A375 cells  
Representative Immunoblot for the expression of CD271 (75 kDa), p62 (62 kDa) or β actin loading 
control (45 kDa) in untreated control A375 (C) or in A375 cells following treatment with 3 µM PLX 4720 
(P) for 3, 6, 9 or 12 days (n=1) 
Increasing evidence supports the clinical benefits of dual inhibition of activated MAPK 
signalling in patients with BRAF or NRAS mutant metastatic melanoma (Robert et al., 2015a) 
and there has been a change in clinical practice to the use of combination targeted therapy 
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since the NICE approval of Dabrafenib (BRAF inhibitor) and Trametinib (MEK inhibitor) for the 
management of patients with stage IV BRAF mutant melanoma.  
To assess the impact of MEK inhibition on CD271 expression and autophagy, BRAF mutant 
A375, WM35 and SK-mel-28 cells were treated continuously with 16 nM trametinib for 9 days 
prior to the analysis of CD271, LC3 I/II and p62 expression. Results demonstrated the 
significant induction of CD271 in all cell lines following treatment with trametinib for 9 days 
(Figure 4-3 A, B, C i and ii, unpaired Student’s T test ***P < 0.001 for WM35 and *P < 0.05 for 
Sk-mel-28 and A375 cells), which was associated with the concurrent increase of lipidated LC3-
II expression (Figure 4-3 A, B, C i and ii, Student’s T test **P < 0.01 for WM35 and *P < 0.05 for 
Sk-mel-28) and significantly decreased expression of p62 (Figure 4-3 A, B, C i and ii, Student’s 
T test, ****P < 0.0001 for WM35 and A375 and *P < 0.05 for SK-mel-28)  indicating a 
concurrent  increase in basal autophagic activity with the induction of CD271 expression.  
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Figure 4-3 Chemoresistance of SK-mel-28, WM35 and A375 melanoma cells to trametinib is 
associated with the induction of CD271 expressing subpopulations and increased basal 
autophagy.  
Representative immunoblots for the expression of CD271 (45 kDa), LC3I/II (16 kDa), p62 (62 kDa) or β 
actin loading control (45 kDa) in WM35 (A (i), control), SK-mel-28 (B (i), control) and A375 (C (i), control) 
cells or following treatment with 16 nM trametinib for 9 days or relative expression levels of CD271, 
LC3-II or p62 relative to β actin in 3 individual experiments (A(ii), B(ii), C(ii)). Each bar is the mean of 3 
experiments ± SD. *P < 0.05, **P<0.01***P<0.001, ****P<0.0001 
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Although the detection of LC3 II induction and p62 degradation by western blotting are key 
indicators of autophagy activity they do not reflect true LC3 autophagic flux, a key and 
universally accepted measure of autophagy (Corazzari et al., 2015). To confirm the observed 
increase in autophagy in trametinib-induced CD271 expressing melanoma subpopulations LC3 
flux was determined in BRAF mutant WM266-4 cells previously engineered to stably express 
LC3-RFP-GFP and allowing the simultaneous detection of autophagosomes as well as 
autolysosomes. As shown in Figure 4-4, treatment of WM266-4 cells with 16 nM trametinib 
for 9 days resulted in the significant induction of CD271 expression (depicted by pink 
fluorescence, Figure 4-4 B and C, unpaired Students T test, ***P < 0.001, Figure 4-4 D) as well 
as the significant induction of LC3 flux (depicted by the presence of red fluorescence only, 
Figure 4-4 A & C) and reflected by a significant decrease in mean GFP fluorescence intensity 
(Figure 4-4 D, unpaired Students T test, **P < 0.01) and a significant increase in mean RFP 
fluorescence intensity (Figure 4-4 D, unpaired Students T test, *P < 0.05), further emphasizing 
the association between drug resistant CD271 expressing melanoma sub populations and 
increased autophagy. 
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Figure 4-4: Trametinib-induced CD271 expression is associated with increased autophagic 
flux   
Representative immunofluorescence of WM266-4 mRFP-GFP-LC3 cells depicting A: basal LC3 green 
fluorescence or B: CD271 expression (pink fluorescence) in control WM266-4 cells or increased LC3 
flux (reflected by decreased green and increased red fluorescence, in A) or CD271 expression (B) in 
cells following 9 days treatment with 16nM trametinib. (C). Merged images of LC3 flux and CD271 
induction as indicated by the presence of pink (CD271) and red dots in trametinib treated WM266-4 
cells. (D) Mean CD271, RFP and GFP fluorescence intensity in RFP-GFP-LC3 WM266-4 cells following 
treatment with 16nM trametinib compared to untreated control cells (*P < 0.05, *** P<0.001). Blue 
fluorescence indicates DAPI labelled cell nuclei, Scale bar = 50 µm  
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4.2.2 Prolonged treatment of human A375 melanoma cells with trametinib 
results in transient induction of CD271 expression and a concurrent 
increase in autophagic activity 
 
Recent literature highlights the transient expression of CD271 in melanoma subpopulations in 
response to treatment with BRAF/MEK inhibitors (Ravindran Menon et al., 2014) suggesting 
CD271 may only be expressed as a transient survival mechanism until tumour repopulation 
and regrowth are re-established, at which point CD271 may not be required for tumour 
maintenance. To investigate this possibility and any associated changes in autophagy, A375 
cells were grown in the presence of 16 nM trametinib for 3, 6, 9, 12, 24 or 42 days prior to the 
analysis of CD271, LC3 I/II, p62, Cleaved PARP, pERK, total ERK or GAPDH expression by 
western blotting. Results demonstrated an increase in trametinib-induced CD271 expression 
at day 6 which peaked at day 9 and then returned to baseline expression from day 14, which 
was accompanied by a concurrent increase in trametinib-induced autophagy as reflected by 
an increase LC3 II and a decrease in p62 expression (Figure 4-5 A & B). LC3 II expression 
increased over time and peaked at 14 days followed by a reduction in expression from day 24 
which was, however, increased compared to baseline expression (Figure 4-4 A, B). P62 
expression was reduced at day 3, 6 and 9 indicating an induction n autophagic activity and 
then steadily increased from day 14 to day 42 (Figure 4-4 A, B). PARP cleavage was also 
induced by trametinib reflecting increased apoptotic cell death at day 3 and 6 which then 
decreased after 14 days treatment (Figure 4-5 A & B). Interestingly, trametinib also abolished 
pERK expression following 3 days treatment, but after 6 days treatment, levels began to 
increase, in line with the development of drug resistance (Figure 4-5A & B).  However, ongoing 
long-term treatment with trametinib for more than 14 days resulted in reduced pERK 
expression indicating fully drug-resistant A375 subpopulations may not depend on the MAPK 
pathway to promote tumour development and growth (Figure 4-5 A, B). Collectively these 
data highlight the transient induction of CD271 in response to trametinib which is lost after 
14 days and is accompanied by an induction in autophagic activity peaking between 9 and 14 
days. The subsequent decline in autophagic activity in trametinib treated cells, albeit still 
above base line even in the absence of CD271 expression additionally supports current 
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literature in other tumour types demonstrating the induction of pro-survival autophagy by 
inhibitors of activated MAPK signalling (Goulielmaki et al., 2016).  
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Figure 4-5 Trametinib induces transient CD271 expression by melanoma cells in vitro  
A: Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), pERK 
(42-44 kDa), total ERK (42-44 kDa), p62 (62 kDa), LC3I/II (16-18 kDa), or GAPDH (37 kDa) loading control 
in A375 control cells (Control) or in cells treated with 16 nM trametinib for 3, 6, 9, 14, 24 and 42 days 
B: Relative expression of CD271, Cleaved PARP, LC3-II or p62 relative to GAPDH loading control in 3 
individual experiments of A375 cells treated in the absence (control) or presence of 16nM trametinib 
for 3-42 days . Each bar is the mean of 3 experiments ± SD (NS P>0.05).  
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Further experiments to confirm these findings were performed by Dr David Hill, Newcastle 
University. Flow cytometry analysis of annexinV/PI stained cells over a time-course treatment 
of A375 cells for 28 days with 16 nM trametinib, demonstrated significant trametinib-induced 
apoptosis up to 14 days post-treatment, however, by day 28 most cells were resistant to the 
cytotoxic effects of trametinib (one-way ANOVA with Tukey’s multiple comparison post hoc 
correlation *p<0.05, **p<0.01, ***p<0.001), ( 
Figure 4-6A). Gating of live, annexinV/PI stained A375 cells that were co-stained with anti-
CD271 antibody indicated trametinib induced a time-dependent increase in CD271 
expression, peaking after 9 days treatment (Figure 4-6 B, C). 
 
Figure 4-6 Trametinib induces apoptotic cell death and CD271 expressing melanoma 
subpopulations 
A.Flow cytometry of AnnexinV-PE/PI stained A375 melanoma cells for percentage Live, Dead, 
Dying/Apoptotic or Dying/Necrotic following treatment in the presence or absence of 16 nM 
trametinib for 3, 6, 9, 14 or 28 days (percentages did not significantly change following DMSO 
treatment, which shown at day 3 only for clarity). Each bar is the mean of 3 experiments ± SD (*P<0.05, 
**P<0.01, ***P<0.001).B. Representative flow cytometry plots of A375 cells stained with AnnexinV-
PE/PI/anti-CD271 following treatment for 9 days with 16 nM trametinib. Each bar is the mean of 3 
experiments ± SD. Oval gate shown for Live cells was used to quantify CD271 expression, shown in 
right panel, which was negative for null-primary control. C. Histogram of CD271 staining of gated live 
cells  
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Collectively these data further demonstrate a transient induction of CD271 in melanoma cells 
in response to trametinib, with a concurrent increase in autophagy. 
Although improving progression free survival over and above monotherapy with BRAF 
inhibitors, the development of acquired resistance to combined BRAF/MEK inhibitor therapy, 
remains the main reason for treatment discontinuation, with similarly to monotherapy with 
BRAF inhibitors, similar mechanisms of drug-induced resistance proposed including the 
activation of pro-survival PI3K-mTOR signalling and immune alterations (Welsh et al., 2016). 
To determine the impact of combined BRAF and MEK inhibition on CD271 expression in drug 
resistant subpopulations and associated autophagy activity, WM35 and A375 cells were 
treated in the presence of 16 nM trametinib and 2 µM PLX4720 for 14 days prior to the analysis 
of CD271, p62 and LC3 I/II expression by Western blotting. Incubation with combined 
trametinib/PLX 4720 was extended to 14 days as initial pilot experiments revealed no 
induction of CD271 expression in either cell line by combined treatment at 9 days (data not 
shown), in line with clinical data indicating resistance to BRAF/MEK inhibition occurs later than 
in patients treated with monotherapy BRAF or MEK inhibitors. Results demonstrated the 
induction of CD271 in both WM35 and A375 cells by single agent trametinib or PLX4720 or by 
combined trametinib/PLX4720, although the combination therapy resulted in lower levels of 
CD271 induction at 14 days indicating that CD271-associated acquired resistance to 
combination therapy requires longer exposure to the inhibitors (Figure 4-7 A and B), which is 
in line with clinical observations that acquired resistance in patients receiving combination 
therapy develops later compared to monotherapy treatment with each drug individually. 
CD271 induction was accompanied in both cell lines by a concurrent decrease in p62 
expression and increased LC3 II expression, again to varying degrees (Figure 4-7 A and B). 
Collectively these data confirm previous studies indicating an association between BRAF/MEK 
inhibitor (as monotherapy or combination therapy) induced drug resistant CD271 expressing 
subpopulations and an associated increase in basal autophagy in such subpopulations. 
However, whether autophagy is induced as a consequence of drug resistance leading to CD271 
induction in resistant subpopulations or whether CD271 induction in drug resistant 
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subpopulations itself results in autophagy activation is unclear and is further addressed in 
section 4.2.6, 4.2.7 and 4.2.8 by modulating the expression of CD271. 
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Figure 4-7: Combined treatment of melanoma cells with trametinib and PLX4720 results in 
induction of CD271 expression and autophagy 
Representative immunoblots or relative expression of CD271 (45 kDa), p62 (62 kDa), LC3I/II (16-18 
kDa), or GAPDH (37 kDa) loading control or relative to GAPDH in 3 individual experiments in WM35 (A) 
or A375 (B) cells in the presence or absence (control) of treatment for 14 days with 16nM Trametinib, 
3 µM PLX4720 (PLX) or combined Trametinib+PLX. Each bar is the mean of 3 experiments ± SD. 
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4.2.3 Trametinib-induced CD271 expression in vitro is not consistently 
associated with the induced expression of other stem cell markers 
 
BRAF or MEK inhibitor- induced resistant melanoma subpopulations are reported to express 
a variety of stem cell markers including ABCB5 (Frank et al., 2005b), Nestin (Akiyama et al., 
2013a), SOX 10 (Graf et al., 2014a) and Jarid1B (Roesch et al., 2013). To investigate whether 
the potential induction of these stem cell markers is  associated with MEK inhibitor-induced 
CD271 expression in drug resistant melanoma subpopulations, SK-mel-28, WM35 and A375 
cells were treated in the presence or absence of 16 nM Trametinib for 9 days prior the analysis 
of ABCB5, Jarid-1B, SOX10 and Nestin by western blotting. Results confirmed the induction of 
CD271 in each cell line while interestingly however, an apparent trend for trametinib-induced 
downregulation of ABCB5 expression in SK-mel-28 and A375 cells was observed, with 
expression increased in WM35 cells (Figure 4-8). Nevertheless, the only significant change in 
ABCB5 expression was a down regulation in expression in response to trametinib in SK-mel-
28 cells (unpaired Student’s T-test, *P<0.05 (Figure 4-8). 
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Figure 4-8: Trametinib-induced CD271 Expression in melanoma cells is associated with 
variable changes in ABCB5 expression 
Representative immunoblots for CD271 (45 kDa), ABCB5 (90 kDa), or β actin loading control (45 kDa) 
or Relative ABCB5 expression (relative to β actin loading control) in WM35 (A), SK-mel-28 (B) and A375 
(C) cells following treatment with vehicle DMSO control or 16 nM trametinib for 9 days. Each bar is the 
mean of 3 experiments ± SD Statistics were acquired using unpaired t test (*P < 0.05). 
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Conversely, trametinib-induced CD271 was associated with a trend for the consistent 
induction of both Jarid 1B (Figure 4-9) and SOX 10 (Figure 4-10) in all cell lines, although 
findings were only significant for trametinib-induced SOX 10 induction in drug resistant CD271 
expressing A375 melanoma subpopulations (unpaired Student’s T-test, ****P<0.0001, Figure 
4-10). Studies of Nestin expression following treatment of SK-mel-28, WM35 or A375 cells for 
9 days treatment with 16nM trametinib, revealed a trend for down regulation in drug -induced 
CD271 expressing subpopulations (Figure 4-11) in all cell lines. However, again this effect was 
only significant in SK-mel-28 cells (unpaired t test, ***P<0.001, Figure 4-11). 
Collectively these data highlight differential co-expression of neuroectodermal stem cell 
markers with the expression of CD271 in trametinib resistant melanoma subpopulations, and 
suggest that in this context, CD271 is not a marker of stemness. 
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Figure 4-9: Trametinib-induced CD271 Expression in melanoma cells is associated with a 
trend for increased Jarid-1B expression.  
Representative immunoblots for CD271 (45 kDa), Jarid-1B (190 kDa) or β actin loading control (45 kDa) 
or Relative Jarid-1B expression (relative to β actin loading control) in WM35 (A), SK-mel-28 (B) and 
A375 (C) cells following treatment with vehicle DMSO control or 16 nM trametinib for 9 days. Each bar 
is the mean or 3 experiments ± SD.    
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Figure 4-10: Trametinib-induced CD271 Expression in melanoma cells is associated with 
increased SOX 10 expression  
Representative immunoblots for CD271 (45 kDa), SOX 10 (37 kDa), or β actin loading control (45 kDa) 
or Relative SOX 10 expression (relative to β actin loading control) in WM35 (A), SK-mel-28 (B) and A375 
(C) cells following treatment with vehicle DMSO control or 16 nM trametinib for 9 days. Each bar is the 
mean or 3 experiments ± SD (****P < 0.0001).  
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Figure 4-11: Trametinib-induced CD271 Expression in melanoma cells is associated with the 
down regulation of Nestin expression 
Representative immunoblots for CD271 (45 kDa), Nestin (177 kDa), or β actin loading control 
(45 kDa) or Relative Nestin expression (relative to β actin loading control) in WM35 (A), SK-
mel-28 (B) and A375 (C) cells following treatment with vehicle DMSO control or 16 nM 
trametinib for 9 days. Each bar is the mean or 3 experiments ± SD. Statistics were acquired 
using unpaired t test, ***P < 0.001.  
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4.2.4 Trametinib-induced drug resistance is associated with reduced cellular 
ATP levels and increased pAMPK activation 
Increasing evidence highlights the crosstalk between the AMPK signalling and autophagy. 
Under conditions of nutrient deprivation, AMPK acts as a metabolic checkpoint and inhibits 
cellular growth and proliferation to sustain hostile micro environmental conditions (Mihaylova 
and Shaw, 2011). One of the major pathways though which AMPK mediates a reduction in cell 
proliferation is through the inhibition of the mammalian target of rapamycin complex 1 
(mTORC1) pathway, resulting in the activation of autophagy. To further investigate the 
association between drug induced CD271 expression and the induction of pro-survival 
autophagy in trametinib-induced drug resistant melanoma subpopulations, BRAF mutant 
A375 and WM35 cells were treated with 16 nM of trametinib for 9 days prior to the analysis 
of ATP release and the endogenous levels of pAMPK. Results demonstrated that treatment 
with trametinib for 9 days resulted in significant reduction in cellular ATP release by both cell 
lines (one-way ANOVA with Tukey’s multiple comparison test, ***P < 0.001, ****P<0.0001), ( 
Figure 4-12). 
 
Figure 4-12 Trametinib treatment results in reduced ATP release in WM35 and A375 
melanoma cells. 
Relative ATP release (relative to ATP release by control vehicle DMSO treated cells) by WM35 (A) or 
A375 (B) cells or following treatment for 9 days with 16 nM of trametinib. Cells previously treated with 
16 nM of trametinib and further treated with 10% SDS for 2 minutes to potentiate ATP release were 
used as positive control for each experiment. Each bar is the mean or 3 experiments ± SD (***P < 0.001, 
****P<0.0001)  
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To further evaluate whether trametinib-induced reduction in cellular ATP levels is associated 
with AMPK activation, WM35 and A375 cells were again treated with 16 nM trametinib for 9 
days prior to evaluation of pAMPK levels using a commercial ELISA assay. Results 
demonstrated a significant increase in pAMPK in both cell lines cells treated with 16 nM 
trametinib for 9 days compared to cells treated with vehicle control (one-way ANOVA, with 
Tukey’s multiple comparison test, *P < 0.05 for the effect of trametinib treatment in WM35 
cells and **P < 0.01 for the effect in A375 cells, (Figure 4-13). 
  
Figure 4-13: Trametinib treatment results in increased AMPK activation in WM35 and A375 
melanoma cells. 
Relative pAMPK levels in WM35 (A) or A375 (B) cells following treatment for 9 days with DMSO vehicle 
control or 16 nM of trametinib.  Cells previously treated with 16 nM of trametinib and further treated 
with 10 mM hydrogen peroxide for 10 minutes were used as positive control for each experiment. 
Each bar is the mean or 3 experiments ± SD (*P < 0.05, **P<0.01). 
 
Collectively these data indicate trametinib–induced drug resistance in melanoma is 
accompanied by reduced ATP release and increased AMPK activation, providing evidence for 
the mechanism by which pro-survival autophagy is activated in MEK inhibitor drug resistant 
melanoma subpopulations.  
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4.2.5 Spheroids derived from trametinib resistant CD271 expressing 
melanoma BRAF mutant subpopulations display reduced collagen 
expansion compared to untreated BRAF mutant melanoma cells 
 
Results from chapter 3 demonstrated isolated CD271 positive subpopulations derived from 
BRAF mutant melanoma cell lines displayed reduced collagen expansion compared to their 
CD271 negative counterparts, in line with recent observations reporting the expression of 
CD271 by melanoma sub populations is associated with a less invasive phenotype (Saltari et 
al., 2016). To confirm if the same phenomenon is also true in drug-resistant CD271 expressing 
melanoma subpopulations WM35 H2B RFP cells were treated with 16 nM trametinib or 
vehicle control prior to incorporation into collagen gels and the assessment of spheroid 
expansion over 7 days.  Results demonstrated significantly reduced spheroid expansion by 
WM35 cells pre-treated with trametinib compared to vehicle control treated cells (Two-way 
ANOVA test with Sidak post hoc correction, ***P<0.001, (Figure 4-14). 
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Figure 4-14: Spheroids derived from trametinib-induced drug resistant WM35 cells display 
reduced collagen expansion compared to untreated WM35 cells. 
A: Representative immunofluorescence images of WM35 H2B RFP spheroid size following treatment 
with DMSO vehicle control or 16nM trametinib for 9 days and incorporation into collagen gels for 0, 2, 
4 or 7 days or B: Relative invasion (µm, relative to initial spheroid size at day 0) of WM35 H2B RFP 
vehicle control treated cells or cells previously treated for 9 days with 16nM trametinib over 7 days.   
Each point represents the mean relative size of 3 replicate experiments ±SD, ***P<0.001, Scale bar 
100 µm 
These data were also in line with findings from previous chapter highlighting the association 
between constitutive CD271 expression and reduced spheroid collagen expansion and 
suggesting as with melanoma cell populations constitutively expressing CD271 that drug-
induced CD271 expression in melanoma is associated with a less invasive phenotype and that 
other mechanisms may be required to promote tumour cell invasion which are further 
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explored in section 4.2.9 or that loss of transient drug-induced CD271 subsequently enhances 
tumour invasion.  
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4.2.6 Stable overexpression of CD271 increases basal autophagy in melanoma 
in vitro and results in reduced tumour invasion and no effect on 
susceptibility to trametinib-induced cell death 
 
To further investigate the link between drug-induced CD271 expression and increased 
autophagy and in an attempt to investigate if autophagy is activated as a consequence of drug-
induced CD271 expression, CD271 was stably over expressed in BRAF mutant melanoma cells 
prior to the analysis of autophagy status and the effect on cell viability or invasive potential.  
Initial experiments using Lipofectamine to stably transfect a mammalian pCMV6-AC plasmid 
vector containing RFP tagged CD271 into A375 cells using G418 antibiotic resistance for 
selection resulted in low transfection efficacy ( 
Figure 4-15). 
 
Figure 4-15: Transfection of CD271 into A375 cells results in low transfection efficacy 
Representative immunofluorescence image of A375 (A) and WM35 (B) cells transfected with 1 µg of 
pCMV6-AC plasmid vector containing RFP tagged CD271 and selected using 500 µg/ml G418. 
Transfected CD271 is depicted as red and DAPI as blue. Blue fluorescence indicates DAPI labelled cell 
nuclei, Scale bar 50 µm 
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To increase the transfection efficacy, the same CD271 expression vector or empty vector 
control was therefore transfected into BRAF mutant A375 and WM35 cells using Xfect 
Transfection Reagent, which resulted in substantially increased transfection efficiency ( 
Figure 4-16). Following G418 selection, CD271 cells were then sorted by flow cytometry to 
obtain pure CD271 expressing subpopulations prior to their use in subsequent experiments. 
 
Figure 4-16: Transfection of CD271 with XFect polymer results in high transfection efficiency 
Representative immunofluorescence image of A375 (A) and WM35 (B) cells transfected with 1 µg of 
pCMV6-AC plasmid vector containing RFP tagged CD271 and selected by continuous treatment with 
500 µg/ml G418. Cells stably expressing CD271 are depicted as red (A i, B i), bright field and RFP channel 
overlay (A ii, B ii). Scale bar 100 µm 
Analysis of LC3 I/II and p62 in WM35 cells stably overexpressing CD271 revealed as expected 
resulted the increased expression of CD271 (Figure 4-17 A and B) compared to expression in 
cells transfected with empty vector control. WM35 cells stably expressing CD271 also 
displayed increased expression of LC3 II and reduced p62 protein expression indicating an 
increased level of basal autophagy, although this effect was not significant (Figure 4-17 A, B 
and C).  
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Figure 4-17:  Overexpression of CD271 in WM35 cells is suggestive of an increase in basal 
autophagy  
A: Representative western blot for the expression of CD271 (75 kDa), p62 (62 kDa), LC3 I/II (16, 18 kDa) 
and β actin loading control (42 kDa) in WM35 cells stably transfected with an empty vector control or 
pCMV6-AC plasmid vector containing RFP tagged CD271 stably overexpressing CD271 (CD271 OE). B: 
Relative expression of CD271 (i), LC3 II (ii) and p62 (iii) (relative to b actin protein expression) in control 
or CD271 OE cells. Each bar represents the mean of 3 replicates for each cell line, and expressed 
relative to the mean of each individual experiment (mean ± SD, N = 3). 
In line with reports demonstrating CD271 expressing melanoma cells display increased 
resistance to BRAF and MEK inhibitors (Lehraiki et al., 2015) and to investigate the cytotoxic 
effects of MEK inhibition in melanoma cells in which CD271 had been over expressed, WM35 
and A375 cells stably expressing CD271 were treated with trametinib for 24, 48 or 72 hours or 
9 days prior to evaluating the effect on cell viability. While treatment of either WM35 (Figure 
4-18 5 A) or A375 (Figure 4-18 B) transfected with empty vector control or stably expressing 
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CD271 with trametinib resulted in time-dependent inhibition of cell viability up to 72 hrs, 
trametinib-induced inhibition of cell viability was partially blocked in both cell lines following 
9 days exposure ( 
Figure 4-18) in both control and cells over expressing CD271. In addition, there were no 
observed differences in trametinib-induced inhibition of cell viability between control and 
CD271 over-expressing cells following 24, 48 or 72 hrs treatment in either cell line ( 
Figure 4-18). However, contrary to published literature (Lehraiki et al., 2015), and albeit in one 
cell line, WM35 cells stably expressing CD271 were significantly more sensitive to trametinib-
induced inhibition of cell viability following 9 days treatment compared to control cells (One 
way ANOVA with Tukey’s post hoc correlation, ****P<0.0001, 
Figure 4-18).  
Collectively however, these data suggest over expression of CD271 in BRAF mutant melanoma 
cells does not significantly alter their sensitivity to the cytotoxic effects of MEK inhibition. 
 
Figure 4-18: CD271 overexpression does not increase resistance of WM35 or A375 cells to 
the cytotoxic effects of trametinib 
Relative cell viability of WM35 (A) or A375 (B) transfected with empty vector control (control) or stably 
expressing CD271 (CD271 overexpressing) and treated with DMSO vehicle control (Control) or 16 nM 
of trametinib for 24, 48, 72 hours or 9 days. Each bar represents the mean of 3 replicates for each cell 
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line, and expressed relative to the mean of each individual experiment (mean ± SD, N = 3) (NS P>0.05, 
****P<0.0001). 
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To investigate the potential effects of CD271 overexpression in melanoma cells on spheroid 
expansion, a mixed population of WM35 spheroids containing stably expressing CD271 (and 
tagged with RFP) or not (non-red) were incorporated into collagen gels prior to assessing the 
relative spheroid size at 24, 48 and 72 hours. Similarly to results derived with isolated 
melanoma cells constitutively expressing CD271, results demonstrated reduced spheroid 
collagen expansion of CD271 overexpressing cells (expressing RFP) compared to control cells 
(Not overexpressing, non-red) (Figure 4-19 A and B). 
 
Figure 4-19: Over expression of CD271 in WM35 cells reduces spheroid expansion compared 
to WM35 not overexpressing cells  
A: Representative immunofluorescence images of a mixed population containing WM35 CD271 
overexpressing (RFP expressing cells) or non CD271 overexpressing (non-red) cells in a collagen 
invasion assay. B: Relative invasion (µm) of control (green line) or CD271 over expressing (red line) 
WM35 cells (relative to initial spheroid size at time 0) over 72 hrs (n=1) 
Interestingly rather than demonstrating a diffuse membranous pattern, the cellular 
localization of CD271 following transfection with CD271 RFP demonstrated a more lobular 
intracellular pattern  
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Figure 4-15 
Figure 4-16) questioning whether increased autophagy in this context is induced as a cellular 
stress response. Previous studies have highlighted the crosstalk between autophagy and ER 
stress (Hoyer-Hansen and Jaattela, 2007) and hence to investigate whether the increase in 
autophagic activity observed in the CD271 overexpressing populations was a direct effect of 
CD271 on autophagic activity rather than CD271 localization leading to ER stress, the mRNA 
expression of a panel of ER stress genes was evaluated in control and CD271 over expressing 
A375 cells (Figure 4-20). Results revealed there was no significant increase in the expression 
of Xbp1, ATF4, ATF6, TRB3 or CHOP mRNA expression in A375 cells stably expressing CD271 
RFP compared control un-transfected cells (Figure 4-20), indicating that the observed 
autophagy induction in the CD271 overexpressing subpopulation is not as a result of ER stress 
activation and therefore more likely directly linked to CD271 overexpression. 
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Figure 4-20: Over-expression of CD271 does not up regulate ER stress gene expression  
Relative mRNA expression of Xbp1 (A), ATF4 (B), ATF6 (C), TRB3 (D) or CHOP (E) in A375 cells (A375 
control) or in A375 cells stably expressing CD271-RFP (A375 CD271). Each bar is the mean of three 
replicates (±SD) relative to L34 loading control (NS P>0.05).  
However, given the conflicting results on the functionality of CD271 overexpression and the 
cellular localisation of CD271 protein following overexpression of CD271, the alternative 
approach of CD271 knockdown was adopted to evaluate the effect of abrogating CD271 
expression on autophagy and response to trametinib treatment.   
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4.2.7 Stable knockdown of CD271 is incompatible with melanoma cell survival 
in vitro 
 
To investigate the impact of abrogating CD271 expression on autophagy, an initial approach 
to knockdown CD271 stably was undertaken in A375 cells using lentiviral shRNA vectors 
(Moore et al., 2010). Results demonstrated the effective reduction of mRNA levels of CD271 
in 5 derived clones ( 
 
Figure 4-21) 2 days after transfection. However, although viable 3 days after transfection, 
within 7 days each clone died, consistent with reports indicating total abrogation of CD271 
expression is incompatible with cell viability (Lehraiki et al., 2015) and that melanoma cells 
likely require some expression of CD271 for maintained cell proliferation and survival. 
 
 
Figure 4-21: mRNA CD271 expression in A375 cell clones following lentiviral ShRNA mediated 
knockdown. 
Relative mRNA expression of CD271 following shRNA mediated knockdown of CD271 in A375 H2B RFP 
cells or transfection with an shRNA control (shCTRL) 2 days after transfection . Each bar is the mean of 
three replicates (±SD) relative to L34 loading control and normalized to shCTRL. 
Since stable knockdown of CD271 was incompatible with melanoma cell viability subsequent 
studies were undertaken using a transient approach with siRNAs to CD271 in order to further 
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determine the effect of abrogating CD271 expression on autophagic activity and invasive 
potential.  
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4.2.8 siRNA mediated knockdown of basal CD271 expression sensitizes 
melanoma cells to the cytotoxic effects of trametinib, has no effect on 
basal autophagy and a trend for reduction in pAMPK expression 
 
To further investigate the effect of CD271 knockdown on melanoma cell viability, autophagic 
activity and sensitivity to trametinib-induced cell death, an alternative approach was adopted 
to transiently knockdown CD271. 
Transient siRNA-mediated knockdown of CD271 was initially performed in WM35 cells which, 
as shown in chapter 3, display increased basal CD271 expression. Results confirmed the 
reduction of CD271 expression following transfection with CD271 siRNA for 24 hrs (1 day) 
which continued to significantly decline 4 days post transfection (One way ANOVA with 
Tukey’s post hoc correlation, ***P<0.001,  ( 
Figure 4-22 A and Bi). Conversely, basal expression levels of LC3-II were not significantly 
altered following siRNA mediated knockdown of CD271 and incubation for 1 or 4 days ( 
Figure 4-22A and Bii), suggesting that the level of knockdown of CD271 may not have been 
sufficient enough to observe any effect on a predicted reduction on autophagic activity.  
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Figure 4-22: siRNA mediated knockdown of CD271 has no effect on basal expression levels 
of LC3 II in WM35 melanoma cells. 
A, Representative immunoblots for the expression of CD271 (75 kDa), LC3 I/II (16,18 kDa) or b actin 
loading control (45 kDa) in WM35 cells following siRNA mediated knockdown of CD271 and continued 
culture for 1 or 4 days. B. Relative CD271 (i) or LC3 II (ii), expression levels relative to b actin in 3 
individual experiments. Each bar is the mean or 3 experiments ± SD (***P<0.001). 
To assess the effect of siRNA mediated knockdown of CD271 on the cytotoxic effects of 
trametinib, WM35 cells were transfected with control siRNA or CD271 siRNA for 24 hours prior 
to treatment with 16 nM trametinib for 24 or 72 hours and the assessment of cell viability. 
Results demonstrated a significant reduction of WM35 cell viability in cells transfected with 
CD271 siRNA compared to cell transfected with control siRNA (One way ANOVA with Tukey’s 
post hoc correlation, ****P<0.0001), (Figure 4-23), suggesting a possible association between 
CD271 knockdown and a decrease in autophagic activity. Nevertheless, given the low levels of 
CD271 expression in the parental cells, to further investigate the effect of CD271 knockdown 
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on autophagic activity, siRNA to CD271 was performed on 9 day trametinib pre-treated cells 
in order to induce CD271 expression prior to knockdown.  
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Figure 4-23: siRNA mediated knockdown of CD271 in WM35 cells sensitises cells to 
trametinib. 
Relative cell viability of control WM35 cells transfected with either a scrambled control siRNA (siCtrl) 
or CD271 siRNA to CD271 (siCD271) following treatment for 24 or 72 hrs with 16nM trametinib 
(Trametinib), Each bar is the mean +/- SD of 3 independent experiments with 4 technical replicates 
****P < 0.0001. 
To assess the impact of CD271 knockdown on both autophagic activity and the cell viability of 
trametinib-induced drug resistant melanoma cells, WM35 and A375 cells were treated in the 
presence of 16 nM trametinib for 9 days prior to siRNA mediated knockdown of CD271 for 72 
hours and the assessment of the effect on cell viability, as well as CD271 expression and 
autophagic activity by western blotting. Results demonstrated the significant reduction in 
CD271 expression following siRNA mediated knockdown of CD271 in WM35 cells pre-treated 
for 9 days with trametinib compared to untreated control cells (Figure 4-24Error! Reference 
source not found. A and Bi, Student’s t-test, * P <0.05) paralleled by a consistent but non-
significant increase in LC3 II expression, and significant reduction in p62 expression (Figure 
4-24 A and B ii, iii, Student’s t-test * P <0.05) and a trend for the reduction in pAMPK 
expression (Figure 4-24A, B iv, Student’s t-test) Results also demonstrated the significant 
reduction in CD271 expression following siRNA mediated knockdown of CD271 in A375 cells 
pre-treated for 9 days with trametinib compared to untreated control cells (Figure 4-25Error! 
Reference source not found. A and Bi, Student’s t-test, * P <0.05) paralleled by a non-
significant increase in LC3 II expression, and significant reduction in p62 expression (Figure 
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4-25 A and B ii, iii, Student’s t-test, * P <0.05) and a trend for the reduction in pAMPK 
expression (Figure 4-25, B iv, Student’s t-test).   
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Figure 4-24: SiRNA mediated CD271 knockdown in trametinib-induced CD271 expressing 
WM35 cells is associated with increased autophagic activity and reduced in pAMPK 
expression 
A.Representative immunoblots for the expression of CD271 (75 kDa), LC3 I/II (16,18 kDa, p62 (62 kDa), 
pAMPK (62 kDa) or GAPDH loading control (38 kDa) in trametinib-induced CD271 expressing WM35 
cells following siRNA mediated knockdown of CD271 for 3 days. B.Relative CD271 (i) or LC3 II (ii), p62 
(III) or pAMPK (iv) expression levels relative to GAPDH in 3 individual experiments. Each bar is the mean 
or 3 experiments ± SD (*P<0.05)  
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Figure 4-25: SiRNA mediated CD271 knockdown in trametinib induced CD271 expressing 
A375 cells is associated with increased autophagic activity and reduced in pAMPK expression 
A.Representative immunoblots for the expression of CD271 (75 kDa), LC3 I/II (16,18 kDa, p62 (62 kDa), 
pAMPK (62 kDa) or GAPDH loading control (38 kDa) in trametinib induced CD271 expressing A375 cells 
following siRNA mediated knockdown of CD271 for 3 days. B.Relative CD271 (i) or LC3 II (ii), p62 (III) or 
pAMPK (iv) expression levels relative to GAPDH in 3 individual experiments. Each bar is the mean or 3 
experiments ± SD (*P<0.05).  
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In the context of the effects of CD271 knockdown in trametinib-induced drug resistant A375 
or WM35 cells, results demonstrated CD271 knockdown induced a significant reduction in cell 
viability of both A375 and WM35 cells pre-treated with 16nM trametinib for 9 days compared 
to either control untreated cells or either cell line transfected control siRNA (One way ANOVA 
with Tukey’s multiple comparison test, ***P<0.001, ****P<0.0001, (Figure 4-26).  
Collectively, these data suggest knockdown of CD271 further re-sensitizes melanoma cells to 
the cytotoxic effects of trametinib. However, despite the expected reduction in autophagic 
activity following CD271 knockdown, siRNA to CD271 is associated with a trend for increased 
in autophagic activity. It is possible that this effect could be a result of the partial knockdown 
achieved using an siRNA approach and further experiments using more robust and modern 
techniques such as using the CRISP/Cas9 technology might be able to further decipher the 
association between CD271 expression and autophagy.  
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Figure 4-26: siRNA-mediated knockdown of CD271 in trametinib induced drug resistant 
WM35 and A375 cells re-sensitises cells to the cytotoxic effects trametinib. 
Relative cell viability of WM35 (A) or A375 (B) cells treated for 9 days with 16nM trametinib (control) 
+/- subsequent transfection with siCtrl or siCD271 RNA and treatment for a further 72 hrs with  16nM 
trametinib (Trametinib), Each bar is the mean +/- SD of 3 independent experiments each containing 4 
technical replicates. ****P < 0.0001. 
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4.2.9 Treatment of trametinib-induced drug resistant CD271 expressing 
melanoma subpopulations with exogenous NGF increases tumour 
proliferation but with no effect on tumour spheroid expansion in vitro 
 
Studies have suggested that NGF stimulation is required to induce invasion of CD271 
expressing melanoma subpopulations (Herrmann et al., 1993). Coupled with observations 
from the present study demonstrating that spheroids derived from CD271 expressing 
melanoma cells display reduced collagen expansion compared to subpopulations lacking 
CD271 expression, this suggests other stimuli such as NGF may be required to promote 
spheroid growth of Trametinib-induced drug resistant CD271 expressing melanoma sub 
populations. To test this hypothesis A375 and WM35 cells were first cultured in the presence 
or absence 16 nM trametinib for 9 days (to induce CD271 expression) prior to treatment with 
a dose range of exogenous NGF (1 mg/ml-0.01 nm/ml) for 3 days and assessment of the effect 
on cell viability. Results demonstrated a significant increase in trametinib-induced drug 
resistant WM35 or A375 cells subsequently treated with 1 mg/ml NGF compared to untreated 
control cells (one-way ANOVA analysis of variance with Tukey’s multiple comparison post hoc 
correction *P<0.05, Figure 4-27). However, there was no significant effect of NGF when used 
at concentrations below 1 mg/ml (Figure 4-27).  
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Figure 4-27: NGF promotes the proliferation of trametinib-resistant WM35 and A375 
subpopulations.  
Relative cell viability of WM35 (A) or A375 (B) cells pre-treated for 9 days with DMSO vehicle control 
or 16 nM trametinib (Trametinib) and subsequently treated for 72 hours in the presence or absence 
of a dose range of NGF (0.01ng/ml to 1 mg/ml NGF). Each bar is the mean of 3 replicate experiments, 
with 4 number of technical replicates/experiment, relative to DMSO untreated control ±SD (* P<0.05). 
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Next, to investigate the effect of exogenous NGF treatment on the spheroid size of trametinib-
resistant (CD271 expressing) melanoma subpopulations, WM35 H2B RFP control spheroids or 
spheroids derived from cells pre-treated for 9 says with 16 nM trametinib and following 
subsequent treatment for 72 hrs in the presence or absence of 1 mg/ml NGF were 
incorporated into collagen gels prior to monitoring tumour spheroid expansion over 7 days. 
Results demonstrated firstly, that there was no apparent increase in the spheroid expansion 
of untreated WM35 control cells compared to control WM35 cells treated with NGF (Figure 
4-28 A) (Two-way ANOVA test with Sidak post hoc correlation, NS P>0.05).  
 
Figure 4-28: NGF does not increase the spheroid size of control untreated WM35 RFP cells 
A. Representative immunofluorescence images of wild-type WM35 spheroids treated in the presence 
of absence (control) of 1mg/ml NGF for 3 days and incorporated into collagen gels for 0, 2, 4 and 7 
days, and B. Relative spheroid size (µm) of WM35 spheroids (red line) or WM35 spheroids treated for 
72 hrs with 1mg/ml NGF (green line) (relative to initial spheroid size at day 0) over 7 days. Each bar is 
the mean of three replicate experiments ± SD. Scale bar 100 µm  
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However, WM35 previously subjected to pre-treatment with 16 nM of trametinib for 9 days, 
and subsequent treatment with NGF demonstrated a trend (albeit not significant) for 
increased spheroid expansion compared trametinib-resistant cells not subjected to treatment 
with NGF ( 
Figure 4-29). Collectively these data suggest, as with melanoma subpopulations constitutively 
expressing CD271, that trametinib-induced drug resistant CD271 expressing melanoma 
subpopulations also display reduced spheroid expansion potential, in line with published 
literature indicating that CD271 expression is associated with a less invasive phenotype both 
in vitro and in vivo (Saltari et al., 2016). Interestingly, exogenous NGF selectively increased 
proliferation of trametinib –induced drug resistant CD271 expressing melanoma cells 
suggesting CD271 expression alone is not adequate to promote tumour cell proliferation.  
Taken together, these data suggest NGF may play an integral role in the promotion of both 
the proliferation and invasion of trametinib-induced CD271 expressing melanoma 
subpopulations.  
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Figure 4-29: NGF does not significantly increase the spheroid expansion of trametinib-
induced resistant WM35 cells 
A. Representative immunofluorescence images of WM35 spheroids pre-treated with 16 nM trametinib 
for 9 days in the presence (Trametinib +NGF) of absence (Trametinib control) of subsequent  treatment 
with 1mg/ml NGF for 3 days and incorporated into collagen gels for 0, 2, 4 and 7 days and B. Relative 
spheroid size (µm) of WM35 spheroids pre-treated for 9 days with 16 nM trametinib  (blue line) or 
with the additional treatment for 72 hrs with 1mg/ml NGF (pink line) (relative to initial spheroid size 
at day 0) over 7 days. Each bar is the mean of three replicate experiments ± SD. Scale bar 100 µm  
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 Discussion 
4.3.1 CD271 expressing melanoma subpopulations emerge in response to 
BRAF and MEK inhibitors 
 
Although the recent introduction of BRAF and MEK inhibitors have revolutionized the 
management of patients with metastatic melanoma (Chapman et al., 2011; Long et al., 2014), 
the development of acquired resistance evolves early following the initiation of these 
treatment modalities and significantly impacts on the durability of clinical response. A number 
of resistance mechanisms have been reported including the paradoxical hyper activation of 
NRAS (Poulikakos et al., 2010), the activation of RTK (Nazarian et al., 2010) or more recently 
the induction of melanoma subpopulations that are innately more resistant to targeted 
therapies and express stem cell surface markers such as CD271 (Ravindran Menon et al., 
2014). Recent literature highlights, in particular, the association of CD271 induction and 
development of resistance to BRAF/MEK inhibitors and standard chemotherapy 
temozolomide and dacarbazine (Chartrain et al., 2012; Ravindran Menon et al., 2014).  
In line with previous observations, results from this present study demonstrate the emergence 
of CD271 expressing melanoma subpopulations in response to both BRAF and MEK inhibitors 
(Chartrain et al., 2012; Ravindran Menon et al., 2014). Interestingly, and again in line with 
published literature, long term exposure of A375 cells to trametinib resulted in the transient 
induction of CD271 expressing melanoma subpopulations which subsequently declined and 
returned to baseline (Ravindran Menon et al., 2014) and therefore suggesting CD271 
induction as a marker of early drug resistance that is possibly not required to sustain tumour 
growth once resistance is established. Data also highlighted the time dependent decrease in 
apoptotic cell death observed in melanoma cells in response to sustained treatment with 
trametinib with a concurrent induction in CD271 expression. Taken together these data 
further support the hypothesis that CD271 expression is associated with increased resistance 
to trametinib.  
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It is interesting and somewhat perplexing that there was a rapid initial reduction in pERK 
expression in BRAF mutant A375 cells following exposure to trametinib which then gradually 
increased in line with the emergence of CD271 expression and development of early drug 
resistance. Expression of pERK continued to decline in A375 cells following long term exposure 
to trametinib, however at these time points CD271 expression had also declined suggesting 
the observed further reduction in pERK expression and continued resistance to trametinib 
may be mediated by additional mechanisms independently to the induction of CD271.  
The development of resistance to BRAF/MEK inhibition is associated with the rapid recovery 
of pERK expression as a result of resistant cells that escape the effects of BRAF/MEK inhibition 
(Paraiso et al., 2010). However, it is still not clear what mediates the recovery of pERK 
expression and re-activation of the MAPK pathway following long term exposure to trametinib 
and the establishment of acquired resistance. It is therefore possible that other generic pro-
survival pathways are activated to mediate trametinib-induced resistance, such as the 
unfolded protein response (Yan et al., 2015), inhibition of anti-apoptotic proteins including 
BCL-2 (Mukherjee et al., 2015) or activation of autophagy to sustain tumour growth 
independently of the MAPK pathway.   
 
4.3.2 Trametinib-induced CD271 expressing melanoma subpopulations are 
associated with increased autophagic activity 
 
There is increasing evidence in other cancer types that autophagy is crucial for the 
maintenance and survival of cancer stem cells (Maycotte et al., 2015a). As autophagy is a 
principal survival mechanism harnessed by cancer cells to survive hostile micro environmental 
conditions and promote metabolic homeostasis, (Rabinowitz and White, 2010), it is therefore 
likely that autophagy contributes to the survival of melanoma cells, including drug resistant 
subpopulations regardless of whether such populations are a true cancer stem cell phenotype 
or not. Results from this present study demonstrated a clear association between trametinib-
induced CD271 expressing subpopulations and activated autophagy, with data demonstrating 
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the concurrent induction of CD271 and autophagy (reflected by increased LC3-II and 
decreased p62 expression) in BRAF mutant cell lines following prolonged exposure to both the 
BRAF inhibitor PLX4720 and the MEK inhibitor trametinib. Studies of autophagic flux in BRAF 
mutant cells with dual tagged LC3-RFP-GFP additionally revealed an increase in LC3 flux in 
trametinib-induced CD271 expressing melanoma cells at a single cell level, further supporting 
the hypothesis that trametinib-resistant CD271 expressing melanoma cells harness autophagy 
to promote tumour cell survival.  
What is still unclear is whether autophagy in this context is activated in response to targeted 
inhibition of MAPK signalling (Goulielmaki et al., 2016) or whether emerging CD271 expressing 
drug resistant subpopulations specifically use autophagy as a survival mechanism. Future work 
could include the evaluation of the association of CD271 induction in the context of trametinib 
resistance with downstream signalling molecules such as RHoA/ROCK or JNK which could 
activate either a pro-survival, pro-apoptotic or migratory response and further tease out 
whether drug-induced CD271 plays a role in tumour cell migration or has a pro-survival role.  
There is also increasing evidence in the literature to suggest AMPK activated by glucose 
starvation or ATP depletion to sustain the metabolic and energetic cellular demands in the 
micro environment may provide the link to the activation of autophagy (Cantó et al., 2009) 
though inactivation of m-TORCH1 (Hardie, 2011) or direct phosphorylation of ULK1 (Kim et al., 
2011a). Indeed data from the present study demonstrated the significant reduction in ATP 
release and concurrent increase in pAMPK levels in trametinib-induced drug resistant CD271 
expressing melanoma subpopulations, supporting the notion that autophagy activation in 
these subpopulations is mediated by a depletion of cellular ATP release that results in 
metabolic reprogramming via pAMPK activation. Nevertheless these observations do not 
preclude from the possibility that autophagy induction observed in trametinib-induced drug 
resistant subpopulations results directly from CD271 induction or is a generic survival 
mechanism induced in response to treatment with trametinib. In an attempt to address these 
possibilities, subsequent experiments focussed on modulating CD271 expression in melanoma 
cells (both wild type and in trametinib-induced drug resistant subpopulations) prior to 
determining the subsequent impact on autophagy. Studies of CD271 over expression in A375 
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and WM35 melanoma cells revealed a concurrent increase in basal autophagy, however, the 
cellular localisation of CD271 was lobular and sub membranous rather than being an expected 
diffuse membranous expression pattern and raising concerns with regard to the functionality 
of CD271 following overexpression and the possibility that autophagy induction may have 
been mediated by cellular stress and the induction of ER stress (Hoyer-Hansen and Jaattela, 
2007). However, studies of ER stress gene expression in melanoma cells following over 
expression of CD271 did not reveal any significant association suggesting the observed 
autophagy induction did not arise as a consequence of cellular stress induced by transfection 
of CD271. Nevertheless, in contrast to published data (Lehraiki et al., 2015) results from the 
present study also revealed there was no protective effect of CD271 expression on trametinib-
induced cell death suggesting that it is possible that CD271 is not functional..  
To further tease out the association between drug-induced CD271 expression and autophagy 
activation CD271 expression was down regulated using a stable (ShRNA) a transient (SiRNA) 
approach in A375 cells. Stable CD271 knockdown resulted in increased cell death, suggesting, 
in line with previous observations (Lehraiki et al., 2015) that CD271 expression plays an 
integral role in melanoma cell survival. Subsequent experiments of CD271 knockdown were 
thus performed using a transient approach (siRNA), however, the observed, albeit non-
significant, increase in autophagic activity and reduction in pAMPK expression in cells 
following transient knockdown of CD271, may not reflect autophagic activity in such cells and 
rather, may have been related to transfection-associated autophagy induction. Nevertheless, 
knockdown of CD271 also resulted in a significant reduction in cell viability in response to 
treatment with trametinib indicating that CD271 might indeed play a protective role in the 
response of BRAF mutant melanoma cells to BRAF/MEK inhibition. Taken together, these data 
suggest that CD271 knockdown impairs the ability of melanoma cells to resist the cytotoxic 
effects of trametinib although the association between drug-induced CD271 abrogation and 
autophagy is not entirely clear. To tease out if drug-induced CD271 initiates autophagy or if 
autophagy is induced by drug resistance resulting in increased CD271 future experiments 
could include the use of modern and more efficacious technologies for gene editing such as 
CRISPR/Cas9 (Sander and Joung, 2014) to guide transcriptional activators/repressors to the 
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CD271 gene promotor region, which will allow for the modulation of CD271 at the DNA level. 
This approach will allow for more physiological activation compared to exogenous cDNA to 
overexpress CD271, and repression could be controlled more accurately than RNAi. 
Alternative approaches would be to manipulate autophagy regulatory genes and 
subsequently evaluate the effect on CD271 expression or the effect of trametinib treatment 
on CD271 induction or tagging autophagy regulatory proteins with a fluorescent probe to 
allow for analysis of the direct interaction between CD271 and autophagy in response to 
trametinib using super-resolution microscopy.  
4.3.3 Trametinib-induced CD271 expressing melanoma subpopulations are not 
consistently associated with the induction of other stem cell markers 
 
The hypothesis that CD271 expressing melanoma subpopulations are a true stem cell 
population is a matter of ongoing debate. Recent literature in this context is controversial with 
some reports indicating a potential association between drug-induced CD271 expressing 
melanoma subpopulations and the co-expression of other stem cell markers (Redmer et al., 
2014a) and other reports contradicting a potential stem cell origin of the CD271 expressing 
cells (Cheli et al., 2014a). The presence of de-differentiated cancer stem cells has been 
reported to be associated with more aggressive disease (Bao et al., 2013; Lasorella et al., 2014) 
via exploiting their ability to escape immunological surveillance (Bruttel and Wischhusen, 
2014). It is also known that cancer stem cells harness pro-survival mechanisms such as 
autophagy (Lei et al., 2017) and increased resistance to apoptosis (Fulda, 2013) and therefore 
to further tease out whether drug-induced CD271 expressing melanoma subpopulations are 
a true stem cells population is of importance. Results derived in chapter 3 highlighted a lack 
of any significant association between constitutively activated CD271 expressing melanoma 
cells and the co-expression of other stem cell markers including Jarid-1B (Roesch et al., 2010), 
ABCB5 (Chartrain et al., 2012) and SOX10 (Graf et al., 2014a). Consistent with finding in 
chapter 3, results from studies of stem cell marker expression in CD271 expressing trametinib 
resistant CD271 expressing melanoma subpopulations also highlight a lack of any association 
between those cells that express CD271 and the co expression of ABCB5, Jarid-1B, Nestin or 
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SOX10 again suggesting such CD271 expressing drug resistant subpopulations are not a stem 
cell phenotype. If, however, CD271 expression is not associated with a stem cell phenotype in 
melanoma, it is still not certain why CD271 expressing cells emerge in drug resistance and 
what their constitutive role is in melanoma development and progression. Recent evidence 
highlights the association between BRAF therapy-induced TNFa/NF-kB pathway and CD271 
induction (Lehraiki et al., 2015). In the context of drug resistance, recent evidence supports 
the activation of the TNFa/NF-kB in response to targeted BRAF inhibition, followed by the 
increased expression of CD271 expressing melanoma subpopulations (Lehraiki et al., 2015), 
indicating that there is possibly a direct link between NF-kB activation and CD271 induction in 
the context of drug resistance. Recent literature indicates that the NF-kB pathway is 
constitutively activated in many cancers (Smith et al., 2014) and in melanoma, TNFa secretion 
by macrophages and T-cells in the tumoural micro environment leads to an alteration in the 
equilibrium between differentiated and de-differentiated melanoma cells and the emergence 
of CD271 expressing melanoma cells, and allowing CD271 positive cells to escape immune 
surveillance (Landsberg et al., 2012). Interestingly, accumulating data also highlight the 
complex interplay between autophagy and NF-kB pathway. Autophagy-dependent 
degradation of NF-κB signaling components such as Hsp90 and IKKa and b (Djavaheri-Mergny 
and Codogno, 2007; Colleran et al., 2011) can either terminate or activate NF-kB activation 
(Trocoli and Djavaheri-Mergny, 2011). Conversely, NF-κB signaling can either activate or 
inhibit signaling pathways that lead to the induction of autophagy by regulating the 
transcription of a subset of pro-autophagic-regulating genes (Djavaheri-Mergny and Codogno, 
2007; Lee et al., 2007a). It is therefore possible that there is a complex regulation between 
BRAF inhibitor-induced NF-kB pathway activation, autophagy activation and CD271 induction. 
However, it is not entirely clear what is the sequence of events following the emergence of 
resistance to BRAF/MEK inhibitors, knowledge which would potentially be of benefit to 
identify novel targets to overcome acquired resistance to BRAF/MEK inhibition in melanoma.   
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4.3.4 Exogenous NGF increases trametinib-induced CD271 expressing cell 
proliferation but has no effect on tumour spheroid expansion in vitro 
 
Data derived from chapter 3 suggest that constitutive expression of CD271 is associated with 
reduced spheroid collagen expansion, supporting previous observations reporting the 
presence of CD271 expression is associated with reduced invasion in vitro and in vivo (Saltari 
et al., 2016). Similarly data from the present chapter also revealed trametinib induced CD271 
expressing melanoma cell populations also display reduced expansion when cultured in 
collagen gels in vitro compared to untreated control cells and collectively supporting the 
notion that although CD271 expression per se might play a role in melanoma survival (Lehraiki 
et al., 2015) and progression (Beretti et al., 2015) it may not be linked or be require to support 
the invasion of drug-resistant subpopulations. However, there is increasing evidence that 
constitutive expressing CD271 melanoma subpopulations may require additional stimuli to 
promote tumour invasion such as the presence of NGF (Herrmann et al., 1993). NGF has been 
suggested to stimulate cell proliferation and survival via its interaction with TrkA and CD271 
(Demont et al., 2012), and in melanoma, the interaction of CD271 with NGF has been 
suggested to increase tumour cell invasion in vitro (Herrmann et al., 1993). To evaluate the 
effect of NGF stimulation on trametinib induced CD271 expressing melanoma cells, drug 
resistant cells were further treated with NGF which resulted in a significant increase in cell 
proliferation. However, although there was some increase in spheroid size, NGF failed to 
significantly induce collagen spheroid expansion of trametinib induced CD271 expressing cells. 
Nevertheless, the observed increase in trametinib induced CD271 expressing spheroid 
expansion following treatment with NGF, although not significant, might indicate that in vitro 
invasion requires the presence of exogenous factors, including NGF, which in vivo could be 
derived from the tumour microenvironment. Recent reports highlight the secretion of NGF by 
human keratinocytes (Pincelli et al., 1994; Shi et al., 2013) indicating that in vivo, CD271 
expression in melanoma cells may be driven by NGF secretion in the tumour 
microenvironment leading to the promotion of tumour invasion. It is still, however, not clear 
how NGF stimulates drug-induced CD271 cell proliferation. It is possible that CD271 requires 
the direct binding of NGF to the ligand to drive tumour cell invasion or requires the activation 
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of downstream target genes such as ESM1 (Chen et al., 2016) to promote tumour invasion. 
However previous reports highlight the use of smaller doses of NGF up to 100 ng/ml (Fabricant 
et al., 1977; Paraiso et al., 2010) which is in contrast with the higher dose of NGF used in this 
study. It is likely that higher dose of NGF could signal through other pathways independent of 
CD271 such as TrkA (Paraiso et al., 2010) and therefore the results involving NGF presented in 
this Thesis should be interpreted with caution. Future work to include further optimisation of 
exogenous NGF dosing and evaluate the effect on trametinib resistant cells is required to 
achieve firm conclusions. To further decipher the role of CD271 in tumour invasion and 
spheroid expansion in collagen gels, subsequent experiments described in chapter 5 
investigated the role of CD271 inhibition using small molecule inhibitors TAT-PEP5 and Ro-08 
to block CD271 expression and evaluate the effect of CD271 blockade on tumour cell spheroid 
expansion  in vitro. 
Collectively results derived from the present chapter highlight the emergence of CD271 
expressing subpopulations following the exposure of BRAF mutant melanoma cells to BRAF or 
MEK specific inhibition. Data also highlight the intimate relationship between pro-survival 
autophagy and CD271 expression in the context of trametinib-induced melanoma resistance. 
However, whether pro-survival autophagy is activated as a consequence of drug-induced 
CD271 expression or vice versa is still not entirely clear. Findings reported in this chapter, 
additionally identify novel therapeutic targets and pave the way to several strategies that 
could potentially overcome the resistance of or re-sensitise patients with MAPK drug-resistant 
metastatic melanoma to the cytotoxic effects of trametinib, discussed fully in chapter 5.   
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 Summary 
 
• BRAF and MEK inhibition in BRAF mutant melanoma cells leads to induction of CD271 
expressing subpopulations in melanoma 
 
• Trametinib-induced CD271 expressing melanoma subpopulations are associated with 
an increase in autophagic activity  
 
 
• Overexpression of CD271 is associated with increased autophagic activity but not 
induction of ER stress markers 
 
• Knockdown of CD271 in BRAF mutant melanoma cell subpopulations in vitro is not 
associated with the co-expression of other neuroectodermal stem cell markers 
 
• Trametinib-induced CD271 expressing melanoma subpopulations display reduced 
spheroid expansion and size when incorporated into collagen gels in vitro compared 
to untreated control BRAF mutant melanoma cells  
 
• Treatment of trametinib-induced CD271 expressing melanoma subpopulations with 
exogenous NGF increases proliferation but does not significantly increase spheroid size 
in vitro 
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Chapter 5 Targeting drug resistant subpopulations in 
melanoma as a strategy to overcome therapeutic 
resistance to MAPK inhibition  
 Introduction 
 
As highlighted throughout the current thesis, the development of acquired resistance is the 
major limiting factor in the targeted treatment of patients with BRAF or NRAS mutant 
metastatic melanoma with BRAF or MEK specific inhibitors, leading to a plethora of studies 
focused towards novel means through which to overcome such resistance. Such approaches 
have included the inhibition of downstream ERK (Ishii et al., 2013), the targeting of other 
activated signalling pathways such as PI3K-PTEN-AKT (Sánchez-Hernández et al., 2012) or 
combined BRAF and MEK inhibition, including combined treatment with the BRAF inhibitor, 
dabrafenib, and the MEK inhibitor, trametinib; a strategy that results in prolonged disease free 
survival (Long et al., 2014) and following adoption by the National Institute for Health and 
Care Excellence (NICE) is now used as first line treatment for patients with BRAF mutant 
metastatic melanoma (NICE, 2016). Additionally in an attempt to delay the emergence of 
acquired resistance, sequential rather than combination approaches with targeted agents 
have been made (Kirk, 2013). However, to date none of these strategies have been able to 
overcome the inevitable development of acquired resistance by BRAF/NRAS mutant 
metastatic melanomas to BRAF and or MEK inhibitor therapy, emphasizing the acute need for 
novel and more effective approach.  
Data from chapter 4 demonstrated the emergence of CD271 expressing subpopulations in the 
drug resistance of BRAF mutant melanoma cells to the BRAF and or MEK specific inhibition, 
paralleled by the activation of AMPK and pro-survival autophagy and thus highlighting the 
potential for CD271, AMPK or autophagy inhibition as a potential therapeutic strategy to 
prevent the survival and invasion of such drug resistant subpopulations.   
Results reported in chapter 4 have also highlighted the intimate relationship between 
trametinib-induced CD271 expressing melanoma subpopulations and activation of pro-
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survival autophagy, possibly via activation of the AMPK pathway. AMPK blockade has been 
shown to act synergistically with radiation therapy and reduce cell viability of colorectal cancer 
cells (Jin et al., 2016). Similarly, targeting tumour cell metabolic reprogramming via AMPK 
activation in breast cancer cells has been proposed as a promising treatment strategy to 
overcome drug resistance (Long et al., 2016). Evidence from other cancer types additionally 
indicates autophagy plays an important role in maintaining tumour cell homeostasis and 
survival, including in BRAF mutant melanoma (Armstrong et al., 2011; Corazzari et al., 2015) 
and leading to a number of pre-clinical and clinical studies of autophagy inhibition as a 
therapeutic approach to prevent drug resistance. Studies in chronic myeloid leukaemia 
demonstrate a superior anti-leukemic effect by combined treatment with tigecycline and 
chloroquine (Lu et al., 2017). Similarly, autophagy inhibition with chloroquine has been shown 
to augment the effects of 5-FU (5-fluorouracil) in colorectal cancer (Li et al., 2010), collectively 
suggesting that inhibiting autophagy in combination with other chemotherapeutic agents may 
present a viable means through which to re-sensitize CD271 expressing MEK inhibitor resistant 
melanoma cells once again to the cytotoxic effects of trametinib. 
Interestingly, recent data also reports autophagy exacerbation as a strategy to promote 
tumour cell death (Scarlatti et al., 2008), with studies in melanoma specifically showing use of 
the cannabinoid derivative THC (Tetrahydrocannabinol) results in autophagy induction, 
already increased basally by the presence of a BRAF mutation (Corazzari et al., 2015) and 
which leads to tumour cell apoptosis (Armstrong et al., 2015b) thereby suggesting this as a 
possible means through which to enhance cell death of drug resistant CD271 expressing 
melanoma subpopulations.   
Given the clear association between MEK-inhibitor induced CD271 expressing melanoma 
subpopulations and pro-survival autophagy, the aim of the current chapter was to evaluate 
the potential for chemical inhibition of CD271 or the modulation of autophagy (either through 
inhibiting pAMPK or by chemical inhibition with chloroquine or specific autophagy inhibitors 
or by exacerbation with agents that promote cytotoxic autophagy) in trametinib-induced drug 
resistant BRAF mutant melanoma subpopulations as a strategy through which to over-come 
resistance to targeted MEK inhibitor therapy. 
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 Results 
5.2.1 Chemical Inhibition of CD271 inhibits cell viability, pAMPK and autophagy 
in trametinib-induced drug resistant subpopulations but has no impact 
on trametinib-induced inhibition of spheroid expansion in vitro 
 
To test the potential for chemical inhibition of CD271 as a strategy to overcome CD271 
associated resistance to MEK inhibitor therapy, two small molecule inhibitors,  TAT-PEP5 
(which inhibits the interaction of CD271 with Rho-GDI (Mochizuki et al., 2016) and Ro 08-2750 
(a small molecule which inhibits the binding of NGF to p75NTR (Niederhauser et al., 2000) 
were used to inhibit CD271 activity in melanoma cells pre-treated with trametinib. 
Dose response experiments were first performed in order to establish the optimal dose of 
each agent able to inhibit the cell viability of A375 or WM35 melanoma cells pre-treated for 9 
days with 16 nM trametinib. Results demonstrated the dose dependent inhibition of both 
A375 and WM35 cell viability following treatment with either TAT-PEP5 or RO-08 for 72 hours, 
( 
 
Figure 5-1 A, B), with the consistent and significant inhibition of cell viability of either cell line 
pre-treated with trametinib induced by 5 µM TAT-PEP5 and 10 µM RO-08 (Figure 5-2A, B) (One 
way ANOVA with Tukey’s multiple comparison test, **P<0.01, ****P<0.0001). 
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Figure 5-1:TAT-PEP5 and RO-08 induce dose dependent inhibition of cell viability of 
trametinib-induced drug resistant WM35 and A375 cells  
Relative cell viability of WM35 (A) or A375 (B) cells, pre-treated for 9 days with 16nM trametinib, and 
subsequently treated for a further 72 hours with trametinib alone or with trametinib in combination 
with 0.01-10 µM TAT-PEP5 (PEP5) or 1-10 µM RO-08 (RO-08). Each bar is the mean +/- SD of 3 
independent experiments expressed relative to control (9 day 16 nM trametinib treated), each 
containing 4 replicate treatment conditions. *P<0.05, ****P < 0.0001. 
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Figure 5-2: TAT-PEP5 and RO-08 significantly inhibit the cell viability of trametinib-induced 
drug resistant WM35 and A375 cells  
Relative cell viability of WM35 (A) or A375 (B) cells pre-treated for 9 days with 16nM trametinib in the 
absence (trametinib) or presence of subsequent treatment for 72 hours with 5 µM TAT-PEP5 (PEP5 5 
uM) or 10 µM RO-08 (RO-08 10uM).  Each bar is the mean +/- SD of 3 independent experiments 
expressed relative to control (9 day trametinib treated WM35 or A375 cells).*P<0.05, ****P < 0.0001. 
To further evaluate the effect of CD271 inhibitors on CD271 expression, autophagic activity 
and pAMPK expression, A375 pre-treated for 9 days with 16nM trametinib were again treated 
with 16 nM trametinib, 5 µM TAT-PEP5, 10 µM RO-08 or combined trametinib and PEP5/RO-
08 for 72 hours prior to assessing the expression of CD271, p62, LC3 I/II or pAMPK by western 
blotting. Results demonstrated TAT-PEP5 and RO-08 induced the down regulation of CD271 
expression which was paralleled with a reduction in autophagic activity and pAMPK expression 
(Error! Reference source not found. A) in cells pre-exposed to trametinib for 9 days. However, f
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urther exposure to trametinib in the presence or absence of either CD271 inhibitor, resulted 
in the induction of CD271 expression to similar levels induced by the original exposure to 
trametinib for 9 days (Figure 5-3 A) which was also paralleled an increase in autophagic activity 
as well as pAMPK expression (Figure 5-3 A), likely reflecting that the CD271 inhibitors although 
they inhibit CD271 protein expression in drug induced CD271 expressing cells, the addition of 
trametinib, which induces CD271 expression, antagonizes the CD271 inhibitor function and 
results in increase in CD271 expression, autophagy and pAMPK levels. It is also likely that the 
observed reduction in CD271 expression in cells treated with the CD271 inhibitors alone is a 
result of the withdrawal of trametinib rather than a direct effect of the CD271 inhibitors on 
CD271 expression and therefore re-introduction of trametinib results in again increased 
expression of CD271.   
Cleaved PARP expression demonstrated increased expression levels in A375 cells that have 
been treated with 16 nM trametinib for 9 days (Figure 5-3 A and v) which were further 
increased in cells that have been subsequently treated with combination of trametinib and 
CD271 inhibitors (Figure 5-3 A and v), albeit non-significant, indicating that the combination 
of trametinib with the CD271 inhibitors induces apoptotic cell death in trametinib induced 
CD271 expressing subpopulations.  
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Figure 5-3: TAT-PEP5 and RO-08 inhibit MEK inhibitor-induced CD271, autophagy and 
pAMPK in A375 melanoma cells, but do not however prevent the induction of CD271, 
autophagy and pAMPK upon re-exposure to trametinib.  
A.Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), pAMPK 
(62 kDa), p62 (62 kDa), LC3 I/II (16,18 kDa) or GAPDH loading control (38 kDa) in DMSO treated A375 
cells (control) or A375 cells pre-treated for 9 days with 16 nM trametinib (trametinib) and subsequently 
for 72 hours with DMSO vehicle control (control), 16 nM trametinib, , 5 µM TAT-PEP5 (PEP5), 10 µM 
RO-08 (RO-08) or combined trametinib and TAT-PEP5 (Trametinib +PEP5) or RO-08 (Trametinib+RO-
08). B. Relative CD271 (i), LC3 II (ii), p62 (iii), pAMPK (iv) or cleaved PARP (v) expression levels relative 
to GAPDH in 3 individual experiments. Each bar is the mean or 3 experiments ± SD (*P<0.05, **P<0.01).  
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To assess the impact of chemical inhibition of CD271 activity on the in vitro invasion of 
trametinib-induced drug resistant WM35 cells, WM35 H2B RFP cells pre-treated for 9 days 
with 16nM trametinib were seeded in collagen gels prior to further treatment for up to 7 days 
with either DMSO control or trametinib in the presence or absence of 5 µM TAT-PEP5 or 10 
µM RO-08, and the monitoring of spheroid size over 7 days. Results demonstrated neither 
TAT-PEP5 or RO-08 alone exerted the capacity to prevent increase in spheroid size of wild-
type control (DMSO treated) WM35 cells (Two-way ANOVA test with Sidak post hoc 
correlation, NS P>0.05,  
Figure 5-4 A, B, Figure 5-5 A,B), while a significant reduction in spheroid size was observed in 
cells pre-treated for 9 days with trametinib or subsequently treated with trametinib for a 
further 7 days in the presence or absence of either CD271 inhibitor  ( 
Figure 5-4 A,B, Figure 5-5 A,B) (Two-way ANOVA test with Sidak post hoc correction, **P<0.01, 
***P<0.001), indicating that the CD271 inhibitors alone do not impact on spheroid size  in 
vitro, whereas the cells treated with combination of trametinib and the CD271 inhibitors 
demonstrate a significant reduction in spheroid size which is, however, not significantly 
different compared to the cells treated with trametinib alone, suggesting that CD271 
inhibitors do not affect the spheroid size of trametinib-induced CD271 expressing 
subpopulations in vitro.  
Collectively these data indicate chemical inhibition of CD271 inhibits the viability of 
trametinib-induced drug resistant melanoma cells and increases their spheroid size. 
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Figure 5-4: TAT-PEP5 does not prevent an increase in spheroid size of Trametinib-induced 
drug resistant WM35 cells in vitro 
A.Representative immunofluorescence images of WM35 H2B RFP untreated control cells (control) or 
pre-treated with 16 nM trametinib for 9 days followed by continuation of 16 nM trametinib 
(trametinib), 5 µM TAT-PEP5 (PEP5) or combination of 16 nM trametinib and 5 µM TAT-PEP5 
(Trametinib+PEP5 ) for up to 7 days in collagen gels for 0 , 2, 4 or 7 days. Scale bar 100 µm. B. 
Quantification of spheroid expansion demonstrated as relative size (µm) compared to initial spheroid 
size (0 day) **P<0.01. 
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Figure 5-5 RO-08 does not prevent an increase in spheroid size of Trametinib-induced drug 
resistant WM35 cells in vitro 
A.Representative immunofluorescence images of WM35 H2B RFP untreated control cells (control) or 
pre-treated with 16 nM trametinib for 9 days followed by continuation of 16 nM trametinib 
(trametinib), 10 µM RO-08 (RO-08) or combination of 16 nM trametinib and 10 µM RO-08 
(Trametinib+RO-08) for up to 7 days in collagen gels for 0 , 2, 4 or 7 days. Scale bar 100 µm. B. 
Quantification of spheroid expansion demonstrated as relative spheroid size (µm) compared to initial 
spheroid size (0 day) **P<0.01. 
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5.2.2 Inhibition of pAMPK increases autophagic activity in trametinib-induced 
CD271 expressing melanoma subpopulations 
 
To evaluate the potential of inhibiting pAMPK activity as a means to inhibit trametinib-induced 
pro-survival autophagy in melanoma cells, trametinib-induced drug resistant WM35 or A375 
subpopulations were re-exposed to trametinib in the presence or absence of a potent cell 
permeable AMPK inhibitor (Liu et al., 2014) prior to assessing the impact on autophagy activity 
by western blotting for p62 and LC3 I/II expression. Experiments using compound C were 
performed in collaboration with Dr Noel Edwards, Newcastle University and results 
demonstrated a reduction in pAMPK expression in both WM35 and A375 following treatment 
with Compound C which was paralleled with a reduction in CD271 expression (Figure 5-6 A, 
Figure 5-7 A). However, LC3 II expression was increased in both cell lines following treatment 
with compound C (Figure 5-6 A, Figure 5-7 A) with a concurrent reduction in p62 expression 
in WM35 cells (Figure 5-6 A) but increase in p62 expression in A375 cells (Figure 5-7 A), 
collectively suggesting pAMPK inhibition enhances rather than reduces autophagic activity in 
trametinib-induced drug resistant melanoma cell populations. The reasons for these findings 
are unclear but may reflect the fact that Compound C has anti-cancer effects that are 
independent of the AMPK pathway and therefore is not a specific AMPK inhibitor (Liu et al., 
2014). 
The alternative approach of directly modulating autophagy either with specific inhibitors or 
through exacerbation with agents to harness its cytotoxic effect was therefore adopted 
subsequently to evaluate the potential of autophagy modulation as a strategy to re sensitize 
MEK inhibitor drug resistant melanoma subpopulations to the cytotoxic effects of trametinib.   
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Figure 5-6: Compound C reduces pAMPK, CD271 expression but increases autophagy 
trametinib-induced drug resistant WM35 melanoma subpopulations.   
A.Representative immunoblots for the expression of CD271 (45 kDa), pAMPK (62 kDa), total AMPK (62 
kDa), p62 (62 kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in WM35 cells following 
treatment with vehicle DMSO control (control) or WM35 cells treated with 16 nM trametinib for 7 days 
and subsequently treated with 16 nM trametinib (trametinib),5 µM Compound C or combination 16 
nM trametinib and 5 µM Compound C (Trametinib+Compound C) for 48 hours. B.Relative CD271 (i), 
LC3 II (ii), p62 (iii), pAMPK (iv) or total AMPK (v) expression levels relative to GAPDH (n=1).  
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Figure 5-7: Compound C reduces pAMPK, CD271 expression but increases autophagy 
trametinib-induced drug resistant A375 melanoma subpopulations.   
A.Representative immunoblots for the expression of CD271 (45 kDa), pAMPK (62 kDa), total AMPK (62 
kDa), p62 (62 kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in A375 cells following 
treatment with vehicle DMSO control (control) or A375 cells treated with 16 nM trametinib for 7 days 
and subsequently treated with 16 nM trametinib (trametinib),5 µM Compound C or combination 16 
nM trametinib and 5 µM Compound C (Trametinib+Compound C) for 48 hours. B.Relative CD271 (i), 
LC3 II (ii), p62 (iii), pAMPK (iv) or total AMPK (v) expression levels relative to GAPDH (n=1).  
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5.2.3 Autophagy Inhibition re-sensitizes MEK inhibitor-induced CD271 drug 
resistant melanoma subpopulations to the cytotoxic effects of 
trametinib.  
 
Autophagy in the context of cancer resistance can be a direct result of cytotoxic chemotherapy 
(Kanzawa et al., 2004) or targeted therapy treatment (Goulielmaki et al., 2016) but also can 
be harnessed by specific chemo resistant tumour cell subpopulations to escape the cytotoxic 
effects of these agents (Brigger et al., 2015). Given the clear association between autophagy 
activation in trametinib-induced CD271 expressing drug-resistant subpopulations, the 
potential for autophagy inhibition was first evaluated in vitro as a strategy to re-sensitize drug 
resistant melanoma subpopulations to the cytotoxic effects of trametinib. To test this 
hypothesis autophagy was inhibited in trametinib-induced drug resistant subpopulations with 
the lysosomal inhibitor chloroquine and a specific inhibitor of the Vps34/Beclin 1 complex, PIK 
III (Ronan et al., 2014). 
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5.2.4 Autophagy inhibition with Chloroquine reduces cell viability, colony 
forming potential and tumour spheroid size of prolonged trametinib-
induced resistant CD271 expressing melanoma subpopulations in vitro. 
 
To evaluate the potential for chloroquine to re-sensitize drug resistant melanoma cells to the 
cytotoxic effects of trametinib, WM35, SK-mel-28, A375 and WM266-4 cells pre-treated for 9 
days with 16nM trametinib were re-exposed to 16nM trametinib for 48 hrs in the presence or 
absence of co-treatment with 10 µM chloroquine prior to the assessment of cell viability and 
colony forming potential. Analysis of the effects on cell viability revealed the combined 
treatment of all cell lines with trametinib and chloroquine significantly increased inhibition of 
cell viability of all cell lines ( 
Figure 5-8 A, B, C, D) (One way ANOVA with Tukey multiple comparison test, *P<0.05, **P 
<0.001, ****P <0.0001), resulting in significant re-sensitization of resistant cells (initially 
treated for 9 days with 16nM trametinib) to the cytotoxic effects of trametinib.  
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Figure 5-8: Chloroquine re-sensitizes trametinib-resistant melanoma cells to trametinib-
induced inhibition of cell viability. 
Relative cell viability of trametinib-resistant WM35 (A), A375 (B), SK-mel-28 (C) and WM266-4 (D) cells 
(initially treated for 9 days with 16 nM trametinib) following treatment for 48 hrs with DMSO vehicle 
control (control), 10 μM chloroquine (CQ), 16 nM trametinib (Trametinib), or combined CQ and 
trametinib (Trametinib+CQ). Each bar is the mean +/- SD of 3 independent experiments each 
containing 4 replicate treatment conditions, expressed relative to untreated control. *P<0.05, **P 
<0.001, ****P < 0.0001. 
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However, the clinically achievable chloroquine concentrations are between 25 and 50 mg/Kg 
(Oduola et al., 1998; Ursing et al., 2016) which might not be equivalent to 10 μM dose used in 
tissue culture experiments. To evaluate the effect of a lower, clinically achievable dose of 
chloroquine on the cell viability of trametinib resistant cells, identical experiments were 
repeated in WM35 and A375 cells using lower doses of 5 μM chloroquine, in which results 
again revealed the significantly increased inhibition of cell viability of both trametinib-induced 
resistant WM35 and A375 cells following combined treatment for a further 48 hours with 16 
nM trametinib and 5 μM chloroquine (one way ANOVA with Tukey multiple comparison test, 
***P < 0.001, **P <0.001, Figure 5-9 A and B).   
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Figure 5-9: Lower dose chloroquine re-sensitizes trametinib-resistant melanoma cells to 
trametinib-induced inhibition of cell viability. 
Relative cell viability of trametinib-resistant WM35 (A) and A375 (B) cells (treated initially for 9 days 
with 16nM trametinib) following treatment for 48 hrs with DMSO vehicle control, 5 μM chloroquine 
(CQ) ,16nM trametinib (Trametinib), or combined CQ and trametinib (Trametinib+CQ). Each bar is the 
mean +/- SD of 3 independent experiments each containing 4 replicate treatment conditions, 
expressed relative to untreated control. **P <0.001. ***P < 0.001. 
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To further confirm the potential for chloroquine to increase cell death of trametinib-induced 
drug resistant melanoma cell populations following re exposure to trametinib, colony forming 
assays were performed in SK-mel-28 and A375 cells. Both cell lines were initially treated with 
16 nM trametinib for 9 days, followed by subsequent treatment for 48 hrs in the presence or 
absence of 10 μM chloroquine, 16 nM trametinib or the combination of both agents. Results 
demonstrated the colony forming efficiency of both SK-mel-28 (Figure 5-10 and B) and A375 
cells (Figure 5-10 A and C) cells was reduced by both single agent chloroquine and trametinib 
but was enhanced by combined treatment with both agents (One way ANOVA with Tukey’s 
post hoc correlation, *P<0.05, NS P>0.05, (Figure 5-10 B and C).  
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Figure 5-10: Chloroquine inhibits the colony forming capacity of trametinib-induced drug 
resistant A375 and SK-mel-28 cells. 
A: Representative images of A375 and SK-mel-28 colonies or % cloning efficiency of A375 (B) or SK-
mel-28 cells (C) untreated control (control) or following initial exposure for 9 days to 16 nM trametinib 
and subsequent treatment for 48 hrs in the presence of 16 nM Trametinib, 10 μM chloroquine (CQ), 
or combined trametinib and CQ chloroquine prior to seeding at a density of 1000 cells/petri dish and 
further culture for 2 weeks. Each bar is the mean of three independent replicate experiments what +/- 
SD compared to untreated control. *P<0.05 
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Collectively these data thus suggest that inhibiting trametinib-induced pro-survival autophagy 
in drug resistant CD271 expressing melanoma subpopulations re-sensitizes them to the 
cytotoxic effects of trametinib. Nevertheless to confirm the effects of chloroquine on the 
inhibition of trametinib-induced CD271 and autophagy as well as the induction of cell death 
and specifically apoptosis, additional experiments were carried out to evaluate the effects of 
chloroquine on trametinib-induced CD271, PARP cleavage and p62 and LC3 I/II expression. 
WM35 and A375 cells were initially treated in the presence of 16 nM trametinib for 9 days 
before subsequent treatment for a further 48 hours with either 16 nM trametinib, 10 µM 
chloroquine or combined trametinib and chloroquine.  
Results demonstrated an increased CD271 expression which was non-significant in drug-
resistant WM35 (Figure 5-11) but a significant increase in CD271 expression was observed in 
A375 cells (One way ANOVA with Tukey’s multiple comparison test, *P<0.05, Figure 5-12 A, 
Bi) following further treatment with trametinib for 48 hrs, which was not, in general, altered 
by treatment with chloroquine or in cells treated subsequently for 48 hrs with combined 
chloroquine and trametinib (Figure 5-11 and Figure 5-12). Data also demonstrated trametinib-
induced LC3 II expression which was further induced in the presence of chloroquine, signifying 
a block in autophagic flux, an observation supported by an associated increase, albeit non-
significant, in p62 expression in trametinib-induced drug resistant cells treated with 
chloroquine and collectively further confirming the inhibition of trametinib-induced 
autophagy by chloroquine in both cell lines (One way ANOVA with Tukey’s multiple 
comparison test, ***P<0.001 for LC3 II in WM35 cells (Figure 5-11 A, Bii), **P<0.01 for LC3 II 
in A375 cells, (Figure 5-12 A, B ii)). Furthermore, results also revealed a non-significant 
increase in cleaved PARP expression in trametinib-induced drug resistant populations in both 
cell lines following exposure to chloroquine, further confirming the potential for autophagy 
inhibition with chloroquine to re-sensitize cells to trametinib-induced apoptosis (Figure 5-11 
and Figure 5-12).  
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Figure 5-11 Chloroquine inhibits trametinib-induced autophagy and potentiates apoptosis 
of drug resistant WM35 cells 
A.Representative immunoblots or B: Relative expression of CD271 (45 kDa, B i), LC3 I/II (16,18 kDa, or 
LC3II, B ii),  p62 (62 kDa, B iii), Cleaved PARP (89 kDa, B iv), or GAPDH loading control (38 kDa) in WM35 
cells following treatment with vehicle DMSO control (control) or pre-treatment with 16 nM trametinib 
for 9 days (trametinib) and subsequent treatment for 48 hours with 10 µM chloroquine (CQ) or 
combined trametinib and chloroquine (Trametinib +CQ) or for 48 hours.  Each bar is the mean or 3 
experiments ± SD relative to GAPDH in 3 individual experiments (**P<0.01, ***P<0.001). 
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Figure 5-12: Chloroquine inhibits trametinib-induced autophagy and potentiates apoptosis 
of drug resistant A375 cells  
A.Representative immunoblots or B:  Relative expression of CD271 (45 kDa, B i), LC3 I/II (16,18 kDa, or 
LC3II, B ii),  p62 (62 kDa, B iii), Cleaved PARP (89 kDa, B iv), or GAPDH loading control (38 kDa) in A375 
cells following treatment with vehicle DMSO control (control) or pre-treatment with 16 nM trametinib 
for 9 days (trametinib) and subsequent treatment for 48 hours with 10 µM chloroquine (CQ) or 
combined trametinib and chloroquine (Trametinib +CQ) or for 48 hours.  Each bar is the mean or 3 
experiments ± SD relative to GAPDH in 3 individual experiments. (*P<0.05, **P<0.01).  
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Together, these data thus support the pro-survival role of autophagy in trametinib-induced 
CD271 expressing drug resistant subpopulations and the therapeutic potential for autophagy 
blockade to overcome trametinib-induced drug resistance of BRAF/NRAS mutant melanoma.  
Finally to investigate the effects of chloroquine on the invasion of trametinib-induced CD271 
expressing drug-resistant melanoma subpopulations in vitro, A375 cells continuously pre-
treated in the presence of 16 nM trametinib for 42 days were seeded into collagen gels and 
subsequently further treated with either complete media control, 16 nM trametinib, 10 µM 
chloroquine or combined trametinib and chloroquine for up to 7 days. Results demonstrated 
the significant reduction in collagen invasion of cells that have been co-treated with 
trametinib and CQ for 7 days in collagen gels compared to the invasion of either control cells 
at the same time point (Two way ANOVA with Sidak post hoc correlation, ****P<0.0001) 
(Figure 5-13 A and B) or cells that have been continuously treated with trametinib for 7 days 
following incorporation in to collagen invasion assays- (Two way ANOVA with Sidak multiple 
comparison test (***P<0.001), (Figure 5-13 A and B).  
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Figure 5-13: Combined treatment of trametinib-induced drug resistant A375 cells (pre 
exposed to trametinib for 42 days) with trametinib and chloroquine inhibits spheroid 
expansion in vitro 
A.Representative bright field images of drug resistant A375 spheres pre-treated with 16 nM trametinib 
for 42 days and incorporated into collagen invasion gels prior to subsequent treatment for 0, 2, 4 or 7 
days with medium control (control), 16 nM trametinib, 10 µM chloroquine (CQ) or combined 
trametinib and chloroquine (Trametinib+CQ). Scale bar 100 µm. B. Quantification of collagen invasion 
of drug resistant A375 cells following subsequent treatment for 0, 2, 4 or 7 days with control, 
trametinib, CQ or trametinib + CQ expressed as relative invasion (µm) compared to initial spheroid size 
at day 0. Each point is the mean of three replicate independent experiments +/-SD compared to control 
(42 day trametinib treated A375 cells), ***P<0.001, ****P<0.0001. 
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5.2.4.1 Vps34 inhibition reduces cell viability, but has no impact on 
the inhibition of invasion of prolonged trametinib-induced 
resistant CD271 expressing melanoma subpopulations in vitro. 
 
To evaluate the potential for specific autophagy inhibition to re-sensitize drug resistant 
melanoma cells to the cytotoxic effects of trametinib, WM35 and A375 cells pre-treated for 9 
days with 16 nM trametinib or prolonged exposure to 16 nM trametinib for 42 days were re-
exposed to 16 nM trametinib for 24 hrs in the presence or absence of co-treatment with 5 µM 
PIK III (a selective inhibitor of the Vps34/Beclin-1 (Dowdle et al., 2014) prior to the assessment 
of cell viability and tumour invasion in vitro. 
Results demonstrated a trend for PIK II-induced inhibition of cell viability of either WM35 or 
A375 cell pre-treated for 9 days with 16 nM trametinib (Figure 5-14). Consistent with previous 
findings re exposure of 9 day resistant WM35 or A375 cells to 16 nM trametinib for 24 hours 
also had no effect on the reduction of cell viability (Figure 5-14). However, subsequent 
treatment of 9 day resistant WM35 or A375 cells with trametinib in combination with PIK III 
resulted in the significant inhibition of viability of both drug-resistant cell lines  (One way 
ANOVA with Tukey’s post hoc correlation, **P <0.001 for WM35 and ****P < 0.0001 for A375 
cells, Figure 5-14 A, B).   
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Figure 5-14: Vps34 inhibition re-sensitizes drug resistant WM35 and A375 cells to the 
cytotoxic effects of trametinib.   
Relative cell viability of trametinib-resistant WM35 (A) and A375 (B) cells pre-treated for 9 days with 
16nM trametinib and subsequently treated for 24 hrs In the presence of DMSO vehicle control, 5 μM 
PIK III (PIK III) ,16nM trametinib (Trametinib), or combined PIK III and trametinib (Trametinib+PIK III). 
Each bar is the mean +/- SD of 3 independent experiments each containing 4 technical replicates and 
expressed relative to untreated control**P <0.001. ****P < 0.0001. 
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To further evaluate the potential effect of PIK III on trametinib-induced CD271 and autophagy, 
as well as apoptosis, drug resistant WM35 and A375 cells (pre-treated with 16 nM trametinib 
for 9 days) were also treated with PIK III in the presence of absence of re-exposure to 16nM 
trametinib prior to assessing the expression of CD271, LC3 I/II, p62, pAMPK and cleaved PARP 
and by Western blotting (Figure 5-15, Figure 5-16). Results demonstrated the significant 
induction of CD271 expression in 9 day resistant WM35 cells in the presence of absence of 
PIKII (One way ANOVA with Tukey’s post hoc correction, * P< 0.05, Figure 5-15 A, Bi) but which 
was reduced in 9 day resistant cell treated subsequently with trametinib and PIK III compared 
to drug resistant WM35 cells subsequently treated with trametinib alone (Figure 5-15 A, Bi). 
However, in drug resistant A375 cells pre-exposed to treatment for 9 days with 16 nM 
trametinib, CD271 was apparently induced by further treatment with PIK III and which was 
not reduced by combined additional treatment with PIK III and trametinib (Figure 5-16 A, Bi), 
perhaps reflected by the highly variable data derived by these experiments and the large error 
bars incurred.  
Treatment of WM35 or A375 cell treated with 16 nM trametinib for 9 days also resulted in 
both the induction of LC3-II and inhibition of p62 expression (Figure 5-15 and Figure 5-16 A 
and B ii and iii), which was significant in WM35 cells (One way ANOVA with Tukey’s multiple 
comparison test ** P< 0.01 for LC3-II and **** P< 0.0001 for p62, Figure 5-15 B ii and iii), albeit 
only significant in case of LC3 II expression in A375 cells (One way ANOVA with Tuckey’s 
multiple comparison test * P< 0.05 for LC3-II and non-significant for p62,Figure 5-16 B ii and 
iii). 
Single agent trametinib and PIK III also appeared to increase pAMPK levels in both 9 day 
trametinib resistant WM35 and A375 cells (although only significant in drug resistant A375 
cells (One way ANOVA with Tukey’s multiple comparison test, **P < 0.01, Figure 5-16 B iv). 
Furthermore, subsequent treatment of both 9 day trametinib resistant WM35 and A375 cells 
for 24 hrs with combined trametinib and PIK III resulted in further induction of pAMPK (One 
way ANOVA with Tukey’s multiple comparison test, **P < 0.01, Figure 5-15 B iv in case of 
WM35 cells and **** P<0.0001, Figure 5-16 B iv in case of A375 cells) suggesting that it is 
possible that autophagy blockade with PIK III in combination with trametinib results in 
paradoxical feedback signalling further activating AMPK possibly to further induce autophagy 
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as a survival mechanism.  Finally, analysis of PARP cleavage revealed induction in 9 day 
trametinib-induced drug resistant WM35 and A375 cells following further treatment for 24 
hours with single agent trametinib or PIK III which was significantly enhanced by the 
combination of both agents (One way ANOVA with Tukey’s multiple comparison test, ** P < 
0.01 for WM35 (Figure 5-15 B v) and ****P <0.0001 for A375 (Figure 5-16 B v). Collectively 
these data suggest that PIK III inhibits trametinib-induced CD271 and autophagy to varying 
degrees and combination of trametinib and PIK III significantly induces apoptosis in 
trametinib-induced CD271 expressing melanoma cells.   
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Figure 5-15 PIK III partially inhibits trametinib-induced CD271 and autophagy in WM35 cells 
A.Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), p62 (62 
kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in WM35 cells pre-treated for 9 days with 
16 nM trametinib and treated subsequently for 24 hrs with vehicle DMSO control (control), 16 nM 
trametinib, 5 µM PIK III (PIK III) or combined trametinib and PIK III (Trametinib +PIK III). B. Relative 
CD271 (i), LC3 II (ii), p62 (iii), pAMPK (iv) or Cleaved PARP (v) expression relative to GAPDH in 3 
individual experiments. Each bar is the mean or 3 experiments ± SD (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001)  
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Figure 5-16: Combination of trametinib with PIK III increases CD271 expression, increases 
autophagic activity, pAMPK and apoptotic cell death in trametinib treated A375 cells 
A.Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), p62 (62 
kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in A375 cells pre-treated for 9 days with 
16 nM trametinib and treated subsequently for 24 hrs with vehicle DMSO control (control), 16 nM 
trametinib, 5 µM PIK III (PIK III) or combined trametinib and PIK III (Trametinib +PIK III). B. Relative 
CD271 (i), LC3 II (ii), p62 (iii), pAMPK (iv) or Cleaved PARP (v) expression relative to GAPDH in 3 
individual experiments. Each bar is the mean or 3 experiments ± SD (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001)  
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To further investigate the effect of Vps34 inhibition on the spheroid expansion of trametinib-
induced drug resistant melanoma cells in vitro, A375 cells subjected to long term exposure to 
16 nM trametinib for 42 days were incorporated into collagen gels further treated in the 
presence or absence of 16 nM trametinib, 5 µM PIK III or combined of trametinib for up to an 
additional 7 days. In contrast to results derived from studies of long term trametinib-resistant 
A375 cells treated with chloroquine, however, these studies revealed no significant effect of 
PIK III alone or in combination with trametinib on relative spheroid size in vitro, (Two-way 
ANOVA with Sidak post hoc correlation, NS P>0.05, (Figure 5-17A, B). 
 
Figure 5-17 PIK III does not inhibit spheroid expansion of A375 cells subjected to prolonged 
trametinib-induced drug resistance  
A.Representative bright field images of A375 spheres pre-treated with 16 nM trametinib for 42 days 
followed by incorporation into collagen gels and subsequent treatment for up to 7 days with DMSO 
vehicle control, 16 nM trametinib (trametinib), 5 µM PIK III (PIK III) or combined trametinib and PIK III 
(Trametinib+PIK III). Scale bar 100 µm. B. Relative spheroid size (in µm) of A375 cells pre-treated for 
42 days with 16 nM trametinib and treated subsequently for 0, 2 , 4 or 7 days with DMSO vehicle 
control, 16 nM trametinib, 5 µM PIK III or combined trametinib and PIK III (Trametinib+PIK III).  Each 
point is the mean three independent replicate experiments ± SD expressed relative to the mean initial 
spheroid size (0 day time point of 42 day trametinib treated A375 cells). 
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5.2.5 Combined MEK and Vps34 inhibition inhibits melanoma dissemination in 
vivo  
5.2.5.1 Optimization of an in vivo zebrafish model of human 
melanoma systemic metastasis  
 
To evaluate the invasive capacity of trametinib-induced drug resistant CD271 expressing 
melanoma subpopulations in vivo and the effect of autophagy inhibition on tumour 
dissemination, a zebrafish model of human metastatic melanoma was established in 
collaboration with Dr David Hill (Institute of Cellular Medicine, Newcastle University) and Dr 
Bill Chaudhry (Institute of Genetic Medicine, Newcastle University, see chapter 2). Initial 
experiments were executed to determine optimal cell growth and temperature conditions for 
zebrafish embryos inoculated with human A375 and WM35 cells.  
To establish optimal temperature and environmental oxygen conditions for the growth of 
both human melanoma cells lines and the transparent transgenic Casper (flk1:GFP) tagged 
zebrafish embryo development, both zebrafish and human melanoma cell lines were first 
cultured at different temperatures and under differing oxygen content before evaluating the 
effects on melanoma cell viability and effect on the growth of zebrafish embryos. Results 
demonstrated that both hypoxia (5% O2) and lower temperatures (28 and 33oC) resulted in 
reduced number of both WM35 and A375 (Figure 5-18A and B) with the most profound effect 
seen in cells grown at 28oC (Figure 5-18A, B, 28oC, 5%O2) effect which is likely due to reduced 
melanoma cell proliferation.  
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Figure 5-18: Hypoxia and low cell culture temperature reduces number of melanoma cells 
Number of live (black bar) or dead (white bar) WM35 (A) or A375 (B) cells X 104/ml following culture 
for 24, 48 or 72 hrs in normal cell culture conditions (37oC, 21% O2) or hypoxic/lower cell culture 
temperature conditions (28oC, 5% O2 or 33oC, 5% O2). Each bar is the mean ±SD of two replicate 
experiments in all conditions apart from both WM35 and A375 cells cultured at 33oC and 5% O2 in 
which the represented bar is the result of a single experiment.  
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Normal conditions for the growth of the zebrafish embryos over 5 days are  28oC, in 21% O2 
and 0.04% CO2 (Figure 5-19) but since melanoma cells proliferated more effectively at higher 
temperatures of 37oC (Figure 5-18) additional experiments were performed to investigate the 
effect of differing temperatures on the development of zebrafish embryos. Results 
demonstrated physiological and morphological anomalies in zebrafish embryos that were 
maintained at 37oC and either 5 or 10% O2 (Figure 5-20). In particular Zebrafish embryos 
developed pericardial effusions when grown at higher temperatures (Figure 5-20) and hence 
all subsequent experiments of Zebrafish embryos inoculated with A375 or WM35 cells were 
performed in zebra fish maintained at 33oC in 5% O2. 
 
Figure 5-19: Normal development of zebrafish larvae from day 1 to day 5 post fertilization 
Representative bright field images of normal development of zebrafish larvae from day 1 to day 5 post 
fertilization. 
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Figure 5-20: Hypoxia and high temperature leads to pericardial effusion of zebrafish 
embryos 
Representative bright field images of day 3, 4 or 5 post fertilization zebrafish embryos following growth 
at 37oC and either 5 or 10% O2 leading to pericardial effusion and abnormal zebrafish growth. 
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5.2.5.2 PIK III inhibits the dissemination and promotes cell death of 
trametinib-induced resistant A375 cells in vivo   
 
To investigate the effect of autophagy inhibition with PIK III on the invasion of trametinib-
induced resistant melanoma cells in vivo, dil (red) labelled A375 cells continually pre exposed 
for 42 days to 16nM trametinib were inoculated into the yolk sac of 2 day zebra fish embryos 
subsequently maintained in E3 media at 33oC in 5% O2 in the presence or absence of 16 nM 
trametinib, 5 µM PIK III or combined trametinib and PIK III for 72 hours (experiments were 
performed in collaboration with Dr David Hill, Institute of Cellular Medicine, Newcastle 
university). Real time confocal microscopy analysis revealed tumour cell dissemination in the 
yolk sac and tail of zebrafish inoculated with control 42 day trametinib-induced drug resistant 
A375 cells (Figure 5-21 A i) and ii), which was partially inhibited following further exposure to 
16nM (Figure 5-21 B i) and ii)) and by the additional treatment with single agent PIK III (Figure 
5-21 C i) and ii)). However, treatment of zebrafish bearing 42 day trametinib-induced dry 
resistant A375 cells with combined trametinib and PIK III, resulted not only in reduced tumour 
cell migration and invasion, but also in reduced tumour cell viability and cell death (Figure 5-21 
D i) and ii), as evidenced by the leakage of RFP fluorescent dye into the yolk sac. Collectively 
these data indicate inhibition of autophagy by Vps34 inhibition may present a viable means 
through which to re-sensitize MEK inhibitor-resistant metastatic melanoma cells to the 
cytotoxic effects of trametinib. However, as discussed in chapter 4, long term exposure to 
trametinib leads to a transient induction of CD271 expressing melanoma subpopulations and 
A375 cells that have been exposed to trametinib for 42 days have lost the expression of CD271. 
Future experiments to investigate the relationship between autophagy inhibition and CD271 
associated tumour cell invasion in vivo will focus on cells that have been treated in the 
presence of the MEK inhibitor for 9 days and at which time point CD271 expression peaks.  
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Figure 5-21: PIK III inhibits invasion and re-sensitizes drug resistant A375 cells to the 
cytotoxic effects of trametinib.  
Representative immunofluorescence images of 5 day post fertilization zebrafish embryos injected with 
A375 cells pre exposed to 16 nM trametinib for 42 days (red cells, A) and subsequently maintained in 
the presence of 16nM trametinib (B), 5 µM PIK III alone (C) or combined trametinib and PIK III. A, B, C, 
Di) × 10 magnification, A, B, C, Dii) x 20 magnification. Scale bar 100 µm 
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5.2.6 Induction of cytotoxic autophagy with THC increases cell death of 
trametinib-resistant CD271 expressing melanoma subpopulations in 
vitro  
 
Previous studies in the Lovat lab have highlighted the ability of the synthetic cannabinoid 
derivative D(9)-tetrahydrocannabinol (THC) to promote cytotoxic autophagy  of metastatic 
melanoma cells (Armstrong et al., 2015b). To evaluate the potential of this strategy as a means 
through which to promote autophagy-mediated death of trametinib-induced CD271 
expressing drug resistant melanoma cells, A375 and WM35 cells previously treated with 16 
nM trametinib for 9 days were further treated with 4.5 µM THC for 24 hours prior to evaluating 
the effect on cell viability, CD271 expression and the expression of LC3 I/II and p62 and cleaved 
PARP.  
Results demonstrated THC induced the inhibition of both WM35 and A375 cells pre-treated 
with trametinib for 9 days (Figure 5-22). Furthermore THC also significantly inhibited the cell 
viability of 9 day trametinib-induced drug resistant WM35 and A375 cells subsequently re-
exposed to trametinib (One way ANOVA with Tukey’s multiple comparison test, *P < 0.05 in 
WM35 and **P<0.01 in A375 cells, (Figure 5-22 A and B).  
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Figure 5-22: THC re-sensitizes trametinib-induced resistant WM35 and A375 cells to 
trametinib-induced inhibition of cell viability.
Relative cell viability of WM35 (A) and A375 (B) cells pre-treated for 9 days with 16nM trametinib and 
treated subsequently for 24 hrs with vehicle control (control), 4.5 μM THC (THC) ,16nM trametinib 
(Trametinib), or combined THC and trametinib (Trametinib+THC). Each bar is the mean +/- SD of 3 
independent experiments each containing 4 technical replicates and expressed relative to control (9 
day trametinib treated cells). *P <0.05. **P < 0.01. 
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To investigate the effect of THC on CD271 expression and to confirm THC-induced autophagy 
and cell death of trametinib-induced drug resistant melanoma cells, the expression of CD271, 
pAMPK, LC3 I/II, p62 and cleaved PARP was also determined in WM35 (Figure 5-23) and A375 
(Figure 5-24) cells initially treated with 16 nM trametinib for 9 days and further treated for 24 
hours with 16 nM trametinib, 4.5 µM THC or combined THC and trametinib by western 
blotting. Results demonstrated trametinib and THC (alone and in combination)-induced 
expression of CD271 which was not significant in case of WM35 cells (One way ANOVA with 
Tukey’s multiple comparison test, Figure 5-23 A and Bi), however significant in case of A375 
cells (One way ANOVA with Tukey’s multiple comparison test, *P<0.05, **P<0.01), (Figure 
5-24 A and Bi) which was paralleled by a significant increase in LC3 II and significant decrease 
in reduction in p62 expression (One way ANOVA with Tukey’s multiple comparison test, 
**P<0.01 for LC3 II and ****P<0.0001 for p62 in WM35 cells Figure 5-23 A, B ii and iii, One 
way ANOVA with Tukey’s multiple comparison test,*P<0.05 for LC3 II, ****P<0.0001 for p62 
in A375 cells Figure 5-24 A, B ii and B iii).  
Interestingly, pAMPK expression increased in both 9 day trametinib resistant WM35 and A375 
cells following re treatment with trametinib (Figure 5-23 A and B iv, Figure 5-24 A and B iv) as 
well as in both drug resistant cell lines treated with THC, with the further induction of pAMPK 
by combined trametinib and THC treatment, at least in drug resistant A375 cells (one way 
ANOVA with Tukey’s post hoc correlation, **P<0.001, Figure 5-24 B iv). Results also 
demonstrated the significant induction of PARP cleavage in drug resistant WM35 and A375 
cells following re exposure to trametinib in the presence of THC (one way ANOVA test with 
Tukey’s post hoc correlation, ****P<0.0001 for WM35, Figure 5-23 B v and ** P< 0.01 for A375 
cells, Figure 5-24 B v). 
Taken together these data indicate that exacerbation of autophagy with THC is an effective 
means through which to promote cytotoxic autophagy in trametinib-induced drug resistant 
melanoma cells. 
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Figure 5-23: Treatment with combination of THC and trametinib increases CD271 expression, 
autophagy induction and apoptosis in trametinib resistant CD271 expressing WM35 cells 
A.Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), pAMPK 
(62 kDa), p62 (62 kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in WM35 cells pre- 
treated for 9 days with 16 nM trametinib and treated subsequently for 24 hours with vehicle DMSO 
control (control), 16 nM trametinib, 4.5 µM THC (THC) or combined trametinib and THC 
(Trametinib+THC). B. Relative CD271 (i), LC3 II (ii), p62 (iii), pAMPK (iv) or cleaved PARP (v) expression 
levels relative to GAPDH in 3 individual experiments. Each bar is the mean or 3 experiments ± SD 
(**P<0.01, ***P<0.001, ****P<0.0001).  
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Figure 5-24: Treatment with combination of THC and trametinib increases CD271 expression, 
autophagy induction and apoptosis in trametinib resistant CD271 expressing A375 cells 
A.Representative immunoblots for the expression of Cleaved PARP (89 kDa), CD271 (45 kDa), pAMPK 
(62 kDa), p62 (62 kDa), LC3 I/II (16, 18 kDa) or GAPDH loading control (38 kDa) in A375 cells pre- treated 
for 9 days with 16 nM trametinib and treated subsequently for 24 hours with vehicle DMSO control 
(control), 16 nM trametinib, 4.5 µM THC (THC) or combined trametinib and THC (Trametinib+THC). B. 
Relative CD271 (i), LC3 II (ii), p62 (iii), pAMPK (iv) or cleaved PARP (v) expression levels relative to 
GAPDH in 3 individual experiments. Each bar is the mean or 3 experiments ± SD (**P<0.01, ***P<0.001, 
****P<0.0001).  
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To evaluate whether the combination treatment with trametinib and THC also reduced the 
cell viability of melanoma cells exposed to prolonged treatment with trametinib, control A375 
cells or A375 cells pre-treated with trametinib for 42 days were further treated for 24 hours 
with either with 16 nM trametinib, 4.5 µM THC or combined trametinib and THC prior to 
assessing cell viability. Results demonstrated THC induced the significant reduction in cell 
viability of both A375 naïve and long term trametinib resistant cells ( 
Figure 5-25 A, B) (One way ANOVA with Tukey’s post hoc correlation, ****P<0.0001). 
 
Figure 5-25: THC promotes the inhibition of cell viability of A375 cells exposed to pronged 
treatment with trametinib  
Relative cell viability of trametinib naive A375 (A) or (B) A375 cells pre-treated for 42 days  with 16 nM 
trametinib resistant A375 (B) cells following treatment for 24 hrs with DMSO vehicle control, 4.5 μM 
THC (THC) ,16 nM trametinib (Trametinib), or combined THC and trametinib (Trametinib+THC). Each 
bar is the mean +/- SD of 3 independent experiments each containing 4 replicate treatment conditions. 
****P < 0.0001  
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 Discussion 
 
Data from the previous chapter implies drug-induced CD271 expression and specifically MEK 
inhibitor-induced CD271 expression appears to be intimately related to the induction of 
autophagy which plays a key role in the survival of such subpopulations, leading to the 
hypotheses tested in the present chapter that inhibition of CD271 directly, the inhibition of 
pAMPK or autophagy modulation may represent potential therapeutic strategies through 
which to overcome the resistance of BRAF/NRAS metastatic melanoma to MEK inhibitor 
targeted therapy with trametinib.  
5.3.1 CD271 inhibition results in reduction of cell viability, inhibition of pAMPK 
and autophagy but increase in spheroid size in vitro of trametinib-
induced CD271 expressing melanoma cells 
 
The potential to target cancer stem cell populations with some success has been shown in 
several cancer types (Wang et al., 2010) including the use of antibodies targeting the cancer 
stem cell surface marker CD47 in acute lymphoblastic leukaemia (Chao et al., 2011) or 
antibodies against CD133 in glioblastoma (Wang et al., 2011). However, data in the present 
study to not support CD271 as a true stem cell marker and coupled with the heterogeneity of 
melanoma, the transient nature of CD271 expression induced by drug resistance and the likely 
contribution of micro environmental factors to tumour cell survival, targeting CD271 in the 
context as a potential cancer stem cell marker may not be the best approach. Nevertheless 
given the recent emergence of small molecule inhibitors to CD271 (Niederhauser et al., 2000; 
Mochizuki et al., 2016) and results from the present study showing knockdown of CD271 in 
trametinib-induced drug resistant melanoma subpopulations re-sensitized them to the 
cytotoxic effects of MEK inhibition, it may be that chemical inhibition of CD271 may present a 
viable strategy.   
Trametinib-induced CD271 expressing subpopulations appear to be associated with the 
development of early resistance to the MEK inhibitor trametinib. Targeting CD271 at the 
critical point of development of early resistance may therefore provide a viable strategy 
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through which to prevent the establishment of trametinib-induced resistance. Supporting this 
hypothesis, data revealed the treatment of early (9 days) trametinib-induced CD271 
expressing drug resistant melanoma cells with specific CD271 inhibitors (TAT-PEP5 and RO-08) 
resulted in significant inhibition of cell viability, paralleled by the reduced expression of CD271, 
and pAMPK as well as autophagy. 
Data showing reduced autophagic activity of drug-resistant melanoma cells in response to 
treatment with CD271 inhibitors suggests a link between autophagy activation and CD271 
expression. However, further work will be required to determine whether there is a direct 
causal relationship between CD271 and autophagy as alternatively drug-resistant melanoma 
cells may activate autophagy independently of CD271 as a parallel pro-survival mechanism in 
response to metabolic stress (Degenhardt et al., 2006; Karantza-Wadsworth et al., 2007) or to 
resist apoptosis (Pattingre et al., 2005). Alternatively autophagy may be activated in response 
to the changing tumour microenvironment, in response to hypoxia or nutrient deprivation 
(Ravindran Menon et al., 2014; Yang et al., 2015d) which occurs in solid tumours such as 
melanoma. Autophagy is also reportedly induced in response to treatment with targeted 
therapies for example in colorectal cancer following treatment with BRAF inhibitors 
(Goulielmaki et al., 2016). 
Data also revealed inhibition of CD271 resulted in the significant inhibition of spheroid 
expansion of trametinib-induced drug resistant subpopulations compared to the wild-type 
WM35 cells. As well as an increase in cell death of CD271 positive populations, it is possible 
that the decreased function and expression of CD271 in trametinib-induced CD271 expressing 
subpopulations mediated by the CD271 specific inhibitors may also have resulted in an 
increase in CD271 negative subpopulations that are inherently more invasive, as highlighted 
in chapters 3 and 4 and in line with the current literature indicating CD271 negative melanoma 
subpopulation exhibit a more invasive phenotype (Saltari et al., 2016). It is perhaps therefore 
not surprising that by reducing the number of CD271 positive tumour cells, the equilibrium 
between CD271 positive and negative subpopulations is distorted, allowing the favoured 
emergence of CD271 negative melanoma cells with a more invasive phenotype. 
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Targeting CD271 at the point of development of early resistance may thus eliminate CD271 
positive drug resistant populations but at the risk of increasing CD271 negative subpopulations 
and therefore contribute to rather than inhibit tumour progression. It is therefore important 
to evaluate the efficiency of targeting the survival mechanism these resistant subpopulations 
use to promote tumour survival, which is the case of trametinib-induced CD271 associated 
cells is likely autophagy. Evidence from other cancer types highlight the alternative approach 
of targeting cancer stem cell survival mechanisms such as the Wnt, Notch and Hedgehog 
pathway (Takebe et al., 2015) and the ability of cancer stem cell populations to resist apoptosis 
(Signore et al., 2013). Since autophagy has been shown to contribute to other cancer stem cell 
survival (Song et al., 2013; Yang et al., 2015a; Yang et al., 2015c) and the current study 
highlights the contribution of autophagy to the survival of drug-induced CD271 expressing 
melanoma subpopulations, it is not surprising that autophagy blockade reduced the cell 
viability of CD271 expressing subpopulations. What would be of interest, however, would be 
to investigate the effect of concomitant autophagy and CD271 blockade in trametinib-induced 
CD271 cell invasion and survival.    
 
5.3.2 AMPK inhibition in trametinib resistant BRAF mutant melanoma cells 
increases autophagic activity 
 
The AMPK pathway is important in regulating metabolic homeostasis and maintaining cellular 
energy supply by activating pathways that generate ATP such as glucose metabolism and fatty 
acid oxidation (Li et al., 2015b).However the direct link between AMPK activation in cancer is 
not fully established. Recent evidence suggests that AMPK activation is associated with a 
reduction in tumour growth in vitro mediated through activation of tumour suppressor 
pathways such as the Hippo pathway (Wang et al., 2015) or cell cycle regulation (Lee et al., 
2007b). Interestingly, AMPK can also act as a tumour promoter by enhancing cellular ability to 
survive conditions of metabolic stress such as nutrient deprivation and hypoxia (Zaugg et al., 
2011) or by activating autophagy (Egan et al., 2011). AMPK is known to activate autophagy by 
phosphorylation of ULK 1 (Egan et al., 2011; Kim et al., 2011b) but also inactivation of 
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mTORCH1 (Wullschleger et al., 2006). In the context of trametinib-induced CD271 expressing 
drug resistant melanoma populations, results demonstrated a reduction in ATP release 
accompanied by an increase in pAMPK. Treatment of control or trametinib-induced drug 
resistant WM35 and A375 cells with the cell-permeable AMPK inhibitor, Compound C (Liu et 
al., 2014) also resulted in efficient AMPK inhibition but had no significant effect on CD271 
expression. Nevertheless, despite the anticipated reduction in autophagic activity, an increase 
in LC3 II expression was observed. A possible explanation for this observation may be related 
to the nature of compound C, which is not a specific AMPK inhibitor (Liu et al., 2014). Several 
studies have reported compound C to inhibit various biological cascades independently of 
AMPK inhibition such as the inhibition of the hypoxic activation of HIF-1 (Emerling et al., 2007) 
or increasing p21 levels (Nam et al., 2008), indicating that compound C may have off target 
effects that could lead to the activation of autophagy. Interestingly recent data have also 
shown compound C mediates an AMPK-inhibition independent increase in autophagy in 
human glioma cells, though blockade of the Akt/mTOR pathway (Vucicevic et al., 2011) further 
reinforcing the complex interaction of the AMPK pathway and autophagy and highlighting the 
complexities of attempting to target AMPK for the therapeutic benefit of melanoma.  
 
5.3.3 Inhibition of autophagy or the promotion of cytotoxic autophagy 
promotes apoptosis of trametinib-induced drug resistant CD271 
expressing melanoma cells 
 
The paradoxical activation of autophagy or its activation by many chemotherapeutics is a well-
known phenomenon linked to chemo resistance (Kanzawa et al., 2004) including the 
resistance to targeted agents (Eritja et al., 2017) of many tumour types and its use by specific 
chemo resistant tumour cell subpopulations to escape the cytotoxic effects of chemotherapy 
(Brigger et al., 2015). Indeed studies have shown that increased autophagy in melanoma is 
associated with decreased survival (Ma et al., 2011), and that basal autophagy is increased in 
BRAF mutant melanoma cells (Corazzari et al., 2015) as well as being induced by temsirolimus 
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(Xie et al., 2013) and collectively suggesting the inhibition of this process may represent a 
viable means through which to overcome trametinib-induced drug resistance.  
Inhibition of autophagy has been the subject of many studies, most frequently employing the 
lysosomal inhibitor chloroquine, in both clinical (Rangwala et al., 2014b) and pre-clinical 
setting (Liang et al., 2016), and has shown to act synergistically to chemotherapeutic agents 
to promote cell death (Schmukler et al., 2014). Promising phase II clinical trial results in 
patients with advanced pancreatic cancer using single agent hydroxychloroquine demonstrate 
a possible therapeutic advantage in patients treated with hydroxychloroquine compared to 
the control group (Wolpin et al., 2014). However, more promising early clinical trial outcomes 
derive from studies in which chloroquine or hydroxychloroquine are combined with standard 
chemotherapy or radiation therapy (Sotelo et al., 2006). A clinical trial in glioblastoma has 
demonstrated a possible advantage in combining hydroxychloroquine to temozolomide and 
radiation therapy (Rosenfeld et al., 2014), however, the poor tolerability of higher doses of 
hydroxychloroquine highlight the need for more specific autophagy inhibitors for clinical use. 
In melanoma, pre-clinical data combining temsirolimus with hydroxychloroquine has 
demonstrated that inhibition of the mTOR and autophagy pathways promotes apoptosis and 
could be a new therapeutic approach for the treatment of melanoma (Xie et al., 2013) and 
there are ongoing clinical trials in melanoma combining mTOR and autophagy inhibitors in 
melanoma (Rangwala et al., 2014a).  
The current study demonstrated that autophagy inhibition with chloroquine in trametinib-
induced CD271 expressing melanoma subpopulations results in increased cell death and 
induction of apoptosis, evidenced by increase in cleaved PARP expression, therefore 
supporting the potential clinical utility of treatment with chloroquine as a means through 
which to prevent the induction of pro-survival autophagy and increase apoptosis of 
trametinib-induced CD271 expressing drug-resistant sub populations.  
Nevertheless autophagy inhibition with chloroquine or hydroxychloroquine may not present 
the most effective clinical approach through which to inhibit pro-survival autophagy. Evidence 
suggests some tumours more sensitive than others (Bristol et al., 2013) and that it sensitizes 
normal cells to the cytotoxic effects of chemotherapeutics (Kimura et al., 2013). In addition, 
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pharmacokinetic studies suggest clinically achievable concentrations of hydroxychloroquine 
may not be as effective at inhibiting autophagy in vivo as in vitro (Bristol et al., 2013). Coupled 
with the fact that pre-clinical models do not clarify the impact on the immune system, likely 
important for effectiveness, and the fact that chloroquine is not a specific inhibitor of 
autophagy, these data have led to the investigation of more specific inhibitors of autophagy 
such as those against Vps34, currently in clinical trials in combination with mTOR inhibitors for 
patients with renal cell carcinoma (Pasquier, 2015). These novel molecules specifically inhibit 
autophagy at early stages, making those inhibitors a promising alternative treatment 
approach to chloroquine (Ronan et al., 2014) 
In the present study treatment of trametinib-induced resistant melanoma subpopulations 
with Vps34 inhibitor PIK III, resulted in significant reduction of cell viability and increased 
apoptosis of such populations both in vitro and in vivo. However, although in vitro, chloroquine 
in combination with trametinib significantly reduced the spheroid size of drug resistant A375 
cells pre-exposed clinically achievable concentrations of trametinib for 42 days, Vps34 
inhibition with PIK III alone or in combination with trametinib did significantly affect spheroid 
expansion in vitro. Such findings may indicate that the utilised dose of PIK III may not have 
been high enough to diffuse through the collagen to have a significant effect on spheroid 
expansion in vitro, and suggests further dose response studies of the Vps34 inhibitor are 
warranted. Alternatively, the effects derived by chloroquine, may not have been specific and 
may have resulted from off target-autophagy independent mechanisms such as direct effect 
on tumour vasculature independent of autophagy (Rubinsztein et al., 2012; Maes et al., 2016) 
or by modulating immune-mediated response (Townsend et al., 2012). Nevertheless, the 
autophagy-independent effects of chloroquine on tumour cells and tumour 
microenvironment remain to be fully elucidated. In contrast however, studies of Vps34 
inhibition trametinib-induced drug resistant melanoma cells in vivo demonstrated the 
combined exposure of zebra fish xenografts bearing trametinib-induced drug resistant 
melanoma cells to PIK III and trametinib resulted in reduction in tumour cell migration away 
from the injection site. However, it is possible that the accumulated doses of trametinib and 
PIK III within the zebrafish xenografts may have been sufficient enough to inhibit autophagy 
and therefore inhibit tumour cell invasion, and facilitating the observed induction in cell death 
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of tumour cells remaining in the yolk sac. Nevertheless more complex pharmacokinetic studies 
are required both in vitro and in vivo to establish drug concentrations reached in the 
environment of both zebrafish xenografts and collagen invasion gels. However, downstream 
autophagy blockade with chloroquine has different effects on cancer cells when compared to 
upstream autophagy blockade using a Vps34/Beclin1 inhibitor such as PIK III. To further 
investigate the contribution of autophagy to the invasion and survival of drug induced 
melanoma subpopulations, blocking autophagy at the transcriptional level, to completely 
abrogate autophagic activity would allow a better understanding of the contribution of 
autophagy to the survival of such subpopulations and the relationship between autophagy 
and CD271 induction in response to MEK inhibitors.  
Finally, since recent studies have shown melanoma cell death can be induced by harnessing 
the cytotoxic effects autophagy induced by the synthetic cannabinoid exacerbation THC 
(Armstrong et al., 2015b) studies were undertaken to test the potential of this strategy to 
enhance apoptosis of trametinib-induced drug resistant melanoma cells. Results 
demonstrated THC induced the significant inhibition of trametinib-induced CD271 expressing 
melanoma cell viability in vitro, however, interestingly this effect was only induced by THC in 
combination with trametinib treatment and not by THC alone. Such observations may indicate 
that THC requires the induction of pro-survival autophagy induced by trametinib in order to 
exert its cytotoxic effect. Nevertheless, taken together, these data indicate that treatment of 
trametinib-induced CD271 expressing melanoma subpopulations with THC may present a 
viable strategy through which to overcome the acquired resistance of BRAF/NRAS mutant 
melanoma to MEK inhibition, and is a strategy that warrants further investigation in vivo.  
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 Summary 
• CD271 inhibition using small molecule CD271 inhibitors inhibits the cell viability of 
trametinib-induced CD271 expressing melanoma cells but increases tumour invasion 
in vitro 
• Inhibition of AMPK activity results in the reduction of trametinib-induced CD271 
expression but increases autophagy in drug resistant subpopulations.  
• Autophagy inhibition with chloroquine re-sensitizes drug resistant CD271 expressing 
melanoma subpopulations to the cytotoxic effects of trametinib and inhibits spheroid 
size in vitro  
• Autophagy inhibition with the Vps34 inhibitor, PIK III re-sensitizes drug resistant CD271 
expressing melanoma subpopulations to the cytotoxic effects of trametinib but does 
not inhibit spheroid expansion in vitro  
• Autophagy inhibition with the Vps34 inhibitor, PIK III re-sensitizes drug resistant CD271 
expressing melanoma subpopulations to the cytotoxic effects of trametinib and 
inhibits tumour invasion and dissemination in vivo 
• THC in combination with trametinib inhibits the cell viability of trametinib-induced 
CD271 expressing melanoma cells 
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Chapter 6 Overall Discussion 
 
Malignant melanoma is the most aggressive form of skin cancer and although associated with 
an excellent prognosis when diagnosed early, once metastatic disease evolves, clinical 
outcome remains poor (Charles et al., 2009). In the past decade however, the management of 
metastatic melanoma has fundamentally changed, with the introduction of novel targeted 
and immunotherapies. Prior to this, treatment approaches were limited to the use of 
chemotherapy with dacarbazine, temozolomide or various chemotherapy combinations 
(Bajetta et al., 2006; Pflugfelder et al., 2011), all of which  only resulted in a low objective 
clinical response (Eggermont and Kirkwood, 2004; Quirbt et al., 2007). The recent discovery 
of driver BRAF mutations in cutaneous melanoma however, has unveiled a new era in the use 
of agents that specifically target these mutations for therapeutic benefit. Approximately 60% 
of all cutaneous melanomas harbour a mutation in BRAF (Ascierto et al., 2012) which leads to 
hyper-activation of MAPK signalling  resulting in enhanced tumour cell proliferation and cell 
cycle progression (Davies et al., 2002; Mar et al., 2015).  As a result, the inhibition of activated 
MAPK signalling has become an attractive therapeutic target for BRAF and NRAS mutant 
melanomas. The recent introduction of BRAF and more recently MEK inhibitors has indeed 
revolutionized the therapeutic management of patients with advanced melanoma, with the 
specific BRAF inhibitors targeting mutant BRAF, (vemurafenib and subsequently dabrafenib), 
demonstrating significantly improved patient survival with an approximate 50% response rate 
and a median duration of response of 6-7 months (Chapman et al., 2011; Hauschild et al., 
2012). However the success of these agents is limited by the development of acquired 
resistance, which occurs within months of treatment initiation resulting in catastrophic clinical 
outcomes for patients (Gowrishankar et al., 2012).  
As melanoma is a heterogeneous cancer, it is perhaps not surprising that the mechanisms 
mediating BRAF/MEK inhibitor-acquired resistance are varied. Paradoxical re-activation of the 
MAPK pathway is a well described mechanism of resistance, mediated for example by 
overexpression of CRAF or COT1 (Montagut et al., 2008; Johannessen et al., 2010a; Poulikakos 
et al., 2011) leading to restored MAPK activity and continued tumour growth. Additionally, 
secondary activating mutations in NRAS and MEK also lead to re-activation of MAPK signalling 
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and tumour cell proliferation (Nazarian et al., 2010). Other MAPK-independent mechanisms 
of resistance include the overexpression of the receptor tyrosine kinases such as platelet-
derived growth factor receptor-β (PDGFRβ) and IGF-1R (Villanueva et al., 2010; Shi et al., 2011) 
or the loss of PTEN and activated PI3K/AKT signalling (Paraiso et al., 2011). 
 Perhaps one of the most recent and controversial mechanisms mediating the resistance of 
BRAF mutant melanoma to BRAF/MEK inhibitor therapy is the emergence of chemo resistant 
stem-like subpopulations (Roesch et al., 2010; Chartrain et al., 2012; Ravindran Menon et al., 
2014), an observation that has led to a flurry of studies investigating the role, if any, of cancer 
stem cells and their contribution to tumour initiation as well as chemo resistance (Boiko et al., 
2010a; Chen et al., 2010; Boyle et al., 2016). The presence and importance of cancer stem cells 
in melanoma remains an area of ongoing debate. Proposed stem cell markers in melanoma 
include CD271 (Boiko et al., 2010a), Jarid-1B (Roesch et al., 2010), ABCB5 (Chartrain et al., 
2012) and SOX10 (Zhang and Herlyn, 2014), with CD271 expressing melanoma subpopulations 
also described as a key stem- like subpopulation that emerges as part of drug-induced chemo-
resistance to BRAF/MEK targeted therapy (Ravindran Menon et al., 2014; Li et al., 2015a; 
Redmer et al., 2017). Understanding the role of constitutive and targeted therapy-induced 
CD271 expression in melanoma, and the mechanisms leading to its induction and the survival 
of CD271 expressing melanoma cells thus presents an opportunity for their targeting and as a 
potential means to overcome MAPK inhibitor induced drug resistance.   
To this aim the present study revealed that constitutive as well as drug-induced CD271 
expression is associated with an increase in autophagic activity and that autophagy blockade 
with either chloroquine of specific Vps34 inhibitors resulted in significant reduction in cell 
viability of CD271 expressing melanoma subpopulations. Alternatively treatment of drug 
resistant CD271 expressing subpopulations with the autophagy inducing agent THC also 
resulted in re-sensitization of trametinib-induced CD271 expressing melanoma cells to the 
cytotoxic effect of MEK inhibition, collectively supporting the concept of autophagy 
modulation as a strategy to overcome trametinib-induced drug resistance. 
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 Understanding the difference between constitutive and drug 
induced CD271 expression, pAMPK and autophagy in melanoma 
 
To understand the difference between constitutive and drug-induced expression of CD271 in 
melanoma, and the association with autophagy, CD271 expression was initially correlated 
with p62 expression in a panel of naevi and primary cutaneous melanomas of differing AJCC 
stage as well as with basal autophagy activity in CD271 expressing subpopulations derived 
from BRAF mutant melanoma cell lines. Results revealed an inverse correlation with p62 
expression in AJCC stage II melanomas in vivo and an increase in LC3-II flux in isolated CD271 
expressing melanoma cells in vitro.   
Furthermore over expression of CD271 in vitro resulted in an increase in autophagic activity, 
collectively suggesting the constitutive expression of CD271 by melanoma cells is associated 
with an increase in basal autophagy. Interestingly however, despite the anticipated decrease 
in autophagic activity expected following knockdown of CD271, autophagic activity increased. 
It is possible that the observed sustained autophagic activity in this case may have reflected 
the only partial decrease in CD271 expression induced by a transient RNAi approach. However, 
experiments of stable CD271 knockdown in A375 cells resulted in cell death indicating that 
CD271 is important for melanoma cell proliferation and growth.  
Although melanoma cells constitutively expressing CD271 are known to be present in 
melanoma cell lines (Saltari et al., 2016) and primary melanoma tissue (Beretti et al., 2015), 
the relevance of such expression in tumour initiation (Boiko et al., 2010a; Quintana et al., 
2010) is controversial. Evidence also suggests that constitutive CD271 expression by primary 
melanomas is associated with more aggressive disease (Beretti et al., 2015). CD271 expression 
is also well known to be regulated by micro environmental factors such as hypoxia and 
nutrient deprivation (Ravindran Menon et al., 2014) which may explain per se the link 
between constitutive expression by melanomas in a hypoxic/nutrient deprived environment 
and the observed increase in autophagy, also induced by hypoxia and nutrient starvation and 
known to promote tumour cell survival in hostile micro-environmental conditions (Hu et al., 
2012a; Kim et al., 2015). Since autophagy is also activated as a pro-survival response 
mechanism to counter act the cytotoxic effects of targeted therapies and chemotherapy (Lee 
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et al., 2015; Goulielmaki et al., 2016), this may also explain the observed increase in autophagy 
observed in drug-induced resistant CD271 expressing melanoma, which could be independent 
of CD271 induction. However, the effect of CD271 on autophagic activity may be different in 
drug-treated cells compared to unstressed cells constitutively expressing CD271. In the 
context of drug-induced CD271 expression, this is a well-known phenomenon associated with 
the resistance of BRAF mutant melanomas to MEK inhibitor therapy (Ravindran Menon et al., 
2014; Lehraiki et al., 2015), and supported by results from the present study.  
However, trametinib-induced CD271 expression observed in the present studies was 
transient, while the associated increase in basal autophagy was sustained in drug-resistant 
subpopulations, indicating that CD271 expression may not be required for autophagy 
induction or that CD271 induction is independent of autophagy induction and further 
questioning whether trametinib-induced autophagy activation in the tumour 
microenvironment contributes to the emergence of CD271 expressing subpopulations or 
whether CD271 expressing subpopulations are induced independently of autophagy but 
harness pro-survival autophagy to survive. It is therefore possible that any increase is CD271 
is a survival response mechanism to micro environmental stress and that autophagy activation 
enables CD271 expressing cells to survive, detach from the original tumour site and gain entry 
to systemic circulation. It is also possible and, again in line with results presented in this thesis, 
that CD271 expression is only required until the tumour has repopulated and once tumour cell 
proliferation is established, CD271 expression is not further required, reflected by a decline in 
its expression. 
Furthermore, If CD271 expressing cells are induced independently of direct autophagy 
activation, other signalling pathways may also be mediating their induction. Recent studies 
have shown BRAF inhibition mediates the activation of NF-κB signalling in melanoma cells  via 
an increase in TNFa secretion leading to the induction of CD271 (Lehraiki et al., 2015). Given 
the fact that NF-κB can either activate or inhibit signalling pathways that lead to the induction 
of autophagy and regulates the transcription of a subset of pro-autophagic regulating genes 
(Trocoli and Djavaheri-Mergny, 2011), it is possible that CD271 induction may result from 
trametinib-induced activation of NF-κB independently of autophagy activation or a complex 
interplay between NF-kB activation resulting in autophagy activation which then leads to 
  Overall Discussion 
 
 
245 
 
induction of CD271 (Figure 6-1). To address this possibility future experiments would need to 
assess the effect of trametinib treatment of melanoma cells in which CD271 expression has 
been abrogated on TNFa/NF-Kb pathway induction and autophagic activity or through 
alternative blockade of the NF-kB pathway with small molecule inhibitors prior to evaluating 
such effects of trametinib on CD271 induction.  
What is also surprising was the lack of correlation between CD271 expression and the 
expression of other stem cell markers such as Nestin, Jarid-1B, ABCB5 and SOX10.  In the 
setting of constitutive CD271 expression the present study demonstrated a lack of any 
correlation the expression of other stem cell markers, supporting data previously highlighting 
a poor overlap between CD271 and ABCB5 expression (Cheli et al., 2014b). However, in the 
context of drug resistance, CD271 appeared to correlate with an increase, albeit non-
significant, in Jarid-1B and SOX10 and a decrease in Nestin expression. What is still not clear, 
however, is whether these subpopulations emerge independently or whether expression 
overlaps in any way. Is it possible that subpopulations expressing different stem cell markers 
emerge in response to targeted therapies independently, contributing to the heterogeneity of 
melanoma and the clinical observation that combination therapy is essential to promote 
tumour shrinkage. Alternatively it is also possible that targeting one subpopulation might 
allow for the growth of subpopulations expressing other markers, and therefore contribute to 
continued tumour growth, and suggesting therefore that the targeting of a generic survival 
mechanism may be a more efficient treatment approach rather than targeting each 
subpopulation independently.  
Whether CD271 initiates autophagy or if autophagy is induced by drug resistance resulting in 
increased CD271 remains enigmatic (Figure 6-1) and to  further delineate this association 
experiments using modern technologies for gene manipulation such as CRISPR/Cas9 (Sander 
and Joung, 2014) to manipulate CD271 or key autophagy regulatory genes such as ULK 1, ATG5 
or ATG7 are hence required and furthermore to allow for a more physiological means through 
which to analyse  the interaction between CD271 and autophagy either in the constitutive 
setting or in response to trametinib. Nevertheless, data from the present study support the 
potential for inhibiting CD271 or autophagy as a therapeutic strategy to re-sensitize drug 
resistant cells to cytotoxic effects of trametinib.  
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Figure 6-1: Proposed model of CD271 expression 
Expression of CD271 in the constitutive and drug-induced setting. Constitutive expression is associated 
with increased basal autophagy in vivo and its expression is regulated by micro-environmental factors. 
Constitutive CD271 expression is associated with reduced collagen invasion in vitro. Drug-induced 
CD271 expression may be induced by the induction in autophagic activity, mediated by NF-kB pathway 
or as a result of other generic pro-survival mechanisms. Drug induced CD271 is associated with an 
increase in basal autophagy and a less invasive and less proliferative phenotype in vitro. 
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 The role of CD271 in tumour cell invasion and the importance of 
micro environmental factors 
 
Results presented in this thesis demonstrate that both constitutive and drug-induced CD271 
expressing melanoma subpopulations is associated with reduced collagen invasion in vitro. It 
is likely that CD271 expression is regulated by micro-environmental stresses or drug induced 
stresses which also contributes to the upregulation of survival pathways such as autophagy. 
However, despite the anticipated result of  CD271 expressing melanoma subpopulations being 
innately  more invasive, and supporting recently published studies, results highlighted both 
the constitutive and drug-induced  expression of CD271 in melanoma cells was associated with 
a less invasive phenotype in vitro, (Saltari et al., 2016) and perhaps in the context of drug 
resistance mediated by trametinib-induced cell cycle arrest (G1 arrest) (Haass et al., 2014). It 
is therefore possible long term exposure of melanoma cells to trametinib results in G1 arrest 
mediated induction of pro-survival autophagy which prevents cell invasion. However, what is 
still unclear is why melanoma cells constitutively expressing CD271 might exhibit a less 
invasive phenotype in the absence of any drug-induced stress. It is possible that melanoma 
cells that constitutively express CD271 cells are more sensitive to external stresses or remain 
in an undifferentiated state which affects cell cycle and metabolism. Such observations could 
also be explained by the hypothesis that CD271 positive cells have a more regulatory/drug 
resistant phenotype and their role in disease progression and metastasis is limited. Coupled 
with the observations that CD271 negative cells were more invasive and CD271 expression in 
vitro is dynamic and unstable, it is possible that CD271 positive cells can switch from a CD271 
positive to a CD271 negative phenotype depending on micro environmental factors and 
stresses and acquire different properties based on tumour progression and migration which 
could be facilitated by CD271 negative cells or tumour survival facilitated by CD271 positive 
cells.   
Taken together these data demonstrate the complex and situational association between 
CD271 activation and autophagic activity which indeed appears to be contextual in the setting 
of the constitutive or drug-induced CD271 respectively and also the dynamic expression of 
CD271 which appears to be regulated by the tumoural need to either promote tumour survival 
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or metastasis and further highlighting the different cellular properties and capabilities CD271 
expressing cells exhibit in constitutive and drug-induced setting.  
 
 Targeting CD271 or pro-survival autophagy as a therapeutic 
strategy to overcome resistance of melanoma cells to trametinib 
 
Despite the complexity of CD271 expression, it is clear that CD271 expressing cells are 
associated with early resistance to targeted therapy, which correlates with an induction in 
autophagic activity. The majority of therapeutic approaches for melanoma only transiently 
effects tumour growth and ultimately, given the heterogeneous nature of melanoma and its 
propensity to activate pro-survival and anti-apoptotic pathways, acquired resistance to 
treatment approaches inevitably occurs. Studies have highlighted the potential role for  
targeting autophagy in combination with chemotherapy (Li et al., 2010) and targeted 
therapies (Goulielmaki et al., 2016)  to overcome resistance in of targeted therapy-associated 
drug resistance. However, the induction of specific cell subpopulations poses the question of 
whether it will be more beneficial to target the chemo resistant subpopulations themselves 
or the processes they harness to survive, including autophagy. Given the upregulation of 
tumour cell subpopulations expressing specific surface markers (Singh et al., 2003; Yamashita 
and Wang, 2013) in response to chemotherapy and bearing in mind that in the case of many 
cancer types these subpopulations contribute to the development of acquired resistance, 
specific antibodies or small molecules have been developed and trialled for their efficiency in 
targeting specifically these subpopulations (Jin et al., 2006; Stratford et al., 2013)) for 
therapeutic benefit. 
Inhibiting CD271 using two small molecule inhibitors, TAT-PEP5 and RO-08 (Ting-Hsien et al., 
2014; Mochizuki et al., 2016) resulted in increased cell death of trametinib-treated melanoma 
cells but also in increased spheroid expansion in vitro suggesting this approach may not be 
beneficial in a clinical setting as it may increase the tumour’s metastatic potential. 
Furthermore, since melanoma is a very heterogeneous cancer and resistance to targeted 
therapies is likely associated with the emergence of a number of resistant subpopulations, it 
  Overall Discussion 
 
 
249 
 
is possible that targeting CD271 expressing subpopulations directly might allow for other, 
smaller subpopulations that differ in resistance profiles and might therefore not be efficiently 
targeted by a single therapeutic agent, to emerge and contribute to chemo resistance.  
Another consideration to take into account when targeting cancer ‘stem-like cells’ is the 
potential for off-target effects, for example targeting CD271 might influence the renewal and 
maintenance of neural crest and neuronal tissue as CD271 is a crucial receptor for neurite cell 
growth and survival (Johnson et al., 1986). Finally, it is still possible that targeting cancer stem 
like cells, in the tumour bulk might facilitate the development of resistance to cancer stem 
cell-directed therapies and therefore, combination therapies that involve both CSC-directed 
agents as well as tumour bulk-targeted regimens would be predicted to prove most effective 
in improving clinical treatment responses and patient outcomes. Taken together, these 
observations suggest that although it is possible to directly target CD271 expressing 
melanoma subpopulations, selecting for CD271 negative subpopulations by eliminating the 
CD271 positive subpopulations might increase the tumour’s metastatic potential or promote 
the emergence of other stem cell subpopulations that do not express CD271. As a result, 
targeting the process these subpopulations use to survive could represent a more efficient 
treatment approach leading to the alternative possibility that modulation of pro-survival 
autophagy or AMPK, harnessed by trametinib-induced CD271 expressing melanoma cells may 
provide a better approach. Blockade of AMPK with compound C resulted in efficient blockade 
of pAMPK but did not have any significant effect on CD271 expression or autophagic activity. 
It should be noted however that Compound C, is not a specific AMPK inhibitor (Liu et al., 2014) 
and since there are no specific AMPK inhibitors currently available, the benefit of AMPK 
inhibition is at present limited. As AMPK is only one of several upstream modulators of 
autophagic activity specific inhibition of autophagy regulatory proteins may therefore present 
a more effective therapeutic strategy.  
Increasing evidence supports a pivotal role of autophagy activation in chemo resistance (Hu 
et al., 2012b; Sui et al., 2013). Manipulating autophagy, either by targeting autophagy in 
combination with chemotherapy (Rangwala et al., 2014b; Lu et al., 2017) or exacerbating 
autophagy (Armstrong et al., 2015b) to target resistant cancer cells (Liu et al., 2013a) appears 
to be beneficial in overcoming resistance to chemotherapy. Inhibition of autophagy with the 
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lysosomal inhibitor chloroquine or the specific Vps34 inhibitor PIK III as well as inducing 
cytotoxic autophagy with THC, all resulted in the re-sensitization of trametinib-induced 
resistant melanoma cells to the cytotoxic effects of MEK inhibition and hence may each 
provide a viable treatment approach to overcome trametinib-associated resistance (Figure 
6-2). However, although autophagy inhibition with chloroquine resulted in effective re-
sensitization of melanoma cells the cytotoxic effects of trametinib results from clinical trials 
indicate that the maximum clinically tolerated dose of chloroquine or hydroxychloroquine 
might not be sufficient to cause efficient autophagy blockade in vivo (Amaravadi et al., 2011). 
Coupled with the fact that chloroquine is not a specific autophagy inhibitor, novel autophagy 
inhibitors may thus provide a more efficacious therapeutic approach. Novel inhibitors 
specifically targeting the Vps34/Beclin-1 complex have been developed and are currently in 
clinical use for patients with follicular lymphoma (Gopal et al., 2014; Miller et al., 2015; 
Pasquier, 2015). Treatment of trametinib-induced CD271 expressing melanoma cells with PIK 
III resulted in significant reduction in cell viability and reduction in tumour cell dissemination 
in a zebrafish model of metastatic melanoma in vivo. However, the combination of trametinib 
and PIK III did not demonstrate a significant effect in reducing spheroid expansion in vitro in a 
collagen gel assay which might, however, be a dose dependent effect. Nevertheless, given the 
safety and applicability of Vps34 inhibitors in clinical practice combined with the pre-clinical 
data supporting the efficiency of these specific inhibitors in targeting drug-induced CD271 
expressing subpopulations, clinical trials of combination of Vps34 inhibitors with MAPK 
inhibition might be of clinical relevance. Finally, since previous studies in melanoma have 
shown  THC promotes autophagy mediated apoptosis (Armstrong et al., 2015b) , which 
coupled with the compelling data from the present study showing THC also promotes 
apoptosis  of trametinib-induced drug resistant CD271 expressing melanoma cells and current 
clinical trials (Chakravarti et al., 2014) in glioblastoma multiforme (Velasco et al., 2016a), 
suggests the use of THC may also represent viable therapeutic option to overcome the 
resistance of BRAF/NRAS mutant melanoma to MEK inhibition. 
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Figure 6-2: Targeting CD271 or pro-survival pathways to overcome resistance to MEK inhibition  
Proposed targets to overcome CD271 mediated resistance to MEK inhibitors. MEK inhibitors can induced CD271 expressing melanoma subpopulations directly or 
induce AMPK release leading to autophagy induction which subsequently can lead to CD271 induction. Alternatively, MEK induced CD271 expressing melanoma cells 
can harness autophagy as a pro-survival mechanism. CD271 associated resistance can be targeted by either blocking the AMPK pathway, CD271 using small molecular 
CD271 inhibitors or by modulating autophagy either by blocking pro-survival autophagy with chloroquine or specific autophagy inhibitors or alternatively 
exacerbating pro-apoptotic autophagy using THC. 
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In conclusion, although there has been extensive research into the signalling pathways 
contributing to drug resistance in melanoma this work highlights the pivotal role of CD271 
expressing melanoma subpopulations in trametinib-induced resistance and their association 
with the activation of pro-survival autophagy. Trametinib-induced CD271 expressing 
melanoma cells contribute to the development of acquired resistance via a complex link with 
activated metabolic pathways such as AMPK and autophagy. Although the link between drug 
induced CD271 expression melanoma subpopulations and autophagy is clear, the association 
between constitutive expression of CD271 in vitro and in vivo is weak and indicates that the 
role of CD271 might differ in a constitutive or drug-induced setting. Drug induced CD271 
expressing cells only transiently emerge in response to long term treatment with trametinib 
therefore suggesting that CD271 might only be important initially in the development of 
acquired resistance and not once full resistance is established. This observation further 
highlights the complex regulation of CD271 and its clinical implications as targeting CD271 to 
overcome resistance in the clinical setting will require regular patient tissue sampling to look 
for the emergence of CD271 expressing cells which will be difficult outside a clinical trial 
setting. However, and more importantly, manipulating autophagy, the pro-survival 
mechanism CD271 expressing cells use to survive might be a more realistic approach. Data 
from the current study highlight that drug- induced CD271 expressing subpopulations harness 
autophagy as a pro-survival mechanism and manipulating autophagy either by blocking pro-
survival autophagy or inducing cytotoxic autophagy sensitizes drug-resistant BRAF mutant 
melanoma cells to the cytotoxic effects of trametinib. Although it is not clear whether 
trametinib-induced activation of autophagy results in CD271 induction of vice versa, targeting 
autophagy as described above nevertheless results in increased cell death irrespective of the 
sequence of these events and therefore may present viable treatment option to overcome 
the resistance of BRAF /NRAS mutant melanomas to MEK inhibition. 
Inhibition of the MAPK pathway is likely to continue to be a cornerstone of therapeutic 
interventions for BARF mutant cutaneous melanoma despite the introduction of 
immunotherapy. However, novel treatment approaches using combination of BRAF/MEK 
inhibition and autophagy modulation might offer a superior therapeutic benefit for BRAF 
mutant cutaneous melanoma, delay the development of acquired resistance and improve 
clinical outcomes. 
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